

Supplementary Materials

Table of Contents

Supplementary Files	2
Supplementary File 1. PRISMA Checklist	2
Supplementary File 2. Search Strategy	4
Supplementary File 3. Tool for assessing study risk of bias	9
Supplementary File 4. Additional data analysis details	12
Supplementary File 5. Methods for selecting and gathering data on cumulative incidence and population size.....	15
Supplementary Tables	18
Supplementary Table 1. Characteristics of studies in the general population and primary seroprevalence estimates	18
Supplementary Table 2. Characteristics of studies in the special populations and primary seroprevalence estimates	50
Supplementary Table 3. Risk of bias results	75
Supplementary Table 4. Summary of seroprevalence data for general and special population sub-groups	103
Supplementary Table 5. Summary of unadjusted meta-analysis results	104
Supplementary Table 6. Summary of serological tests used.....	105
Supplementary Table 7. Summary of meta-regression results.....	108
Supplementary Figures	109
Supplementary Figure 1. Map of serosurvey distribution by global burden of disease region	109
Supplementary Figure 2. Seroprevalence to cumulative case incidence ratios using cumulative incidence on the same day as the serosurvey end date	110
Supplementary Figure 3. Seroprevalence to cumulative case incidence ratios using cumulative incidence 14 days prior to the serosurvey end date	111
References	112

Supplementary Files

Supplementary File 1. PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5, Supplementary file 3, Supplementary file 4, Supplementary file 5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5 Supplementary file 2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5, Supplementary file 4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5, 6, Supplementary file 4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5, 6, 7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Supplementary file 3
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-8, Supplementary file 4
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6-8 Supplementary file 4

Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-8, Supplementary file 4
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9, 10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Supplementary table 1 and 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Figure 3, Supplementary table 3
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Supplementary table 1, 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	16, Supplementary table 4 Supplementary table 5
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	16, 17, Supplementary file 7
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	19-22
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	21
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	22
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	23

Supplementary File 2. Search Strategy

The strategies for MEDLINE and EMBASE were an expanded version of the published COVID-19 search strategies created by OVID librarians for these databases¹ Search terms related to serologic testing were identified by infectious disease specialists (MC, CY, and JP)² and expanded using Medical Subject Heading (MeSH) or Emtree thesauri. These searches were adapted for the other databases.

We searched for grey literature using three approaches. First, we searched for pre-print articles via the Europe PMC platform. Second, we searched for reports from national and international health agencies using their website search functions and examining their recurring COVID-19 reports (World Health Organization, European Centres for Disease Control, Centres for Disease Control, National Institutes of Health). Third, we searched Google News for reports of seroprevalence studies. When we encountered reports of potentially eligible government, non-governmental organizations (NGO), or academic studies, we conducted a targeted Google search to locate and include the full study. All updates of routinely reported NGO and government studies (e.g., Public Health England's weekly COVID-19 serosurveillance reports) were screened after the date they first appeared in the Google News search.

We conducted two types of secondary searches. First, we consulted with international experts via e-mail to identify additional literature after all other sources had been searched. Second, we invited submission of seroprevalence study results on our live dashboard SeroTracker.com.

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily

Dates: January 1, 2020 to August 28, 2020

Notes: Covid-19 search terms were adapted from Ovid Expert Searches

#	Search terms
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or nCoV* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).tw,kf.[EB2]
4	or/1-3
5	4 not ((MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or coudence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV).mp. or (animals/ not humans/))
6	((pneumonia or covid* or coronavirus* or corona virus* or nCoV* or 2019-nCoV or sars* or virus).tw,kf. or exp pneumonia/) and Wuhan.tw,kf.
7	(2019-nCoV* or 2019nCoV* or nCoV19 or nCoV-19 or 2019-novel CoV or sars-cov2* or sars-cov-2* or sarscov2* or sarscov-2* or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus 2 or coronavirus2* or corona or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19* or covid-19) and pandemic*2) or (coronavirus* and pneumonia)).tw,kf.
8	COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os.
9	or/6-8
10	5 or 9
11	immunoglobulins/ or antibodies/ or antibodies, blocking/ or exp antibodies, neutralizing/ or antibodies, viral/ or antigen-antibody complex/ or immune sera/ or exp immunoglobulin isotypes/ or immunoglobulin a/ or immunoglobulin d/ or immunoglobulin e/ or immunoglobulin g/ or immunoglobulin m/
12	serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/
13	immunoassay/ or fluoroimmunoassay/ or exp immunoblotting/ or immunoenzyme techniques/ or exp enzyme-linked immunosorbent assay/ or exp enzyme-linked immunospot assay/ or immunosorbent techniques/ or serologic tests/ or complement fixation tests/ or hemagglutination inhibition tests/ or neutralization tests/ or Serology/di
14	(enzyme linked immunosorbent or enzyme-linked immunosorbent or ELISA or immunofluorescence or complement fixation or hemagglutination inhibition or immunoblot or western blot or neutrali*).tw,kf.
15	(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutrali* or sera or serum or serolog* or saliva).tw,kf.
16	or/11-14
17	seroepidemiologic studies/
18	incidence/ or prevalence/
19	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog*).mp.
20	(inciden* or prevalen* or count* or rate*).mp.
21	(serosurvey or sero-survey or screen* or diagnostic).mp.
22	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or silent or asymptomatic or serosurvey or sero-survey).tw,kf.
23	or/17-21
24	10 and (16 and 23)
25	10 and 15
26	10 and 22
27	or/24-26
28	limit 27 to yr="2020-Current"
29	remove duplicates from 28

Database: Embase

Dates: January 1, 2020 to August 28, 2020

Notes: Covid-19 search terms were adapted from Ovid Expert Searches

#	Searches
1	exp Coronavirus/
2	exp Coronavirus Infections/
3	(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).tw,kw.
4	or/1-3
5	4 not ((MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or covidence* or coviden or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV).mp. or (animals/ not humans/))
6	((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars*).tw,kw. or exp pneumonia/) and Wuhan.tw,kw.
7	(2019-ncov or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2 or sars-cov-2 or sarscov2 or sarscov-2 or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or coronavirus-19 or covid19 or covid-19 or covid 2019 or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or ((covid or covid19 or covid-19) and pandemic*2) or (coronavirus* and pneumonia)).tw,kw.
8	(coronavirus disease 2019 or severe acute respiratory syndrome coronavirus 2).sh,dj.
9	6 or 7 or 8
10	5 or 9
11	virus antibody/ec [Endogenous Compound]
12	neutralizing antibody/ec [Endogenous Compound]
13	exp immunoglobulin/ or exp immunoglobulin A antibody/ or exp immunoglobulin class/ or exp immunoglobulin M antibody/ or exp immunoglobulin G antibody/ or exp immunoglobulin antibody/
14	11 or 12 or 13
15	serology/
16	serodiagnosis/ or complement fixation test/ or hemagglutination inhibition test/ or hemolytic plaque assay/
17	fluorescent antibody technique/
18	immunofluorescence test/ or viral disease immunofluorescence assay/
19	enzyme linked immunosorbent assay/
20	western blotting/
21	(enzyme linked immunosorbent or enzyme-linked immunosorbent or ELISA or immunoassay or immunofluorescence or fluorescent antibody or complement fixation or hemagglutination inhibition or hemolytic plaque assay or immunoblot or western blot or neutrali*).tw,kw.
22	(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutrali* or sera or serolog* or serum or saliva).tw,kw.
23	15 or 16 or 17 or 18 or 19 or 20 or 21
24	14 or 23
25	exp seroepidemiology/
26	*prevalence/
27	*incidence/
28	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or count* or rate* or serosurvey or sero-survey or screen* or diagnostic).mp.
29	(seroconver* or seroprevalence or sero-prevalence or seroincidence or sero-incidence or seroepidemiolog* or sero-epidemiolog* or inciden* or prevalen* or silent or asymptomatic or serosurvey or sero-survey).tw,kw.
30	25 or 26 or 27 or 28
31	10 and (24 and 30)
32	10 and 22
33	10 and 29
34	31 or 32 or 33
35	limit 34 to yr="2020-Current"
36	remove duplicates from 35

Database: Web of Science Core Collection

Date: January 1, 2020 to August 28, 2020

#	Searches
1	TS=(coronavirus* or corona virus* or OC43 or NL63 or 229E or HKU1 or HCoV* or ncov* or covid* or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*)
2	TS=(MERS or MERS-CoV or Middle East respiratory syndrome or camel* or dromedar* or equine or coronary or coronal or covidence* or covidien or influenza virus or HIV or bovine or calves or TGEV or feline or porcine or BCoV or PED or PEDV or PDCoV or FIPV or FCoV or SADS-CoV or canine or CCov or zoonotic or avian influenza or H1N1 or H5N1 or H5N6 or IBV)
3	#1 NOT #2
4	TS=((pneumonia or covid* or coronavirus* or corona virus* or ncov* or 2019-ncov or sars* or virus) AND Wuhan)
5	TS=(2019-ncov* or 2019nCov* or ncov19 or ncov-19 or 2019-novel CoV or sars-cov2* or sars-cov-2* or sarscov2* or sarscov-2* or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or corona or coronavirus-19 or covid19 or covid-19 or covid 2019 or (novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus*)) or (coronavirus* and pneumonia).
6	TS=(COVID-19 or "severe acute respiratory syndrome coronavirus")
7	#6 OR #5 OR #4 OR #3
8	TS=(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutralization or sera or serolog* or saliva or serum).
9	TS=("enzyme linked immunosorbent assay" or "enzyme-linked immunosorbent assay" or "immunoenzyme" or ELISA or "lateral flow immunoassay" or LFIA or "immunofluorescence assay" or immunochromatography or "complement fixation test" or "hemagglutination inhibition" or immunoblot or "western blot" or "neutralization assay")
10	#9 OR #8
11	TI=(seroconversion or seroprevalence or seroincidence or seroepidemiolog* or incidence or prevalence or asymptomatic or sero-survey*) or AK=(seroconversion or seroprevalence or seroincidence or seroepidemiolog* or incidence or prevalence or asymptomatic or sero-survey*)
12	ALL=(prevalence or incidence or seroconversion or seroconvert or seroprevalence or seroincidence or seroepidemiolog* or serosurvey or sero-survey or survey or screen* or diagnostic test)
13	#12 AND #10 AND #7
14	#11 AND #7
15	TI=(antibod* or immunoglobulin* or immune globulin* or titer* or isotype* or IgG or IgM or IgA or neutralization or sera or serolog* or saliva or serum).
16	#15 AND #7
17	#16 OR #14 OR #13

Database: Europe PMC [Secondary search for pre-prints]

Dates: January 1, 2020 to August 28, 2020

#	Searches
	("2019-nCoV" OR "2019nCoV" OR "COVID-19" OR "SARS-CoV-2" OR "COVID19" OR "COVID" OR "SARS-nCoV" OR ("wuhan" AND "coronavirus") OR "Coronavirus" OR "Corona virus" OR "corona-virus" OR "corona viruses" OR "coronaviruses" OR "SARS-CoV" OR "Severe Acute Respiratory Syndrome Coronavirus" OR ("SARS" AND "coronavirus")) AND ABSTRACT:(sera* OR sero* OR immun* OR Ig* OR "enzyme-linked immunosorbent assay" OR ELISA OR "neutralization assay" OR seroprevalence) AND (SRC:"PPR")

Sources: Health organizations

Dates: January 1, 2020 to August 28, 2020

Source	Search strategy	
WHO Situation Reports	1	"antibod", "sero", "immun", "ELISA"
National Institutes of Health	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:nih.gov -site:ncbi.nlm.nih.gov
	3	2 AND 3
United States Centres for Disease Control and Prevention	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:cdc.gov
	5	2 AND 3
European Centres for Disease Control and Prevention	1	("COVID" OR "SARS-CoV-2")
	2	("sero*" OR "antibod*" OR "immun*" OR "RDT" OR "ELISA" OR "LFIA")
	3	allintext:(1 AND 2) site:ecdc.europa.eu
	5	2 AND 3

Sources: Google News

Dates: January 1, 2020 to August 28, 2020

Source	Search strategy	
Google news	1	(antibody OR antibodies OR surveillance OR screen OR serology OR serological OR serosurvey OR ELISA OR LFIA OR assay OR blood OR serum OR immune OR immunity OR herd immunity OR random test)

Supplementary File 3. Tool for assessing study risk of bias

Item 1: Was the sample frame appropriate to address the target population?	
Yes	Sample frame described and it approximated the target population
No	Sample frame did not approximate the target population (e.g., blood donors do not represent general population, doctors do not represent all health care providers)
Exclude	Sample frame not described
*Notes	The term “target population” should not be taken to infer every individual from everywhere or with similar disease or exposure characteristics. Instead, give consideration to specific population characteristics in the study, including age range, gender, morbidities, medications, and other potentially influential factors. For example, a sample frame may not be appropriate to address the target population if a certain group has been used (such as those working for one organisation, or one profession) and the results then inferred to the target population (i.e. working adults). A sample frame may be appropriate when it includes almost all the members of the target population (i.e. a census, or a complete list of participants or complete registry data).

Item 2: Were study participants recruited in an appropriate way?	
Yes	Probability sampling method (simple or stratified random) or entire sample (e.g., an entire town) was used
No	Non-probability sampling
Exclude	Sampling method not reported

Item 3: Was the sample size adequate?	
Yes	>599
No	<599
Exclude	Sample size not reported
*Notes	To calculate the required sample size we used an assumed prevalence of 2.5%, which was the global average estimated by the WHO in April, 2020. ³ Based on guidance by the Joanna Briggs Institute and published medical statistical recommendations we selected a precision value that was half the assumed prevalence (1.25%) ^{4,5} We calculated a minimum sample size of 599 using these inputs: Sample size calculation: $n = \frac{Z^2 P(1-P)}{d^2}$ Where n = sample size; Z = Z statistic for level of confidence (95%); P = expected prevalence (2.5% WHO global estimate); d = precision (1.25%)

Item 4: Were the study subjects and setting described in detail?	
Yes	Average age and distribution of gender/sex provided
No	Neither age or gender/sex is provided, or only one of age and gender/sex is provided

Item 5: Was data analysis conducted with sufficient coverage of the identified sample?	
Yes	The demographic characteristics (gender/sex, age, and ethnicity) of the sample is at least somewhat representative of the population
No	The demographic characteristics (gender/sex, age, and ethnicity) of the sample is not representative of the population
Unclear	Information is not provided about demographic characteristics of the sample (gender/sex, age, and ethnicity)

Item 6: Were valid methods used for the identification of the condition?	
Yes	The test used met the FDA standards for Emergency Use Authorizations for COVID-19 serological tests: sensitivity minimum 90%, specificity minimum 95%, as reported in the study. ⁶
No	The test used did not meet the FDA standards for Emergency Use Authorizations for COVID-19 serological tests: sensitivity minimum 90%, specificity minimum 95%.
Exclude	Test sensitivity and specificity not reported

Item 7: Was the condition measured in a standard, reliable way for all participants?	
Yes	The same serology test was used for all participants
No	Different serology tests were used for participants
Unclear	No details were provided about which participants received which serology tests

Item 8: Was there appropriate statistical analysis?	
Yes	Does all of the following: corrects for population characteristics or the sample is somewhat representative of the population (probability sampling), corrects for test characteristics, and provides the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval.
No	Does not correct for population characteristics and the sample is not likely representative of the population (non-probability sampling), does not correct for test or provide the information necessary to correct for test characteristics, or does not provide the information necessary to determine the numerator, denominator, prevalence estimate, and confidence interval.

Item 9: Was the response rate adequate, and if not, was the low response rate managed appropriately?	
Yes	Response rate > 60% or the demographics of the sample were a reasonable match to those of the target population
No	Response rate < 60% and the demographics of the sample were not a reasonable match to those of the target population
Unclear	Response rate not provided and it was unclear if the demographics of the sample differed from the target population
*Notes	https://onlinelibrary.wiley.com/doi/full/10.1111/j.1753-6405.2012.00854.x

Item 10: Overall risk of bias	
Low	The estimates are very likely correct for the target population. To obtain a low risk of bias classification, all criteria must be met or departures from the criteria must be minimal and unlikely to impact on the validity and reliability of the prevalence estimate. These include sample sizes that are just below the threshold when all other criteria are met, reporting only some of characteristics of the sample, test characteristics below the threshold but corrections for the test performance.
Moderate	The estimates are likely correct for the target population. To obtain a moderate risk of bias classification, most criteria must be met and departures from the criteria are likely to have only a small impact on the validity and reliability of the prevalence estimates.
High	The estimates are not likely correct for the target population. To obtain a high risk of bias, many criteria must not be met or departures from criteria are likely to have a major impact on the validity and reliability of the prevalence estimates.
Unclear	There was insufficient information to assess the risk of bias.

Supplementary File 4. Additional data analysis details

Sub-group data extraction

We extracted sub-group data when they were stratified by one variable (e.g., seniors) but not two variables (e.g., female seniors). Antibody isotype and time period were not considered as stratifying variables.

Counting articles and studies

If multiple articles provided unique information about a study, both were included. Articles reporting identical information to previously included articles were excluded as duplicates.

We defined a single study as an effort to test a defined population over a specified period of time to estimate the prevalence of SARS-CoV-2 antibodies.⁷ Articles that provided information on two or more distinct cohorts (different sample frames or different samples at different time points) without a pooled estimate were considered to be multiple studies.

Data Processing and Descriptive Statistics

Data processing and descriptive statistics were conducted in Python. The packages used were as follows: data manipulation: numpy, pandas, geopandas; Bayesian analysis: PyStan, arviz; regression modelling: statsmodels; data visualization: matplotlib, seaborn.

Grouping variables for analysis

Each study was grouped according to the WHO's seven Global Burden of Disease (GBD) regions, as well as by the income status (high vs. low/middle) which is embedded in the GBD categories.^{8,9}

Age

Estimates were classified into four groups based on the reported ages of the included study participants: children (0-12), youth (13-17), adults (18-64), and seniors (65+). The following rules were used to categorize estimates when studies included participants of different ages:

- Participant age mean/median: select the category that it falls within
 - Participant age mean +/- SD: selected all categories within one standard deviation on either side of the mean
 - Participant age median and interquartile range: selected all categories that were included in the interquartile range
- Total age ranges: The age range needed to cover 30% or more of an age category to be classified in that category. As such, thresholds defining 30% for each category were defined.
 - Children: Include "Children" tag if age minimum was 8 or lower.
 - Youth: Include "Youth" tag if the age maximum of a younger group was 14 or higher
 - Youth: Include "Youth" tag if age minimum of an older group was 16 or lower
 - Adults: Include "Adults" tag if age minimum was 57 or lower
 - Adults: Include "Adults" tag if age maximum was 25 or higher.
 - Adults: Include "Adults" tag if age not reported but sample frame was health care workers
 - Seniors: Include "Seniors" tag if age maximum was 70 or higher.
 - For the seniors category, an upper limit of 72 was used (WHO reported world-wide life expectancy) in order to determine a 30% overlap¹⁰

Dates

When explicit dates were not provided, we inferred dates based on the reporting sampling where possible using the following rules:

- Description of a single month: selected first and last date of month
 - Example: "Samples were gathered in April" = April 1 - 30
- Description of a full month as part of a range: selected mid-month
 - Example: "Samples were gathered from April to June" = April 15 to June 15
- Description of early month: selected first two weeks as start and end end (14 days)
 - Example: "Samples were gathered in early April" = April 1 to April 13
- Description of mid-month: selected middle two weeks (14 days)
 - Example: "Samples were gathered in mid April" = April 6 to April 19
- Description of late month: selected the last two weeks as start and end date (14 days)

- Example: “Samples were gathered in late April” = April 17 to April 30

Test correction

The sensitivity and specificity values for correction were derived, in order of preference, from: (i) the FINDDx-McGill database of independent evaluations of serological tests¹¹; (ii) independent test evaluations conducted by serosurvey investigators and reported alongside serosurvey findings; (iii) manufacturer-reported sensitivity and specificity; (iv) published pooled sensitivity and specificity by immunoassay type.¹² If uncorrected estimates were unavailable, we used author-reported corrected seroprevalence estimates in lieu of performing our own correction. Details of this order of priority follow:

1. The FINDDx-McGill database of independent evaluations of serological tests.¹¹ We only considered evaluations reporting both sensitivity and specificity for test performance across all sickness days (as opposed to day 1, day 5, etc). Where multiple evaluations were available, we prioritized in the following order:
 - a. The evaluation needed to match the test name, manufacturer, and target isotype used in the study
 - b. The evaluation needed to match the sample specimen type used in the study
 - i. For sample types that were not reported in either the test evaluation or the serosurvey study we assumed whole blood was used for LFIA tests and serum/plasma was used for non-LFIA tests
 - ii. Plasma/Serum were used interchangeable when no direct match for index sample type was available
 - c. Prioritized reference specimen type which yield the most virus according to a systematic review and meta-analysis published in July 2020 that compared RT-PCR positivity of different specimens¹³
 - i. It was assumed that “respiratory specimen” was referring to upper respiratory specimen as a conservative assumption as these viral loads are lower than bronchoalveolar lavage or sputum. We ranked it along side throat swab.
 - ii. “Lower respiratory specimen” was ranked with with bronchoalveolar lavage fluid
 - iii. “Upper respiratory specimen” was ranked with throat swab
 - iv. If a mixed reference sample was used in the independent evaluation then an even distribution of sample types was assumed; the average % yield of the viral load was calculated and the sample type was ranked accordingly
 - d. Largest sample size
2. Serological test evaluations conducted by study authors, where those authors were at arms length from the design of the study in questions
3. Manufacturer-reported sensitivity and specificity, which includes evaluations of in-house serological tests published by the research group that developed the same test
4. Published pooled sensitivity and specificity results for ELISAs, LFIAs, and CLIAs, based on the test type known to have been used, and using the definitions for these test types provided in the cited article.¹²

Where crude estimates were unavailable, we used author-reported corrected seroprevalence estimates in lieu of performing our own correction. When none of the above corrections were possible, we excluded estimates from further analysis. Where evaluation sample sizes were not reported (primarily for manufacturer-conducted evaluations), we used the minimum required sample sizes for US Food and Drug Administration Emergency Use Authorization approval (30 true positive samples, 80 true negative samples).

Using the best available sensitivity and specificity values and the corresponding denominators, we corrected seroprevalence estimates for test sensitivity and specificity using Bayesian measurement error models, with binomial test evaluation data for test sensitivity and specificity, as described in Section 2 of Gelman and Carpenter (2020).¹⁴ We built the Bayesian model described therein using the statistical package PyStan.

For each seroprevalence estimate, we used the matching seroprevalence, sensitivity, and specificity, and the corresponding denominators, to fit the specified model. The model was fit with four chains and 2000 iterations per chain (1000 warmup, 1000 sampling iterations). A model fit was considered “good” if said fit met all five of PyStan’s Hamiltonian Monte Carlo diagnostic criteria (no iterations ending with a divergence, no iterations saturating the max tree depth of 10, effective Bayesian fraction of missing information over 0.2 for all chains, a R-hat value between 0.9 and 1.1 for all parameters, the effective sample size n_{eff} being at least 0.001x the number of

iterations).¹⁵ Model fits not meeting these criteria were discarded, and the model was rerun until five good fits were obtained for each seroprevalence estimate.

Corrected seroprevalence values were obtained for each model fit by taking the expectation of the true prevalence parameter across all sampling iterations. For each seroprevalence estimate, the corrected seroprevalence was taken to be the median corrected seroprevalence across the five good model fits. The credible interval was defined as the highest posterior density interval (equivalent to the shortest credible interval for these unimodal distributions), and was calculated using the `hpd` function from the `arviz` package.

Calculating Overall Seroprevalence Estimates

Some studies did not report a single overall seroprevalence estimate. In most cases, this was because the study reported different sets of results for different non-overlapping subsets of the data: e.g., for multiple non-overlapping time points (e.g., May and June 2020), multiple distinct populations (e.g., teachers and schoolchildren), or multiple non-overlapping regions (e.g., two regions of the same city). In these cases, we pooled these non-overlapping seroprevalence estimates to generate one overall seroprevalence estimate by taking the total numerator across all estimates and dividing by the total denominator across all estimates. We considered the sampling time frame of these pooled estimates to be the full range of sampling dates; the population studied to be the combination of the distinct populations examined; and the geography examined to be the combination of geographies studied. We used the same procedure to generate overall estimates for subgroups, where necessary (e.g., when separate estimates for doctors and nurses were reported, we used this procedure to calculate an overall health care worker estimate if one was not already provided).

In some cases, studies did not report a single overall seroprevalence estimate because they reported different sets of results for different assays. When studies reported estimates derived from multiple assays used in combination, we prioritized a sub-group estimate based on a single test using the following prioritization (i) independent evaluation available; (ii) pan-Ig: IgG +/- IgM/IgA; IgM +/- IgA; IgA; (iii); highest combined sensitivity and specificity value. These prioritization criteria were designed to minimize bias: using data from independent evaluations is the most reliable way to correct seroprevalence estimates for test sensitivity and specificity; non-IgG antibodies appear to decline over time, especially among individuals without repeated exposure, while IgG antibodies against the spike protein appear to persist for at least three to five months after infection; and estimates that use tests with the highest sensitivity and specificity likely exhibit the least bias to begin with.¹⁶⁻¹⁹

Population differences in seroprevalence

Male and female estimates were included in the sex/gender analysis, with Female as the reference group. Estimates from White, Black, and Asian people were included for the race/ethnicity analysis, with White as the reference group. Youth (0-17), adult (18-64), and older adult (65+) estimates were included for the age analysis, with adults as the reference group. When reported age groups did not conform to these categories, they were treated as the category with which they most overlapped. Reported age groups with substantial overlap with multiple categories were excluded from this analysis. Health care workers and caregivers and the general population were included in the occupation analysis. Known and no known contact with a positive COVID-19 case were included in the exposure level analysis.

Supplementary File 5. Methods for selecting and gathering data on cumulative incidence and population size

Evidence-based timeline for COVID-19 clinical course and cumulative case data collection

- Day 0: Symptom onset
 - FYI: Exposure occurs a mean of -5 days from symptom onset¹⁷
- Day 5: Confirmation on pneumonia
 - Median of 5 days from symptom onset to confirmation of pneumonia^{20,21}
 - This is the assumed days of diagnosis
- Day 7: Presentation to hospital
 - Median of 7 days from symptom onset to presentation to hospital²²
 - Alternative assumption for day of diagnosis
- Day 14: Seroconversion
 - Median of 14 days from symptom onset to seroconversion (IgG)²³
 - Therefore, cumulative case data from -14 days from the serosurvey sampling end date would correspond to the seroconverted patients from the study

Data collection decisions

- Three cumulative case dates were selected for analyses based on the evidence above:
 - Primary analysis: -9 days before serosurvey sampling end date, which assumes that the day of radiological confirmation of pneumonia is approximately equivalent to the reporting date for laboratory confirmed cases of COVID-19. This corresponds to a median of 5 days after symptom onset and assumes a median of 14 days from symptom onset to seroconversion
 - Sensitivity analysis: same day of serosurvey sampling end date (0 days), which is a United States Centres for Disease Control recommended timeframe to account for lags in presentation of patients for testing and in reporting of case data – this may correspond to patients with mild disease
 - Sensitivity analysis: -14 days before serosurvey sampling end date, which accounts for patients that present for testing early (pre-symptomatic) and that may receive a case diagnosis in close proximity to the day of their symptom onset

Sources of data on cumulative incidence and population size

For studies targeting the general population, we gathered the number of total confirmed SARS-CoV-2 infections at zero days, nine days, and fourteen days before the study end-date. We extracted case and population data matching the study sample frame (e.g., province-level case counts for provincial studies). Our sources were, in order of preference: the Johns Hopkins University (JHU) COVID-19²⁴ tracker, with population denominators from the UN Population Division estimates²⁵; the worldwide COVID-19 data source list from the European Centres for Disease Control^{26,27}; and targeted Google searches for government, NGO, and health system

Where possible data were obtained from the John Hopkins COVID-19 tracker through the John Hopkins Center for Systems Science and Engineering GitHub repository.²⁸ If the John Hopkins COVID-19 tracker did not provide the necessary case count data, the worldwide COVID-19 data source list provided by the European Centres for Disease Control (CDC) was accessed.^{26,27} If neither of these sources provided the necessary case count data, then we attempted to obtain data from government, NGO and health system reports, locating these reports from the citations on the 2019-2020 coronavirus Wikipedia page for that country or territory.²⁹

The John Hopkins COVID-19 tracker was also used to determine the date of the 100th case for each country and calculate the time since the 100th case for each included study.

The terminal data sources used for national, regional, local and sublocal case counts when John Hopkins COVID-19 and European CDC data were unavailable are listed below:

Austria

https://covid19-dashboard.ages.at/dashboard_Tod.html

Brazil

https://brasil.io/dataset/covid19/caso_full/

Canada

<https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html>

China

http://en.hubei.gov.cn/special/coronavirus_2019/update_2019ncov/

Denmark

<https://www.ssi.dk/sygdomme-beredskab-og-forskning/sygdomsovervaagning/c/covid19-overvaagning>

Ecuador

<https://www.coronavirusecuador.com/datos-provinciales/>

France

<https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-tests-de-depistage-de-covid-19-realises-en-laboratoire-de-ville/> (Covid-19 cases before May 13, 2020)

<https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-resultats-des-tests-virologiques-covid-19/> (Covid-19 cases after May 13, 2020)

Germany

https://experience.arcgis.com/experience/478220a4c454480e823b17327b2bf1d4/page/page_1/

https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html

India

<https://api.covid19india.org/>

Italy

<https://github.com/pcm-dpc/COVID-19>

Ireland

<https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/casesinireland/epidemiologyofcovid-19inireland/july2020/>

Japan

<https://stopcovid19.metro.tokyo.lg.jp/en/>

Korea

http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&brdGubun=125&dataGubun=&ncvContSeq=&contSeq=&board_id=&gubun=

Malaysia

<http://covid-19.moh.gov.my/>

Nigeria

<https://ncdc.gov.ng/diseases/sitreps/?cat=14&name=An%20update%20of%20COVID-19%20outbreak%20in%20Nigeria>

Peru

https://www.datosabiertos.gob.pe/group/datos-abiertos-de-covid-19?sort_by=changed&f%5B0%5D=field_tags%3A913&f%5B1%5D=field_tags%3A489

Pakistan

<https://covid.gov.pk/>

Russia

Xinhuanet Moscow Covid Case reports (e.g., http://www.xinhuanet.com/english/2020-11/06/c_139496392.htm).

Search terms: Xinhuanet Moscow Covid Cases [Date]

Spain

<https://cneccovid.isciii.es/covid19/#distribuci%C3%B3n-geogr%C3%A1fica>

Sweden

<https://experience.arcgis.com/experience/19fc7e3f61ec4e86af178fe2275029c5>

Switzerland

<https://www.corona-data.ch/>

United Kingdom (including Scotland and Jersey)

<https://coronavirus.data.gov.uk/cases> (England)

<https://www.gov.je/Health/Coronavirus/Pages/CoronavirusCases.aspx> (Jersey)

<https://www.gov.scot/publications/coronavirus-covid-19-trends-in-daily-data/> (Scotland)

United States of America

<https://www.kingcounty.gov/depts/health/covid-19/data/daily-summary.aspx> (Seattle)

<https://www.mass.gov/info-details/archive-of-covid-19-weekly-public-health-reports#may-2020-> (Chelsea, Massachusetts)

<https://www.mass.gov/doc/confirmed-covid-19-cases-in-ma-by-citytown-january-1-2020-may-13-2020-0/download> (Boston, Massachusetts)

<https://coronavirus.dc.gov/data> (Washington DC)

Appropriate case counts could not be obtained for Addis Ababa or Oromia, Ethiopia; Amman, Jordan; or Alzintan City, Libya.

Supplementary Tables

Supplementary Table 1. Characteristics of studies in the general population and primary seroprevalence estimates

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Central Europe, Eastern Europe, and Central Asia													
Hungary													
Merkely (Semmelweis University) ³⁰	2020-05-01 to 2020-05-16		National	Moderate	10474	Mean 48.7 (SD 18)	53.6	Stratified probability	Household and community samples	0.7% (0.5- 0.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	69.9, 100.0 (FINDDx / MUHC independent evaluation)	0.5% (0.0- 1.0%)
Russian Federation													
Tickle (City of Moscow) ³¹	2020-06-05 to 2020-06-18	Central Russia Moscow	Local	High	90000	NR	nan	Simplified probability	Household and community samples	19.9% (19.6- 20.2%)	Not reported Not Reported Not reported	No data	-
Kiselyov (Russian National Council for Combating Coronavirus) ³²	2020-06-10		National	Moderate	650000	NR	nan	Unclear	Household and community samples	14.0% (13.9- 14.1%)	Invitro Not Reported Not reported	95.0, 98.0 (Test developer / manufacturer evaluation)	12.0% (8.4- 15.5%)
High-income													
Austria													
Knabl (Medical University of Innsbruck) ³³	2020-04-21 to 2020-04-27	Tyrol	Local	Moderate	1473	Mean 40.3 (Male); 40.9 (Female); 10.2 (Children); 45.8 (Adults) (SD 19.5 (Male); 20.1 (Female); 4.9 (Children); 16.5 (Adults))	51.5	Entire sample	Household and community samples	42.4% (39.9- 45.0%)	Abbott; EUROIMMUN Abbott SARS- CoV-2 IgG immunoassay; Euroimmun Anti-SARS- CoV-2 IgG IgA ELISA IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	54.6% (51.1- 58.0%)
Belgium													
Herzog (University of Antwerp) ³⁴	2020-06-29 to 2020-07-04	Wallonia, Brussels, Flanders	National	Moderate	3023	0-10 (n=110); 10-20 (n=413); 20-	51.3	Stratified non- probability	Household and	4.5% (3.8- 5.3%)	EUROIMMUN Euroimmun Anti-SARS-	76.9, 97.0 (FINDDx / MUHC	2.2% (0.0- 4.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						30 (n=394); 30-40 (n=396); 40- 50 (n=403); 50-60 (n=400); 60- 70 (n=403); 70-80 (n=204), 80- 90 (n=160); >90 (n=140)			community samples		CoV-2 ELISA IgG IgG	independent evaluation)	
Herzog (University of Antwerp) ³⁴	2020-06-08 to 2020-06-13	Wallonia, Brussels, Flanders	National	Moderate	2960	0-10 (n=124); 10-20 (n=375); 20- 30 (n=383); 30-40 (n=395); 40- 50 (n=394); 50-60 (n=393); 60- 70 (n=399); 70-80 (n=201), 80- 90 (n=166); >90 (n=130)	51.9	Stratified non- probability	Household and community samples	5.5% (4.7- 6.4%)	EUROIMMUN Euroimmun Anti-SARS- CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	2.8% (0.0- 5.2%)
Herzog (University of Antwerp) ³⁴	2020-05-18 to 2020-05-25	Wallonia, Brussels, Flanders	National	Moderate	3242	0-10 (n=174); 10-20 (n=431); 20- 30 (n=414); 30-40 (n=424); 40- 50 (n=411); 50-60 (n=419); 60- 70 (n=417); 70-80 (n=236), 80- 90 (n=163); >90 (n=153)	51.0	Stratified non- probability	Household and community samples	6.9% (6.1- 7.8%)	EUROIMMUN Euroimmun Anti-SARS- CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	4.1% (0.2- 7.1%)
Herzog (University of Antwerp) ³⁴	2020-04-20 to 2020-04-26	Wallonia, Brussels, Flanders	National	Moderate	3397	0-10 (n=85); 10-20 (n=442); 20- 30 (n=375); 30-40 (n=407); 40- 50 (n=406); 50-60 (n=430); 60- 70 (n=426); 70-80	52.9	Stratified non- probability	Household and community samples	6.0% (5.2- 6.9%)	EUROIMMUN Euroimmun Anti-SARS- CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	3.2% (0.0- 5.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						(n=316), 80-90 (n=315); >90 (n=195)							
Herzog (University of Antwerp) ³⁴	2020-03-30 to 2020-04-05	Wallonia, Brussels, Flanders	National	Moderate	3910	0-10 (n=36); 10-20 (n=294); 20-30 (n=436); 30-40 (n=461); 40-50 (n=468); 50-60 (n=498); 60-70 (n=507); 70-80 (n=506), 80-90 (n=493); >90 (n=211)	54.0	Stratified non-probability	Household and community samples	2.9% (2.4-3.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	1.1% (0.0-2.3%)
Canada													
Héma-Québec ^{35 36}	2020-05-25 to 2020-07-09	Quebec	Regional	Unclear	7691	NR	nan	Stratified probability	Blood donors	2.2% (1.9-2.6%)	Not reported Not Reported Not reported	No data	-
Public Health Ontario ^{37 38}	2020-06-05 to 2020-06-30	Ontario	Regional	Moderate	7014	0-19 (n=978); 20-59 (n=3996); >=60 (n=2040)	51.2	Stratified probability	Residual sera	1.1% (0.9-1.4%)	Abbott; Ortho-Clinical Diagnostics Abbott Architect SARS-CoV-2 IgG assay; Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	90.4, 100.0 (Test developer / manufacturer evaluation)	0.8% (0.0-1.3%)
Canadian Blood Services ³⁹	2020-05-09 to 2020-06-18	Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador	National	Moderate	37737	17-25 (n=3581); 25-39 (n=10781); 40-59 (14147); 60+(n=9228)	46.9	Sequential	Blood donors	0.7% (0.6-0.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	1.1% (0.1-1.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Public Health Ontario ^{37, 38}	2020-05-26 to 2020-05-31	Ontario	Regional	Moderate	1061	0-19 (n=218); 20-59 (n=521); >=60 (n=322)	50.5	Stratified probability	Residual sera	1.4% (0.8-2.3%)	Abbott; Ortho-Clinical Diagnostics Abbott Architect SARS-CoV-2 IgG assay; Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	90.4, 100.0 (Test developer / manufacturer evaluation)	1.0% (0.0-1.8%)
Skowronski (British Columbia Centre for Disease Control) ⁴⁰	2020-05-15 to 2020-05-27	British Columbia Greater Vancouver Area	Regional	Moderate	889	Median 45 (Range <10-80+)	50.3	Stratified probability	Residual sera	0.8% (0.3-1.6%)	Ortho-Clinical Diagnostics VITROS anti-SARS-CoV-2 total antibody IgA; IgG; IgM	85.0, 99.4 (FINDDx / MUHC independent evaluation)	0.5% (0.0-1.0%)
Public Health Ontario ^{37, 38}	2020-03-27 to 2020-04-30	Ontario	Regional	Moderate	827	0-19 (n=182); 20-59 (n=503); >=60 (n=142)	59.3	Stratified probability	Residual sera	0.4% (0.1-1.1%)	Abbott; Ortho-Clinical Diagnostics Abbott Architect SARS-CoV-2 IgG assay; Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	90.4, 100.0 (Test developer / manufacturer evaluation)	0.3% (0.0-0.6%)
Skowronski (British Columbia Centre for Disease Control) ⁴⁰	2020-03-05 to 2020-03-13	British Columbia Greater Vancouver Area	Regional	Moderate	870	Median 45 (Range <10-80+)	51.0	Stratified probability	Residual sera	0.8% (0.3-1.6%)	Ortho-Clinical Diagnostics VITROS anti-SARS-CoV-2 total antibody IgA; IgG; IgM	85.0, 99.4 (FINDDx / MUHC independent evaluation)	0.5% (0.0-0.9%)
Denmark													
Jespersen (Aarhus University Hospital) ⁴¹	2020-06-17 to 2020-06-30	Central Denmark Region	Regional	High	180	NR	nan	Unclear	Blood donors	1.2% (0.2-4.1%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA Total Antibody	96.7, 99.5 (Used author-adjusted estimate)	1.2% (0.4-3.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Jespersen (Aarhus University Hospital) ⁴¹	2020-06-17 to 2020-06-30	Central Denmark Region	Regional	High	180	NR	nan	Unclear	Blood donors	0.6% (0.0-3.1%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA Total Antibody	96.7, 99.5 (Used author-adjusted estimate)	0.6% (0.1-2.2%)
Erikstrup (Copenhagen University Hospital) ⁴²	2020-04-06 to 2020-05-03		National	Moderate	20640	17-69 (n=20640)	50.5	Entire sample	Blood donors	2.0% (1.8-2.2%)	Livzon Diagnostics 2019-nCoV IgG/IgM Antibody Detection Kit IgG; IgM	68.6, 63.6 (FINDDx / MUHC independent evaluation)	0.4% (0.0-0.9%)
Petersen (University of the Faroe Islands) ⁴³	2020-04-27 to 2020-05-01	Faroe Islands	Regional	Low	1075	Mean 42.1 (SD 23.1)	50.0	Randomized	Household and community samples	0.6% (0.2-1.3%)	Beijing Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG; IgM	95.7, 98.7 (FINDDx / MUHC independent evaluation)	0.2% (0.0-0.5%)
Iversen (University of Copenhagen) ⁴⁴	2020-04-15 to 2020-04-22	Capital Region of Denmark	Regional	High	4672	NR	nan	Sequential	Blood donors	3.0% (2.6-3.6%)	Livzon Diagnostics Not Reported IgM; IgG	73.4, 99.9 (Used author-adjusted estimate)	3.0% (2.6-3.5%)
France													
Cohen (Association Clinique et Thérapeutique Infantile du Val-de-Marne) ⁴⁵	2020-04-14 to 2020-05-12	Paris Paris	Local	High	605	Mean 4.9 (SD 3.9)	46.8	Sequential	Residual sera	10.7% (8.4-13.4%)	Biosynex Biosynex COVID-19 BSS test IgG; IgM	91.8, 99.2 (Test developer / manufacturer evaluation)	9.8% (5.9-13.9%)
Fontanet (Institut Pasteur) ⁴⁶	2020-04-28 to 2020-04-30	Oise Crepy-en-Valois	Local	Moderate	1340	Median NR (Pupils); 40 (parents); 47.5 (teachers); 47.5 (non-teaching staff) (IQR TR: 6-11)	57.4	Convenience	Household and community samples	10.4% (8.8-12.2%)	Institut Pasteur S-Flow assay Not reported	99.4, 100.0 (Test developer / manufacturer evaluation)	9.9% (8.3-11.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						Pupils; 37-44 (Parents); 40-51 (Teachers); 32-54 (non-teaching staff))							
Gallian (Unite des Virus Emergents) ⁴⁷	2020-03-25 to 2020-04-07	Bouches du Rhone, Haut Rhin, Oise, Seine Saint Denis	National	High	998	Median 41 (NR)	49.0	Sequential	Blood donors	2.7% (1.8-3.9%)	Author-designed N/A - Author-designed Not reported	No data	-
Germany													
Fischer (Heart and Diabetes Center NRW) ⁴⁸	2020-03-09 to 2020-06-03	North Rhine-Westphalia, Lower Saxony, Hesse	Regional	High	3186	NR	70.8	Sequential	Residual sera	0.9% (0.6-1.3%)	Abbott; EUROIMMUN ; DiaSorin Abbott Architect SARS-CoV-2 IgG assay; Euroimmun Anti-SARS-CoV-2 ELISA IgG; LIAISON SARS-CoV-2 S1/S2 IgG IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.1% (0.0-0.3%)
Weis (Jena University Hospital) ⁴⁹	2020-05-12 to 2020-05-22	Thuringia Ilm-Kreis	Local	Moderate	620	Mean 58.1 (adults); 9.6 (children) (SD 16.5 (adults); 4.38 (children))	51.3	Entire sample	Household and community samples	8.4% (6.3-10.9%)	Epitope Diagnostics; EUROIMMUN ; DiaSorin; Snibe Diagnostic; Abbott; Roche EDI Novel Coronavirus SARS-CoV-2 IgG ELISA kit; SARS-CoV-2 IgG ELISA kit; SARS-CoV-2 S1/S2 IgG CLIA kit; 2019-nCoV IgG kit; SARS-CoV-2 IgG CMIA kit; Elecsys Anti-	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.6% (4.6-8.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
											SARS-CoV-2 kit IgG		
Reisinger (Universitätsmedizin Rostock) ⁵⁰	2020-04-20 to 2020-04-22	Mecklenburg-Westpomerania Rostock	Sublocal	High	401	Mean 36.9 (NR)	100.0	Self-referral	Household and community samples	3.0% (1.6-5.2%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 IgG IgA ELISA IgG; IgA	87.4, 82.0 (FINDDx / MUHC independent evaluation)	0.6% (0.0-1.3%)
Streeck (University of Bonn) ⁵¹	2020-03-31 to 2020-04-06	North Rhine-Westphalia Gangelt	Local	Low	919	Median 53 (Range 1-90)	50.8	Simplified probability	Household and community samples	13.6% (11.4-16.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	86.7, 85.0 (FINDDx / MUHC independent evaluation)	3.1% (0.0-6.4%)
Greece													
Bogogiannidou (University of Thessaly) ⁵²	2020-03-01 to 2020-04-30	Central Macedonia, Attica, Peloponnese, Thessaly, Western Macedonia, Central Greece, Western Greece, Epirus	National	Moderate	6586	0-29 (n=1464); 30-49 (n=2066); 50-69 (n=1762); >=70 (n=1294)	55.0	Convenience	Residual sera	0.4% (0.2-0.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	0.5% (0.0-0.9%)
Ireland													
Igoe (HSE Health Protection Surveillance Centre (HPSC)) ⁵³	2020-06-22 to 2020-07-16	Connaught, Leinster	National	Moderate	1733	NR	nan	Randomized	Household and community samples	1.7% (1.1-2.4%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	3.1% (0.6-5.1%)
Israel													
Bachner (Israeli Pandemic Task Force) ^{54,55}	Until 2020-06-02	Israel	National	High	1700	NR	nan	Stratified probability	Household and community samples	2.5% (1.8-3.4%)	Not reported Not Reported IgG	No data	-
Italy													
Pagani (Università degli Studi di Milano) ⁵⁶	2020-05-18 to 2020-06-07	Lombardy	Local	Moderate	509	0-19 (n=61); 20-39 (n=111); 40-	48.9	Stratified probability	Household and	22.6% (19.0-26.5%)	Abbott Abbott SARS-CoV-2 IgG	69.9, 100.0 (FINDDx / MUHC)	32.0% (24.7-38.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						59 (n=182); >=60 (n=155)			community samples		immunoassay IgG	independent evaluation)	
Amante (Bergamo Health Agency) ⁵⁷	2020-04-23 to 2020-06-03	Lombardy Bergamo	Regional	Moderate	9965	NR	nan	Simplified probability	Household and community samples	57.0% (56.0-58.0%)	Not reported Not Reported Not reported	No data	-
Fiore (University of Foggia) ⁵⁸	2020-05-01 to 2020-05-31	Apulia Foggia	Local	High	904	18 to 25 (n=112, 12.4%), 26 to 35 (n=195, 21.6%), 36 to 45 (n=202, 22.3%), 46 to 55 (n=149, 27.2%), 56 to 65 (n=149, 16.5%)	26.4	Convenience	Blood donors	1.0% (0.5-1.9%)	New Industries Biomedical Engineering Co., Ltd Not Reported IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.4%)
Landro (ATS Bergamo) ⁵⁹	2020-04-23 to 2020-04-28	Lombardy Bergamo	Local	Unclear	750	NR	nan	Unclear	Household and community samples	61.0% (57.4-64.5%)	Not reported Not Reported Not reported	No data	-
Valenti (Fondazione IRCCS Ca' Granda Ospedale Maggiore) ⁶⁰	2020-02-24 to 2020-04-08	Lombardy Milan	Local	Moderate	789	Mean 42.6 (SD 13.4)	35.0	Simplified probability	Blood donors	5.1% (3.7-6.9%)	Prima Lab PRIMA COVID-19 IgG/IgM Rapid Test IgG; IgM	79.1, 85.4 (FINDDx / MUHC independent evaluation)	0.9% (0.0-2.0%)
Percivalle (IRCCS Policlinico San Matteo) ⁶¹	2020-03-18 to 2020-04-06	Lombardy Lodi	Local	High	390	Median 46 (Range 19-70)	30.3	Sequential	Blood donors	23.0% (18.9-27.5%)	Author-designed N/A - Author-designed Not reported	95.0, 100.0 (Test developer / manufacturer evaluation)	22.0% (16.0-28.6%)
Milani (University of Milan) ⁶²	2020-03-30 to 2020-03-31	Lombardy Milan	Local	High	197	NR	nan	Self-referral	Household and community samples	5.6% (2.8-9.8%)	Beijing Wantai Biological Pharmacy Enterprise Wantai SARS-CoV-2 Ab ELISA IgG; IgM; IgA	93.1, 99.1 (FINDDx / MUHC independent evaluation)	5.1% (1.9-8.4%)
Japan													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Nawa (Tokyo Medical and Dental University) ⁶³	2020-06-14 to 2020-07-05	Kantō region Utsunomiya City	Local	Moderate	742	<10 (n=56); 10-17 (n=42); 18-65 (n=463); >65 (n=181)	52.6	Simplified probability	Household and community samples	1.2% (0.6-2.3%)	Shenzhen YHLO Biotech Co Not Reported IgG	73.1, 100.0 (FINDDx / MUHC independent evaluation)	1.3% (0.0-2.4%)
Takita (Navitas Clinic Tachikawa) ^{64,65}	2020-04-20 to 2020-05-20	Kanto, Chūbu Tokyo, Kangawa, Saitama, Chiba, Yamanashi	Local	High	1071	<=17 (n=13); 18-34 (n=134); 35-54 (n=653); =>55 (n=271)	46.2	Self-referral	Household and community samples	3.8% (2.8-5.2%)	Kurabo Industries SARS-CoV-2 Antibody Testing Kit IgG (RC - NC002) IgG	76.4, 100.0 (Test developer / manufacturer evaluation)	4.2% (1.6-6.8%)
Luxembourg													
Snoeck (Luxembourg Institute of Health) ⁶⁶	2020-04-15 to 2020-05-05		National	Moderate	1820	Mean 47 (SD 15)	52.1	Stratified probability	Household and community samples	2.1% (1.5-2.9%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	0.8% (0.0-1.7%)
Netherlands													
Slot (Amsterdam UMC) ⁶⁷	2020-04-01 to 2020-04-15		National	Moderate	7361	18-30 (n=1251); 31-40 (n=882); 41-50 (n=1354); 51-60 (n=2132); 60-72 (n=1742)	nan	Sequential	Blood donors	3.1% (2.7-3.5%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgG; IgA; IgM	72.7, 97.0 (FINDDx / MUHC independent evaluation)	1.4% (0.0-2.8%)
Norway													
Tunheim (Norwegian Institute of Public Health) ⁶⁸	2020-04-20 to 2020-05-17		National	Moderate	900	0-4 (n=41); 5-14 (n=115); 15-24 (n=166); 25-59 (n=372); ≥60 (n=206)	56.6	Sequential	Residual sera	1.1% (0.5-2.0%)	Department of Immunology, Oslo University Hospital N/A - Author-designed IgG	86.0, 100.0 (Test developer / manufacturer evaluation)	0.9% (0.0-1.6%)
Portugal													
Rodrigues (Instituto Nacional de Saúde Doutor Ricardo Jorge) ⁶⁹	2020-05-21 to 2020-07-08		National	Moderate	2301	1-9 (n=404); 10-19 (n=377); 20-39 (n=377);	54.1	Stratified non-probability	Household and community samples	1.9% (1.4-2.5%)	EUROIMMUN Euroimmun Anti-SARS-	42.9, 98.0 (FINDDx / MUHC)	1.7% (0.0-3.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						40-59 (n=479); >=60 (n=664)					CoV-2 ELISA IgG IgG	independent evaluation)	
Republic of Korea													
Ji-Ho (Korea Centers for Disease Control and Prevention) ^{70,71}	Until 2020-07-09	Korea	National	Unclear	3055	NR	nan	Unclear	Household and community samples	0.0% (0.0-0.2%)	Not reported Not Reported Not reported	No data	-
Noh (Korea University) ⁷²	2020-05-25 to 2020-05-29		Local	High	1500	0-19 (n=226); 20-29 (n=258); 30-39 (n=261); 40-49 (n=254); 50-59 (n=255); >60 (n=246)	51.3	Convenience	Residual sera	0.1% (0.0-0.4%)	Roche elecsys Elecsys Anti-SARS-CoV-2 kit IgG	99.5, 99.8 (Test developer / manufacturer evaluation)	0.1% (0.0-0.2%)
Singapore													
Kurohi (Singapore National Centre for Infectious Diseases) ⁷³	2020-02-15 to 2020-04-15	Singapore	Local	Unclear	774	NR	nan	Unclear	Household and community samples	0.0% (0.0-0.5%)	Not reported Not Reported Not reported	No data	-
Spain													
Flores (Municipality of Torrejon de Ardoz) ⁷⁴	2020-05-29 to 2020-06-03		Local	Moderate	104299	>=1	nan	Entire sample	Household and community samples	23.1% (22.8-23.3%)	Not reported Not Reported IgG; IgM	No data	-
Pollán (Institute of Health Carlos III) ⁷⁵	2020-04-27 to 2020-05-11		National	Low	51958	0-19 (n=11422); 20-34 (n=8469); 35-49 (n=14532); 50-64 (n=15094); >=65 (n=11558)	61.1	Stratified probability	Household and community samples	4.6% (4.4-4.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	10.2% (6.5-13.6%)
Sweden													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
The Local News Sweden (Werlabs) ⁷⁶	2020-07-01 to 2020-07-22	Skåne, Västra Götaland, Uppland Stockholm, Gothenburg, Malmö	Local	High	83000	NR	nan	Unclear	Household and community samples	14.4% (14.2-14.6%)	Werlabs Not Reported Not reported	No data	-
Stockholm Region Government (Sweden Public Health Authority) ⁷⁷	2020-06-15 to 2020-07-15		Local	High	149616	NR	nan	Self-referral	Household and community samples	17.6% (17.4-17.8%)	Not reported Not Reported Not reported	No data	-
Lundkvist (Uppsala University) ⁷⁸	2020-06-17 to 2020-06-18	Södermanland, Uppland	Sublocal	High	90	Mean 50 (NR)	28.9	Simplified probability	Household and community samples	30.0% (20.8-40.6%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	69.5% (47.1-95.0%)
Lundkvist (Uppsala University) ⁷⁸	2020-06-17 to 2020-06-18	Södermanland, Uppland	Sublocal	High	123	Mean 37 (NR)	57.7	Simplified probability	Household and community samples	4.1% (1.4-9.3%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	7.0% (0.1-13.8%)
Sweden Public Health Authority ⁷⁹	2020-06-08 to 2020-06-14	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	5.6% (4.4-7.1%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.3% (2.4-6.0%)
Sweden Public Health Authority ⁷⁹	2020-06-01 to 2020-06-07	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	7.0% (5.6-8.6%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.2% (4.3-8.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Sweden Public Health Authority ⁷⁹	2020-05-25 to 2020-05-31	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	5.6% (4.4-7.1%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.3% (2.5-6.1%)
Sweden Public Health Authority ⁷⁹	2020-05-18 to 2020-05-24	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	5.4% (4.2-6.8%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.0% (2.2-5.8%)
Roxhed (KTH Royal Institute of Technology) ⁸⁰	2020-04-01 to 2020-05-21	Uppland Stockholm	Local	Moderate	878	20-29 (n=135); 30-39 (n=174); 40-49 (n=165); 50-59 (n=151); 60-69 (n=130); 70-74 (n=79); Missing (n=44)	55.0	Simplified probability	Household and community samples	5.4% (4.0-7.1%)	Author-designed N/A - Author-designed IgG; IgM	100.0, 100.0 (Test developer / manufacturer evaluation)	5.4% (4.1-6.8%)
Sweden Public Health Authority ⁷⁹	2020-05-11 to 2020-05-17	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	4.6% (3.5-5.9%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.9% (1.1-4.5%)
Sweden Public Health Authority ⁷⁹	2020-05-04 to 2020-05-10	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten	National	High	1200	NR	nan	Stratified non-probability	Residual sera	4.1% (3.1-5.4%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.3% (0.7-3.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
		Västra Götaland, Örebro										adjustment available)	
Sweden Public Health Authority ⁷⁹	2020-04-27 to 2020-05-03	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	4.1% (3.1-5.4%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.3% (0.7-3.8%)
Sweden Public Health Authority ⁷⁹	2020-04-20 to 2020-04-26	Jämtland-Härjedalen, Jönköping, Kalmar, Skåne, Stockholm, Uppsala, Västerbotten Västra Götaland, Örebro	National	High	1200	NR	nan	Stratified non-probability	Residual sera	5.2% (4.0-6.6%)	Sci LifeLab / KTH Not Reported Not reported	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.7% (2.0-5.5%)
Switzerland													
Fenwick (University of Lausanne) ⁸¹	2020-05-04 to 2020-06-27	Vaud	Regional	High	311	NR	nan	Simplified probability	Household and community samples	6.4% (3.9-9.7%)	Author-designed Luminex S protein trimer IgG assay IgG	97.0, 100.0 (Test developer / manufacturer evaluation)	6.3% (3.8-8.8%)
Stringhini (Geneva University Hospitals) ⁸²	2020-04-06 to 2020-05-09	Geneva Geneva	Regional	Moderate	2766	5-9 (n=123); 10-19 (n=332); 20-49 (n=1096); 50-54 (n=840); >65 (n=369)	52.6	Stratified probability	Household and community samples	7.8% (6.8-8.9%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	5.1% (0.7-8.6%)
United Kingdom													
Public Health England ⁸³	2020-07-20 to 2020-08-16	England	National	Moderate	8940	>16	nan	Stratified probability	Blood donors	5.5% (5.0-6.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	83.0, 99.3 (Used author-adjusted estimate)	5.5% (5.1-5.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Public Health Scotland ⁸⁴	2020-06-29 to 2020-08-09	Scotland	National	High	3220	NR	nan	Sequential	Blood donors	3.1% (2.5-3.8%)	Not reported Not Reported Not reported	nan, nan (Used author-adjusted estimate)	3.1% (2.6-3.6%)
Public Health England ⁸⁵	2020-06-01 to 2020-08-02	England	National	Moderate	2062	<30	nan	Stratified probability	Residual sera	3.2% (2.5-4.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	6.6% (3.3-9.9%)
Public Health England ⁸⁵	2020-06-01 to 2020-08-02	England	National	Moderate	285	<20	nan	Stratified probability	Household and community samples	4.9% (2.7-8.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	10.9% (4.8-17.0%)
Office of National Statistics ⁸⁶	2020-04-26 to 2020-07-26	England	National	Moderate	5248	(n=5248)	nan	Stratified probability	Household and community samples	6.2% (5.6-6.9%)	University of Oxford Oxford immunoassay IgG	99.1, 99.0 (Test developer / manufacturer evaluation)	5.2% (4.4-5.9%)
Public Health England ⁸³	2020-07-13 to 2020-07-21	England	National	Moderate	11351	>16	nan	Stratified probability	Blood donors	6.8% (6.3-7.3%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	83.0, 99.3 (Used author-adjusted estimate)	6.8% (6.4-7.2%)
Ward (Imperial College London) ⁸⁷	2020-06-20 to 2020-07-13	England	Regional	Low	99908	18-24 (n=6499); 25-34 (n=13366); 35-44 (n=17052); 45-54 (n=20634); 55-64 (n=20404); 65-74 (n=15543); 75+ (n=6410)	56.1	Stratified probability	Household and community samples	5.6% (5.5-5.7%)	Fortress Diagnostics LFIA Fortress IgG	84.4, 98.6 (Author-reported independent evaluation)	4.9% (3.9-6.0%)
Office of National Statistics ⁸⁸	2020-04-26 to 2020-07-08	England	National	Moderate	4309	(n=4309)	nan	Stratified probability	Household and community samples	6.3% (5.6-7.1%)	University of Oxford Oxford immunoassay IgG	99.1, 99.0 (Test developer / manufacturer evaluation)	5.3% (4.4-6.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Public Health England ⁸³	2020-06-08 to 2020-07-06	England	National	Moderate	11385	>16	nan	Stratified probability	Blood donors	7.1% (6.6-7.6%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	7.1% (6.7-7.5%)
Public Health England ⁸⁹	2020-03-16 to 2020-06-30	England	National	Moderate	6000	>64	nan	Stratified probability	Residual sera	3.9% (3.4-4.4%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	nan, nan (Used author-adjusted estimate)	3.9% (3.5-4.3%)
Public Health Scotland ⁸⁴	2020-04-20 to 2020-06-21	Scotland	National	High	4744	NR	nan	Sequential	Residual sera	4.3% (3.7-4.9%)	Not reported Not Reported Not reported	nan, nan (Used author-adjusted estimate)	4.3% (3.8-4.8%)
Public Health England ⁸³	2020-05-22 to 2020-06-08	England	National	Moderate	5893	>16	nan	Stratified probability	Blood donors	8.2% (7.5-8.9%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	8.2% (7.6-8.8%)
Wells (King's College London) ⁹⁰	2020-04-27 to 2020-06-02	South East England	Regional	High	431	Mean 48.38 (SD 28)	85.2	Unclear	Household and community samples	12.0% (9.1-15.4%)	Imperial College London Not reported IgG; IgM	90.0, 100.0 (Author-reported independent evaluation)	12.9% (4.9-19.3%)
Public Health England ⁸⁵	2020-05-01 to 2020-05-31	England	National	Moderate	143	<20	nan	Stratified probability	Household and community samples	2.7% (0.7-6.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	5.8% (0.2-10.6%)
Public Health England ⁸⁵	2020-05-01 to 2020-05-31	England	National	Moderate	1061	<30	nan	Stratified probability	Residual sera	7.8% (6.3-9.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	18.4% (12.2-23.9%)
Jersey Government (Statistics Jersey) ⁹¹	2020-05-15 to 2020-05-27	Jersey	Regional	Moderate	1062	16-34 (n=247); 35-44 (n=168); 45-54 (n=189); 55-64 (n=211); >=65 (n=47)	55.2	Stratified probability	Household and community samples	4.4% (3.2-5.8%)	CTK Biotech CTK Biotech Onsite COVID 19 IgG/IgM rapid test kit IgG; IgM	56.9, 95.6 (FINDDx / MUHC independent evaluation)	2.3% (0.0-4.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Public Health England ⁸³	2020-04-30 to 2020-05-22	England	National	Moderate	7694	>16	nan	Stratified probability	Blood donors	8.6% (8.0-9.2%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	8.6% (8.1-9.1%)
Thompson (University of Oxford) ⁹²	2020-03-17 to 2020-05-18	Scotland	Regional	High	3500	NR	nan	Sequential	Blood donors	3.2% (2.6-3.8%)	Author-designed N/A - Author-designed Not reported	94.1, 100.0 (Test developer / manufacturer evaluation)	2.8% (1.1-4.4%)
Public Health England ⁸⁵	2020-04-01 to 2020-04-30	England	National	Moderate	201	<20	nan	Stratified probability	Household and community samples	4.5% (2.1-8.4%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	11.0% (3.8-17.7%)
Public Health England ⁸⁵	2020-04-01 to 2020-04-30	England	National	Moderate	647	<30	nan	Stratified probability	Residual sera	6.6% (4.8-8.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	15.4% (9.2-21.0%)
Public Health England ⁸³	2020-04-24 to 2020-04-26	England Southwest England	Regional	Moderate	865	>16	nan	Stratified probability	Blood donors	5.0% (3.6-6.7%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	5.0% (3.9-6.3%)
Public Health England ⁸³	2020-04-23 to 2020-04-24	England Midlands	Regional	Moderate	1043	>16	nan	Stratified probability	Blood donors	7.3% (5.8-9.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	7.3% (6.1-8.7%)
Public Health England ⁸³	2020-04-15 to 2020-04-20	England Northwest England	Regional	Moderate	936	>16	nan	Stratified probability	Blood donors	6.2% (4.7-7.9%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	79.0, 99.0 (Used author-adjusted estimate)	6.2% (5.0-7.6%)
Thompson (University of Oxford) ⁹²	2020-04-18 to 2020-04-20	Scotland	Local	High	490	NR	nan	Sequential	Blood donors	8.6% (6.2-11.4%)	Author-designed N/A - Author-designed Not reported	94.1, 100.0 (Test developer / manufacturer evaluation)	9.2% (5.5-12.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Public Health England ⁸³	2020-04-14 to 2020-04-16	England Northeast England	Regional	Moderate	1017	>16	nan	Stratified probability	Blood donors	4.6% (3.4-6.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	79.0, 99.0 (Used author-adjusted estimate)	4.6% (3.6-5.8%)
Public Health England ⁸³	2020-04-09 to 2020-04-13	England London	Regional	Moderate	1085	>16	nan	Stratified probability	Blood donors	11.1% (9.3-13.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	11.1% (9.6-12.7%)
Public Health England ⁸³	2020-04-02 to 2020-04-03	England Midlands	Regional	Moderate	916	>16	nan	Stratified probability	Blood donors	2.4% (1.5-3.6%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	2.4% (1.7-3.3%)
Public Health England ⁸⁵	2020-02-01 to 2020-03-31	England	National	Moderate	443	<30	nan	Stratified probability	Residual sera	1.8% (0.8-3.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	3.4% (0.1-6.0%)
Public Health England ⁸⁵	2020-02-01 to 2020-03-31	England	National	Moderate	106	<20	nan	Stratified probability	Household and community samples	1.4% (0.1-5.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	4.0% (0.0-8.3%)
Public Health England ⁸³	2020-03-26 to 2020-03-27	England London	Regional	Moderate	757	>16	nan	Stratified probability	Blood donors	2.6% (1.6-4.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	82.5, 99.1 (Used author-adjusted estimate)	2.6% (1.8-3.7%)
United States of America													
ABC7 (Riverside University Health System) ⁹³⁻⁹⁵	2020-07-06 to 2020-07-20	California	Local	Unclear	1726	NR	nan	Randomized	Household and community samples	5.9% (4.8-7.1%)	Not Reported Not Reported Not reported	No data	-
Zauzmer (Washington DC Public Health) ⁹⁶	2020-06-15 to 2020-07-15	District of Columbia Washington DC	Local	High	13706	NR	nan	Self-referral	Household and community samples	5.9% (5.5-6.3%)	DiaSorin LIAISON; Abbot Alinity i Not Reported Not reported	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author)	3.9% (3.3-4.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Viglienzoni (University of Vermont) ⁹⁷	Until 2020-06-30	Vermont Chittenden	Local	High	500	NR	nan	Convenience	Household and community samples	2.2% (1.1-3.9%)	University of Vermont Not Reported Not reported	No data	-
Mahajan (Yale School of Medicine) ⁹⁸	2020-06-04 to 2020-06-23	Connecticut Fairfield, Hartford, Litchfield, Middlesex, New Haven, New London, Tolland, Windham	Regional	Moderate	505	18 to 29 (n=36, 7.1%); 30 to 44 (n=76, 15%); 45 to 54 (n=93, 18.4%); 55 to 64 (n=128, 25.3%); >65 (n=170, 33.7%)	57.8	Simplified probability	Household and community samples	3.1% (1.8-5.0%)	Ortho-Clinical Diagnostics Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	77.4, 99.6 (FINDDx / MUHC independent evaluation)	3.4% (1.6-5.4%)
Spectrum News (University of Louisville) ⁹⁹	2020-06-10 to 2020-06-19	Kentucky	Local	High	2237	18-34 (n=470); 35-59 (n=895); =>60 (n=895)	nan	Self-referral	Household and community samples	4.0% (3.2-4.9%)	Not reported Not Reported Not reported	No data	-
Sutton (Oregon Health Authority) ¹⁰⁰	2020-05-11 to 2020-06-15	Oregon	Regional	High	897	0-4 (n=5); 5-17 (n=24); 18-49 (n=274); 50-64 (n=211); 65-74 (n=178); 75-84 (n=144); >=85 (n=61)	nan	Stratified probability	Residual sera	1.0% (0.5-1.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	1.7% (0.0-3.1%)
Hynes (Washoe County Health District) ¹⁰¹	2020-06-09 to 2020-06-10	Nevada Washoe County	Local	High	234	NR	nan	Stratified probability	Household and community samples	2.3% (0.8-5.1%)	Abbott Not Reported Not reported	No data	-
Harden (Routt County Board of Health) ¹⁰²	Until 2020-06-10	Colorado	Local	High	649	NR	nan	Self-referral	Household and community samples	2.6% (1.5-4.1%)	Not reported Not Reported Not reported	No data	-
Rudavsky (Indiana University Fairbanks School of Public Health) ¹⁰³	2020-06-03 to 2020-06-08	Indiana	Regional	Unclear	3600	NR	nan	Stratified probability	Household and community samples	1.5% (1.1-2.0%)	Not reported Not Reported Not reported	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Ohnesorge (Psalms/Solid Rock Medicine Group) ¹⁰⁴	2020-05-29 to 2020-05-29	North Carolina Burke County	Local	Unclear	329	NR	nan	Self-referral	Household and community samples	1.5% (0.5-3.5%)	Not reported Not Reported Not reported	No data	-
Hayden (Desert Healthcare District) ¹⁰⁵	Until 2020-05-28	California Coachella Valley	Local	Unclear	896	NR	50.0	Self-referral	Household and community samples	6.0% (4.5-7.8%)	Phamatech Not Reported IgG; IgM	86.7, 93.8 (FINDDx / MUHC independent evaluation)	2.0% (0.0-4.2%)
Mukherjee (Humboldt County Department of Health and Human Services) ¹⁰⁶	Until 2020-05-26	California Humboldt County	Local	High	1000	NR	nan	Unclear	Household and community samples	1.0% (0.5-1.8%)	Not reported Not Reported Not reported	No data	-
Alfini (UW Health) ¹⁰⁷	2020-05-13 to 2020-05-20	Wisconsin Madison	Local	Unclear	433	NR	nan	Self-referral	Household and community samples	0.3% (0.0-1.4%)	Not reported Not Reported Not reported	No data	-
Alfini (UW Health) ¹⁰⁷	2020-05-13 to 2020-05-20	Wisconsin Madison	Local	Unclear	5303	NR	nan	Self-referral	Household and community samples	1.5% (1.2-1.9%)	Not reported Not Reported Not reported	No data	-
McLaughlin (University of Washington) ¹⁰⁸	2020-05-04 to 2020-05-19	Idaho Blaine County	Local	Moderate	917	18-29 (n=96); 30-39 (n=151); 40-49 (n=186); 50-59 (n=225); 60-69 (n=172); >=70 (n=87);	52.2	Self-referral	Household and community samples	22.7% (20.0-25.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	56.5% (42.4-70.6%)
Feehan (Oschner Clinic Foundation) ¹⁰⁹	2020-05-09 to 2020-05-15	Louisiana	Local	Moderate	2640	Mean 50.6 (NR)	63.5	Stratified probability	Household and community samples	6.9% (6.0-7.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	16.1% (11.5-20.9%)
Boston (Boston Public Health Commission) ^{110,111}	Until 2020-05-15	Massachusetts Boston	Local	Moderate	750	Median 42.4 (NR)	61.6	Simplified probability	Household and community samples	9.9% (7.9-12.3%)	Not reported Not Reported Not reported	No data	-
Sood (Stanford University School of Medicine) ¹¹²	2020-04-10 to 2020-05-14	California Los Angeles County	Local	Moderate	863	18-34 (n=191); 35-54 (n=475);	59.6	Stratified probability	Household and	4.3% (3.1-5.9%)	Premier Biotech Not	70.5, 97.2 (FINDDx / MUHC)	2.6% (0.0-4.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						>= 55 years (n=197)			community samples		Reported IgG; IgM	independent evaluation)	
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-30 to 2020-05-12	Minnesota	Regional	Moderate	860	0-18 (n=49); 19-49 (n=370); 50-64 (n=239); >=65 (n=202)	52.8	Convenience	Residual sera	2.4% (1.5-3.7%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	2.4% (1.7-3.4%)
Angeles (University of Southern California) ¹¹⁴	2020-05-08 to 2020-05-12	California Los Angeles County	Local	Unclear	1014	NR	nan	Self-referral	Household and community samples	2.1% (1.3-3.2%)	Not reported Not Reported Not reported	No data	-
Nesbitt (New York Blood Center) ¹¹⁵	2020-04-27 to 2020-05-11	Rhode Island	Regional	Moderate	1996	Median 56 (NR)	47.3	Sequential	Blood donors	0.7% (0.4-1.2%)	Ortho-Clinical Diagnostics Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay IgG	77.4, 99.6 (FINDDx / MUHC independent evaluation)	0.4% (0.0-0.8%)
Biggs (CDC COVID-19 Response Team) ¹¹⁶	2020-04-28 to 2020-05-03	Georgia	Local	Low	696	NR	54.2	Stratified probability	Household and community samples	2.7% (1.7-4.2%)	Ortho-Clinical Diagnostics VITROS anti-SARS-CoV-2 total antibody IgG; IgA; IgM	85.0, 99.4 (FINDDx / MUHC independent evaluation)	2.3% (0.7-3.6%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-26 to 2020-05-03	Connecticut	Regional	Moderate	1431	0-18 (n=219); 19-49 (n=297); 50-64 (n=300); >=65 (n=615)	50.9	Convenience	Residual sera	4.9% (3.8-6.1%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	4.9% (4.0-5.9%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-20 to 2020-05-03	Utah	Regional	Moderate	1132	0-18 (n=25); 19-49 (n=470); 50-64 (n=328); >=65 (n=315)	59.5	Convenience	Residual sera	2.2% (1.4-3.2%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	2.2% (1.6-3.0%)
Shafa (Indiana University Fairbanks School of Public Health) ¹¹⁷⁻¹¹⁹	2020-05-02 to 2020-05-03	Indiana Indianapolis	Local	High	898	<20 (n=77); 20-39 (n=277); 40-59 (n=369); 60-79 (n=169); >=80 (n=6)	58.2	Self-referral	Household and community samples	5.8% (4.4-7.5%)	Not reported Not Reported IgG	100.0, 99.6 (Test developer / manufacturer evaluation)	3.9% (1.0-6.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Shafa (Indiana University Fairbanks School of Public Health) ¹¹⁷⁻¹¹⁹	2020-04-25 to 2020-04-29	Indiana	Regional	Moderate	3518	<40 (n=1017); 40 to 59 (n=1328); >=60 (n=1313)	56.7	Stratified probability	Household and community samples	1.1% (0.8-1.5%)	Not reported Not Reported IgG	100.0, 99.6 (Test developer / manufacturer evaluation)	0.5% (0.0-0.9%)
Chamie (University of California, San Francisco) ¹²⁰	2020-04-25 to 2020-04-28	California	Local	High	3861	4-10 (n=109); 11-17 (n=135); 18-50 (n=2466); 51-70 (n=916); >70 (n=190)	42.6	Self-referral	Household and community samples	3.4% (2.9-4.0%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	7.2% (4.0-10.0%)
Rosenberg (New York State Department of Health) ¹²¹	2020-04-19 to 2020-04-28	New York	Regional	Moderate	15101	18-34 (n=3151); 35-44 (n=2628); 45-54 (n=3345); >=55 (n=5977)	56.1	Convenience	Household and community samples	12.5% (12.0-13.0%)	NYSDOH Wadsworth Center SARS-CoV IgG Microsphere Immunoassay IgG	60.5, 99.2 (FINDDx / MUHC independent evaluation)	17.9% (12.9-23.5%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-23 to 2020-04-27	California	Regional	Moderate	1224	0-18 (n=45); 19-49 (n=371); 50-64 (n=323); >=65 (n=485)	53.3	Convenience	Residual sera	1.0% (0.5-1.7%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	1.0% (0.6-1.6%)
Zou (Georgia State University) ¹²²	2020-04-17 to 2020-04-27	Georgia Atlanta	Local	High	127	NR	nan	Convenience	Household and community samples	2.4% (0.5-6.7%)	Author-designed Krammer and colleagues ELISA S1 IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.6% (0.0-3.6%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-20 to 2020-04-26	Missouri	Regional	Moderate	1882	0-18 (n=158); 19-49 (n=394); 50-64 (n=405); >=65 (n=925)	54.1	Convenience	Residual sera	2.7% (2.0-3.5%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	2.7% (2.1-3.4%)
Bryan (University of Washington School of Medicine) ¹²³	2020-04-20 to 2020-04-26	Idaho Boise	Local	High	4856	0-19 (n=240); 20-29 (n=301); 30-39 (n=831); 40-49 (n=1102); 50-59 (n=1142);	54.2	Self-referral	Household and community samples	1.8% (1.4-2.2%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	3.3% (1.0-5.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						60-69 (n=888); 70-79 (n=327); >=80 (n=25)							
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-13 to 2020-04-25	Pennsylvania	Regional	Moderate	824	0-18 (n=75); 19-49 (n=193); 50-64 (n=221); >=65 (n=355)	51.2	Convenience	Residual sera	3.2% (2.1-4.6%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	3.2% (2.3-4.3%)
Waymer (OMNI Healthcare) ^{124,125}	2020-04-17 to 2020-04-24	Florida Brevard County	Local	High	1000	NR	nan	Self-referral	Household and community samples	1.0% (0.5-1.8%)	Not reported Not Reported IgM; IgG	100.0, 100.0 (Test developer / manufacturer evaluation)	0.7% (0.0-1.3%)
Dingens (Fred Hutchinson Cancer Research Center) ¹²⁶	2020-03-03 to 2020-04-24	Washington Seattle	Local	High	1076	0-4 (n=192); 5-9 (n=214); 10-14 (n=301); >15 (n=369)	49.7	Convenience	Residual sera	0.7% (0.3-1.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	1.2% (0.0-2.3%)
Appa (University of California, San Francisco) ¹²⁷	2020-04-20 to 2020-04-24	California	Local	High	1880	<18 (n=193); 18-44 (n=596); 45-60 (n=444); 60+ (n=657)	37.5	Self-referral	Household and community samples	0.5% (0.2-0.9%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	0.8% (0.0-1.5%)
Paterson (Baton Rouge General Hospital) ¹²⁸	Until 2020-04-21	Louisiana Baton Rouge	Local	Unclear	432	NR	nan	Unclear	Household and community samples	4.4% (2.7-6.8%)	Mayo Clinic Not Reported Not reported	No data	-
Stadlbauer (Icahn School of Medicine at Mount Sinai) ¹²⁹	2020-02-02 to 2020-04-19	New York New York City	Local	High	3412	0-20 (n=265); 21-40 (n=1380); 41-60 (n=674); >=61 (n=1093)	65.8	Convenience	Residual sera	4.3% (3.6-5.0%)	Mount Sinai Hospital New York N/A - Author-designed IgG	95.0, 100.0 (Test developer / manufacturer evaluation)	3.5% (1.7-5.1%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-05 to 2020-04-10	Florida	Regional	Moderate	1742	0-18 (n=69); 19-49 (n=491); 50-64 (n=326); >=65 (n=856)	55.3	Convenience	Residual sera	1.9% (1.3-2.7%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	1.9% (1.4-2.5%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-01 to 2020-04-08	Louisiana	Regional	Moderate	1184	0-18 (n=33); 19-49 (n=619); 50-	57.2	Convenience	Residual sera	5.8% (4.5-7.3%)	CDC CDC Non-	96.0, 99.3 (Used author-	5.8% (4.8-7.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						64 (n=322); >=65 (n=212)					commercial ELISA IgG	adjusted estimate)	
Bendavid (University of Stanford) ¹³⁰	2020-04-03 to 2020-04-04	California Santa Clara Valley	Local	High	3330	0-4 (n=70); 5-18 (n=549); 19-64 (n=2541); >=65 (n=167)	63.1	Stratified probability	Household and community samples	1.5% (1.1-2.0%)	Premier Biotech COVID-19 IgG/IgM Rapid Test Cassette IgG; IgM	70.5, 97.2 (FINDDx / MUHC independent evaluation)	0.6% (0.0-1.2%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-03-23 to 2020-04-01	Washington	Regional	Moderate	3264	0-18 (n=219); 19-49 (n=1213); 50-64 (n=782); >=65 (n=1050)	59.1	Convenience	Residual sera	1.1% (0.8-1.5%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	1.1% (0.8-1.4%)
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-03-23 to 2020-04-01	New York	Regional	Moderate	2482	0-18 (n=311); 19-49 (n=909); 50-64 (n=455); >=65 (n=807)	53.7	Convenience	Residual sera	6.9% (5.9-8.0%)	CDC CDC Non-commercial ELISA IgG	96.0, 99.3 (Used author-adjusted estimate)	6.9% (6.1-7.8%)
Schuchat (University of Washington) ¹³¹	2020-03-01 to 2020-03-31	Washington Seattle	Local	High	221	NR	nan	Convenience	Residual sera	0.4% (0.0-2.4%)	Not reported Not Reported Not reported	No data	-
Latin America and Caribbean													
Brazil													
Menezes (Universidade Federal de Pelotas) ¹³²	2020-06-21 to 2020-06-24		National	Moderate	31869	0-4 (n=637); 5-9 (n=862); 10-19 (n=2789); 20-29 (n=2789); 30-39 (n=4999); 40-49 (n=5078); 50-59 (n=5032); 60-69 (n=4234); >70 (n=3273)	58.5	Stratified probability	Household and community samples	2.7% (2.5-2.9%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	2.1% (0.4-3.7%)
Pelotas (Universidade Federal de Pelotas) ¹³³	2020-06-04 to 2020-06-07		National	Moderate	31165	0 to 80+	nan	Simplified probability	Household and community samples	3.1% (2.9-3.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	84.8, 99.0 (Used author-adjusted estimate)	3.1% (2.9-3.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Vieira (Centro de Operações de Emergências em Saúde Pública)	2020-05-31 to 2020-05-31	Piauí Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	8.3% (6.6-10.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	9.7% (6.1-13.6%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-24 to 2020-05-24	Piauí Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	5.8% (4.3-7.5%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	6.1% (2.9-9.5%)
Hallal (Universidade Federal de Pelotas) ¹³⁵	2020-05-14 to 2020-05-21		National	Low	24995	0-4 (n=430); 5-9 (n=682); 10-19 (n=2287); 20-29 (n=3866); 30-39 (n=3834); 40-49 (n=3975); 50-59 (n=4015); 60-69 (n=3381); 70-79 (n=1797); >=80 (n=728)	57.8	Simplified probability	Household and community samples	1.4% (1.2-1.5%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	0.9% (0.0-1.6%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-17 to 2020-05-17	Piauí Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	3.8% (2.6-5.2%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	3.5% (0.6-5.8%)
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ¹³⁶	2020-05-13 to 2020-05-15	Espírito Santo	Regional	Moderate	1163	NR	nan	Stratified probability	Household and community samples	0.3% (0.1-0.8%)	Celer Technologies Inc. Not Reported IgG; IgM	86.4, 97.6 (Test developer / manufacturer evaluation)	0.2% (0.0-0.4%)
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ¹³⁶	2020-05-13 to 2020-05-15	Espírito Santo	Regional	Moderate	4612	<=20 years (n=434); 21-40 (n=1367); 41-60 (n=1583); 61-80 (n=1081); >= 81 (n=143)	60.9	Stratified probability	Household and community samples	2.1% (1.7-2.6%)	Celer Technologies Inc. Not Reported IgG; IgM	86.4, 97.6 (Test developer / manufacturer evaluation)	0.9% (0.0-1.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Tess (Universidade de São Paulo) ¹³⁷	2020-05-04 to 2020-05-12	São Paulo São Paulo	Local	Moderate	517	18-44 (n=269); >= 45 (n=248)	54.9	Simplified probability	Household and community samples	4.7% (3.0-6.9%)	SNIBE – Shenzhen New Industries Biomedical Engineering Co. MAGLUMI 2019-nCoV IgG (CLIA) IgG; IgM	100.0, 99.5 (Test developer / manufacturer evaluation)	3.0% (0.5-5.3%)
Watanabe (Grupo Fleury) ¹³⁸	2020-05-04 to 2020-05-12	São Paulo São Paulo	Sublocal	Unclear	520	NR	nan	Stratified probability	Household and community samples	5.2% (3.4-7.5%)	Not reported Not Reported Not reported	No data	-
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-05-09 to 2020-05-11	Rio Grande do Sul Uruguainana, Ijuí, Passo Fundo, Caxias, Canoas, Porto Alegre, Pelotas, Santa Maria, Santa Cruz do Sul	Regional	Low	4500	0-9 (n=113); 10-19 (n=266); 20-29 (n=581); 30-39 (n=684); 40-49 (n=689); 50-59 (n=769); 60-69 (n=734); 70-79 (n=464); >=80 (n=202);	58.9	Stratified probability	Household and community samples	0.2% (0.1-0.4%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgM; IgG	78.3, 98.4 (FINDDx / MUHC independent evaluation)	0.1% (0.0-0.2%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-10 to 2020-05-10	Piauí Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	2.0% (1.2-3.1%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	1.6% (0.0-2.8%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-03 to 2020-05-03	Piauí Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	1.4% (0.8-2.5%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	1.0% (0.0-2.0%)
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-04-25 to 2020-04-27	Rio Grande do Sul Uruguainana, Ijuí, Passo Fundo, Caxias, Canoas, Porto Alegre, Pelotas,	Regional	Low	4501	0-9 (n=116); 10-19 (n=227); 20-29 (n=508); 30-39 (n=753); 40-49 (n=647);	58.9	Stratified probability	Household and community samples	0.1% (0.0-0.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgM; IgG	78.3, 98.4 (FINDDx / MUHC independent evaluation)	0.1% (0.0-0.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
		Santa Maria, Santa Cruz do Sul				50-59 (n=798); 60-69 (n=798); 70-79 (n=459); >=80 (n=156)							
Filho (Universidade do Estado do Rio de Janeiro) ¹⁴⁰	2020-04-14 to 2020-04-27	Rio de Janeiro Rio de Janeiro	Local	Moderate	2857	18-29 (n=870); 30-49 (n=1443); 50-69 (n=544)	49.2	Sequential	Blood donors	4.0% (3.3-4.8%)	MedLevensohn MedTest Coronavirus 2019-nCoV IgG/IgM IgM; IgG	85.0, 99.0 (Test developer / manufacturer evaluation)	2.7% (0.1-4.5%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-04-26 to 2020-04-26	Piaui Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	0.9% (0.4-1.7%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	0.7% (0.0-1.4%)
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-04-19 to 2020-04-19	Piaui Teresina	Local	Moderate	900	NR	nan	Stratified probability	Household and community samples	0.6% (0.2-1.3%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgG; IgM	69.0, 99.1 (FINDDx / MUHC independent evaluation)	0.5% (0.0-1.0%)
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-04-11 to 2020-04-13	Rio Grande do Sul Uruguainana, Ijuí, Passo Fundo, Canoas, Porto Alegre, Pelotas, Santa Maria, Santa Cruz do Sul	Regional	Low	4151	0-9 (n=149); 10-19 (n=224); 20-29 (n=506); 30-39 (n=635); 40-49 (n=643); 50-59 (n=734); 60-69 (n=685); 70-79 (n=3985); >=80 (n=183)	58.3	Stratified probability	Household and community samples	0.0% (0.0-0.2%)	Wondfo Biotech Co. WONDFO SARS-CoV-2 Antibody Test IgM; IgG	78.3, 98.4 (FINDDx / MUHC independent evaluation)	0.0% (0.0-0.1%)
Ecuador													
Brutto (Universidad Peruana Cayetano Heredia) ¹⁴¹	2020-05-25 to 2020-05-31	El Oro	Local	High	673	Mean 59.2 (SD 12.8)	56.6	Entire sample	Household and community samples	45.0% (41.2-48.8%)	Biohit Health Care Ltd Not Reported IgG; IgM	97.5, 100.0 (Test developer / manufacturer evaluation)	47.5% (42.4-52.5%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Brutto (The Atahualpa Project) ¹⁴²	2020-05-01 to 2020-05-31	El Oro Atahualpa	Local	High	319	Mean 70.5 (SD 7.8)	58.6	Convenience	Household and community samples	44.2% (38.7-49.8%)	Biohit Health Care Ltd BIOHIT SARS-CoV-2 antibody test kit (Colloidal gold method) IgG; IgM	96.7, 95.0 (Test developer / manufacturer evaluation)	43.2% (36.3-50.8%)
Peru													
Peruvian Government (National Center for Epidemiology, Prevention and Control of Diseases) ¹⁴³⁻¹⁴⁵	2020-06-28 to 2020-07-09	Metropolitan Lima and Callao	Local	High	3118	NR	nan	Stratified probability	Household and community samples	21.6% (20.2-23.1%)	Not reported Not Reported IgG; IgM	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	29.1% (27.1-31.4%)
North Africa and Middle East													
Iran													
Shakiba (Guilan University) ¹⁴⁶	2020-04-01 to 2020-04-30	Guilan Rasht, Anzali, Astara, Lahijan, Rudbar	Regional	Moderate	528	<5 (n=27); 5-18 (n=107); 18-60 (n=343); >60 (n=74)	51.1	Stratified probability	Household and community samples	21.0% (17.6-24.7%)	VivaChek VivaDiag COVID-19 IgM/IgG Rapid Test IgM; IgG	83.3, 66.7 (FINDDx / MUHC independent evaluation)	5.4% (0.0-11.3%)
Jordan													
Sughayer (King Hussein Cancer Centre) ¹⁴⁷	2020-01-15 to 2020-06-15	Jordan Amman	Regional	High	734	18-30 (n = 301); 31-40 (n=158); 41-50 (n=73); 51-63 (n=30); Unknown (n=172)	14.7	Simplified probability	Blood donors	0.0% (0.0-0.5%)	Roche elecsys Elecsys Anti-SARS-CoV-2 kit IgG; IgM; IgA	73.0, 100.0 (FINDDx / MUHC independent evaluation)	0.1% (0.0-0.5%)
South Asia													
India													
Bedi (Delhi National Centre for Disease Control) ¹⁴⁸	2020-08-01 to 2020-08-07	Delhi	Regional	Unclear	15289	NR	nan	Randomized	Blood donors	28.3% (27.6-29.0%)	Not reported Not Reported Not reported	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Husain (King George's Medical University) ¹⁴⁹	2020-07-05 to 2020-07-19	Uttar Pradesh Lucknow	Local	High	1235	NR	nan	Convenience	Blood donors	3.7% (2.7- 4.9%)	Not reported Not Reported IgG	No data	-
Hindustan Times (Thyrocare) ^{150,151}	2020-06-28 to 2020-07-19	New Dehli, Thane, Madurai, Chennai, Samastipur, Mumbai, Tiruvallur, Valsad, Hooghly, Gautam Buddha Nagar, Ghaziabad, Erode, Nalgonda, Faridabad, Howrah, Surat, Bhojpur, Hyderabad, Kolkata, K.V.Rangaredd y, Aurangabad, Ananthapur, Bellary, Vaishali, Patna, Bhagalpur, South 24 Parganas, Mahendragarh, Mahabub Nagar, Ahmedabad, Gurgaon, Khammam, Muzaffarpur, Navi Mumbai, Ganjam, North 24 Parganas, Vadodara, Pondicherry, Karim Nagar, Bangalore, Nashi, Khorda, Bulandshahr, Kanchipuram, West Godavari, East Godavari, Jaipur, Mahseana, Ranshi, Warangal, Pune, Medak,	National	High	53000	NR	nan	Simplified probability	Household and community samples	15.0% (14.7- 15.3%)	Not reported Not Reported Not reported	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	13.4% (12.9- 14.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
		Bardhaman, South Goa, Dharwad, Visakhapantam, Katihar, Guntur, Chittoor, Lucknow, Bhopal, East Singhbhum, Kolhapur, Thanjavur, Alibaug, Coimbatore											
Kakani (University of Chicago) ^{152,153}	2020-07-03 to 2020-07-19		Regional	Low	2702	12-24 (n=176); 25-39 (n=733); 40-60 (n=1349); 60+ (444)	29.7	Stratified probability	Household and community samples	16.1% (14.7-17.5%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	39.8% (30.5-49.2%)
Mishra (Haryana Health Department) ¹⁵⁴	2020-06-21 to 2020-07-15	Haryana Gurugram, Faridabad, Ambala, Panchkula, Sonipat	Regional	High	1544	NR	nan	Stratified probability	Household and community samples	12.0% (10.4-13.7%)	Not reported Not Reported IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	13.0% (10.8-15.1%)
Saxena (Indian Center for Disease Control) ^{155,156}	2020-06-27 to 2020-07-10	Delhi	Regional	Moderate	21387	NR	nan	Stratified probability	Household and community samples	23.5% (22.9-24.1%)	Zydus Cadila Healthcare COVID KAVACH IgG	98.7, 100.0 (Test developer / manufacturer evaluation)	24.1% (21.5-26.5%)
Kumar (Thiruvananthapuram Health Department) ¹⁵⁷	2020-06-09 to 2020-07-10	Kerala Thiruvananthapuram	Local	Unclear	450	NR	nan	Unclear	Household and community samples	2.7% (1.4-4.6%)	Not reported Not Reported IgM; IgG	No data	-
Koshy (Indian Council of Medical Research) ¹⁵⁸⁻¹⁶¹	2020-05-11 to 2020-05-25	Andhra Pradesh, Assam, Bihar, Chhattisgarh, Gujarat, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Odisha, Punjab,	National	Moderate	26400	NR	nan	Stratified probability	Household and community samples	0.7% (0.6-0.8%)	ICMR-National Institute of Virology Not Reported IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
		Haryana, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh, Uttarakhand, Himachal Pradesh, West Bengal, Jammu, Kashmir											
Pakistan													
Younas (National Institute of Blood Diseases & Bone Marrow Transplantation) ¹⁶²	2020-05-15 to 2020-07-15	Sindh	Local	High	370	Mean 30.6 (SD 6.3)	0.0	Sequential	Blood donors	34.6% (29.8- 39.7%)	Roche Diagnostics Elecys Anti- SARS-Cov2 Immunoassay IgA; IgM; IgG	73.0, 100.0 (FINDDx / MUHC independent evaluation)	51.1% (39.1- 63.3%)
Southeast Asia, East Asia, and Oceania													
China													
Chang (Beijing Hospital) ¹⁶³	2020-01-15 to 2020-04-30	Hubei Wuhan	Local	High	17794	Median 33 (IQR 19-47)	39.7	Sequential	Blood donors	2.3% (2.1- 2.5%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgA; IgG; IgM	93.1, 99.1 (FINDDx / MUHC independent evaluation)	1.2% (0.2- 2.1%)
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	19555	Mean 41.6 (95% CI 41.4-41.8)	50.2	Convenience	Household and community samples	4.6% (4.3- 4.9%)	YHLO SARS- CoV-2 IgM/IgG CLIA kits IgG	73.1, 100.0 (FINDDx / MUHC independent evaluation)	5.1% (1.4- 7.8%)
Ling (Chinese Center for Disease Control and Prevention) ¹⁶⁵	2020-03-25 to 2020-04-28	Hubei Wuhan	Local	Moderate	18712	Median 40 (Range 4-81)	39.1	Self-referral	Household and community samples	3.3% (3.0- 3.5%)	Innovita 2019- nCoV Ab Test (Colloidal Gold) IgG; IgM	56.9, 96.3 (FINDDx / MUHC independent evaluation)	1.6% (0.0- 3.2%)
Xu (Institute of Blood Transfusion) ¹⁶⁶	2020-03-23 to 2020-04-02	Guangdong	Local	High	2199	Median 34 (Range 18 to 59)	32.3	Simplified probability	Blood donors	0.3% (0.1- 0.7%)	Wantai Biological Pharmacy Enterprise;	75.6, 97.6 (Used Bastos SR/MA data; no sens,	0.1% (0.0- 0.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
											Lizhu Diagnostics Wantai SARS CoV-2 Total Antibody ELISA IgA; IgG	spec, or author adjustment available)	
To (Queen Mary Hospital) ¹⁶⁷	2020-03-04 to 2020-03-17	Hubei	Regional	Moderate	452	Median 41 (NR)	58.6	Convenience	Household and community samples	2.9% (1.5-4.9%)	Author-designed Not Reported IgG	73.3, 100.0 (Test developer / manufacturer evaluation)	3.6% (1.5-6.1%)
Chang (Beijing Hospital) ¹⁶³	2020-01-23 to 2020-03-15	Hebei Shijiazhuang	Local	High	13540	Median 40 (IQR 33-48)	17.7	Sequential	Blood donors	0.0% (0.0-0.0%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgA; IgG; IgM	93.1, 99.1 (FINDDx / MUHC independent evaluation)	0.0% (0.0-0.0%)
Chang (Beijing Hospital) ¹⁶³	2020-02-02 to 2020-03-15	Guangdong Shenzhen	Local	High	6810	Median 36 (IQR 19-53)	35.0	Sequential	Blood donors	0.0% (0.0-0.1%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA IgA; IgG; IgM	93.1, 99.1 (FINDDx / MUHC independent evaluation)	0.0% (0.0-0.0%)
To (Queen Mary Hospital) ¹⁶⁷	2020-02-01 to 2020-02-13	Hong Kong	Regional	High	233	NR	nan	Sequential	Household and community samples	0.4% (0.0-2.4%)	Author-designed Not Reported IgG	73.3, 100.0 (Test developer / manufacturer evaluation)	1.0% (0.0-2.2%)
To (Queen Mary Hospital) ¹⁶⁷	2020-01-01 to 2020-01-31	Hong Kong	Regional	High	580	NR	nan	Sequential	Household and community samples	2.6% (1.5-4.2%)	Author-designed Not Reported IgG	73.3, 100.0 (Test developer / manufacturer evaluation)	3.2% (1.1-5.2%)
Hallowell (US Centers for Disease Control and Prevention) ¹⁶⁸	2020-01-28 to 2020-01-28	Hubei Wuhan	Sublocal	Moderate	186	Median 42.0 (NR)	47.8	Convenience	Household and community samples	0.5% (0.0-3.0%)	SeraCare Life Sciences HRP-conjugated anti human	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or	0.8% (0.0-2.0%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
											IgM/IgA/IgG IgG; IgA; IgM	author adjustment available)	
Malaysia													
Sam (University Malaya) ¹⁶⁹	2020-01-29 to 2020-06-06	Selangor	Regional	High	588	NR	62.6	Convenience	Residual sera	0.4% (0.1-1.3%)	Author-designed N/A - Author-designed IgG	97.0, 100.0 (Test developer / manufacturer evaluation)	0.4% (0.0-0.8%)
Sub-Saharan Africa													
Ethiopia													
Kempen (Kuwait University) ¹⁷⁰	2020-05-18 to 2020-05-21	Oromia Addis Ababa	Local	High	99	(n=99)	nan	Convenience	Residual sera	3.0% (0.6-8.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	6.4% (0.1-12.3%)
Kenya													
Uyoga (KEMRI-Wellcome Trust Research Programme) ¹⁷¹	2020-04-30 to 2020-06-16	Rift Valley, Coast, Central, Nyanza	National	High	3098	15-24 (n=808); 25-34 (n=1242); 35-44 (n=714); 45-54 (n=263); 55-64 (n=71)	18.0	Convenience	Blood donors	4.9% (4.2-5.7%)	Krammer Krammer Enzyme linked Immunosorbent assay IgG	83.0, 99.0 (Test developer / manufacturer evaluation)	5.2% (3.4-6.9%)
Nigeria													
Majiya (Ibrahim Badamasi Babangida University) ¹⁷²	2020-06-26 to 2020-06-30	Niger State	Regional	Moderate	185	NR	44.3	Stratified probability	Household and community samples	25.4% (19.3-32.3%)	Cambridge Network COVID-19 IgG and IgM Rapid Test IgG	100.0, 100.0 (Author-reported independent evaluation)	18.7% (3.8-31.5%)

Supplementary Table 2. Characteristics of studies in the special populations and primary seroprevalence estimates

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Central Europe, Eastern Europe, and Central Asia													
Armenia													
Grigoryan (Ministry of Health of the Republic of Armenia) ¹⁷³	Until 2020-06-29	Yerevan	Local	High	380	NR	nan	Convenience	Health care workers and caregivers	16.1% (12.5-20.1%)	Not reported Not Reported Not reported	100.0, 99.8 (Test developer / manufacturer evaluation)	14.3% (10.4-18.9%)
Bulgaria													
Tsaneva-Damyanova (Medical Diagnostic Laboratory "STATUS") ¹⁷⁴	2020-03-26 to 2020-04-20	Varna Varna	Local	High	586	NR	56.1	Self-referral	Patients seeking care for non-COVID-19 reasons	4.8% (3.2-6.9%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	6.3% (0.3-11.4%)
Croatia													
Vilibic-Cavlek (University of Zagreb) ¹⁷⁵	2020-04-25 to 2020-05-24		National	High	592	20-65	74.3	Convenience	Health care workers and caregivers	2.7% (1.6-4.3%)	Vircell Spain S.L.U Not Reported IgG	74.0, 97.0 (FINDDx / MUHC independent evaluation)	1.3% (0.0-2.6%)
Jerkovic (University of Split) ¹⁷⁶	2020-04-23 to 2020-04-28	Split-Dalmatia County, Šibenik-Knin County	Local	High	1494	Median 46 (Range 19-79)	11.9	Convenience	Essential non-healthcare workers	1.3% (0.8-2.0%)	AMP Diagnostics AMP Rapid Test SARS-CoV-2 IgG/IgM IgM; IgG	91.8, 96.4 (Test developer / manufacturer evaluation)	0.4% (0.0-0.9%)
Czechia													
Malickova (Clinical and Research Center for Inflammatory Bowel Disease) ¹⁷⁷	Until 2020-04-15	Central Bohemian Prague	Sublocal	Unclear	92	Median 45 (IQR 38-57)	71.7	Convenience	Health care workers and caregivers	2.2% (0.3-7.6%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	1.9% (0.0-4.4%)
Romania													
MedLife (MedLife) ¹⁷⁸	2020-03-24 to 2020-04-21	Nord-Est, Sud-Est, Sud-Mutenia, Sud-Vest Oltenia,	National	Unclear	371	NR	nan	Convenience	Health care workers and caregivers	3.0% (1.5-5.2%)	Abbott; Maglumi; YHLO Multiple tests used in combination IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec,	1.1% (0.0-2.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
		Vest, Nord-Vest, Centru, Bucuresti-Ilfov Bucharest, Arad, Brasov, Sibiu, Piatra Neamt, Braila, Timisoara, Pitesti, Galati, Targoviste, Ploiesti										or author adjustment available)	
High-income													
Argentina													
Figar (Minister of Health, Buenos Aires City) ¹⁷⁹	2020-06-10 to 2020-07-01	Buenos Aires Buenos Aires	Sublocal	High	60	NR	nan	Convenience	Persons living in slums	36.0% (24.0-49.4%)	Laboratio Lemos COVIDAR IgG ELISA IgG	95.0, 100.0 (Test developer / manufacturer evaluation)	38.7% (26.5-50.3%)
Figar (Minister of Health, Buenos Aires City) ¹⁷⁹	2020-06-10 to 2020-07-01	Buenos Aires Buenos Aires	Sublocal	Moderate	873	Median 38 (IQR 28-49)	57.2	Simplified probability	Persons living in slums	53.4% (50.0-56.8%)	Laboratio Lemos COVIDAR IgG ELISA IgG	95.0, 100.0 (Test developer / manufacturer evaluation)	58.7% (51.6-64.8%)
Australia													
Macartney (University of Sydney) ¹⁸⁰	2020-01-25 to 2020-04-10	New South Wales	Regional	Moderate	173	NR	nan	Convenience	Contacts of COVID patients	2.3% (0.6-5.8%)	Author-designed N/A - Author-designed IgG; IgA; IgM	91.3, 98.9 (Test developer / manufacturer evaluation)	1.6% (0.0-3.2%)
Austria													
Hackner (Karl Landsteiner University of Health Sciences) ¹⁸¹	2020-04-01 to 2020-04-30		Sublocal	High	130	Median 41 (Range 19-64)	76.9	Convenience	Health care workers and caregivers	2.3% (0.5-6.6%)	Epitope Diagnostics Not Reported IgG; IgM	75.4, 89.8 (FINDDx / MUHC independent evaluation)	1.4% (0.0-3.1%)
Reiter (Medical University of Vienna) ¹⁸²	2020-03-15 to 2020-03-29		Sublocal	High	235	Mean 44.2 (SD 11.4)	70.2	Convenience	Health care workers and caregivers	25.5% (20.1-31.6%)	ImmunoDiagnostics ImmunoDiagnostics test system IgG IgM IgM; IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec,	31.2% (24.9-37.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												or author adjustment available)	
Orth-Höller (Innsbruck Clinical Microbiology Laboratory) ¹⁸³	2020-03-20 to 2020-03-27	Tyrol	Regional	High	377	Median 51 (NR)	46.7	Convenience	Health care workers and caregivers	0.3% (0.0-1.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	0.4% (0.0-1.0%)
Belgium													
Blairon (Iris Hospitals South) ¹⁸⁴	2020-05-25 to 2020-06-19	Brussels	Local	High	1485	Median 47.45 (Males); 43.90 (Females) (Range 46.00-48.84 (Males); 42.80-45.10 (Females))	73.1	Convenience	Health care workers and caregivers	14.6% (12.9-16.5%)	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	11.9% (6.0-18.8%)
Berardis (Cliniques universitaires Saint-Luc) ¹⁸⁵	2020-04-16 to 2020-05-19		Local	High	149	Mean 24.9 (SD 15)	49.0	Convenience	Patients seeking care for non-COVID-19 reasons	2.7% (0.7-6.8%)	SNIBE – Shenzhen New Industries Biomedical Engineering Co., Ltd MAGLUMI 2019-nCov IgG/IgM CLIA IgG; IgM	95.6, 96.0 (Test developer / manufacturer evaluation)	1.6% (0.0-3.4%)
Martin (Université Libre de Bruxelles) ¹⁸⁶	2020-04-15 to 2020-05-18	Brussels City of Brussels	Local	High	326	Mean 37 (Range 21-66)	73.3	Convenience	Health care workers and caregivers	11.0% (7.8-14.9%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	42.9, 98.0 (FINDDx / MUHC independent evaluation)	22.0% (8.8-34.6%)
Steensels (ZiekenhuisOost-Limburg) ¹⁸⁷	2020-04-22 to 2020-04-30	Limburg Genk	Sublocal	High	3056	Mean 39.5 (staff with antibodies); 41.3 (staff without antibodies) (SD 13.1 (staff with antibodies); 12.4 (staff without antibodies))	nan	Convenience	Health care workers and caregivers	6.4% (5.6-7.3%)	Multi-G COVID-19 IgG/IgM Rapid Test Cassette IgG	64.7, 97.1 (FINDDx / MUHC independent evaluation)	4.5% (0.1-8.0%)
Chile													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Torres (Universidade de Chile) ¹⁸⁸	2020-05-04 to 2020-05-19	Santiago Vitacura	Sublocal	High	1009	Mean 10.8 (SD 4.1)	46.0	Stratified probability	Students	9.9% (8.1-11.9%)	Genrui Biotech Genrui Biotech IgG/IgM Test Kit (Colloidal Gold) IgG; IgM	91.0, 95.4 (Test developer / manufacturer evaluation)	5.1% (1.6-8.2%)
Torres (Universidade de Chile) ¹⁸⁸	2020-05-04 to 2020-05-19	Santiago Vitacura	Sublocal	High	235	Mean 42.8 (SD 10.4)	73.2	Stratified probability	Essential non-healthcare workers	16.6% (12.1-22.0%)	Genrui Biotech Genrui Biotech IgG/IgM Test Kit (Colloidal Gold) IgG; IgM	91.0, 95.4 (Test developer / manufacturer evaluation)	13.3% (7.9-18.7%)
Denmark													
Jespersen (Aarhus University Hospital) ⁴¹	2020-05-18 to 2020-06-19	Central Denmark Region	Regional	Moderate	17971	<29 (n=2032); 30-39 (n=3938); 40-49 (n=4735); 50-59 (n=4666); >60 (n=2577)	85.8	Convenience	Health care workers and caregivers	3.7% (3.4-4.0%)	Wantai Biological Pharmacy Enterprise Wantai SARS CoV-2 Total Antibody ELISA Total Antibody	93.1, 99.1 (FINDDx / MUHC independent evaluation)	2.6% (1.2-3.8%)
Iversen (University of Copenhagen) ⁴⁴	2020-04-15 to 2020-04-22	Capital Region of Denmark	Regional	Low	28792	Mean 44.4 (SD 12.6)	78.9	Entire sample	Health care workers and caregivers	4.0% (3.8-4.3%)	Livzon Diagnostics Not Reported IgM; IgG	80.4, 100.0 (FINDDx / MUHC independent evaluation)	4.0% (2.5-5.4%)
France													
Mesnil (Rothschild Foundation Hospital) ¹⁸⁹	2020-06-06 to 2020-06-22	Paris Paris	Sublocal	High	646	Mean 39 (Range 28-50)	73.1	Convenience	Health care workers and caregivers	12.0% (9.6-14.8%)	Roche Elecsys Anti-SARS-CoV-2 Roche COBAS 6000 IgG	99.5, 99.8 (Test developer / manufacturer evaluation)	10.5% (7.0-14.5%)
Fumery (Picardie University) ¹⁹⁰	2020-03-25 to 2020-05-11	Somme Amiens	Sublocal	High	146	Median 38 (Range 17-81)	49.3	Convenience	Patients seeking care for non-COVID-19 reasons	4.8% (2.0-9.6%)	DiaSorin Liaison® SARS-CoV-2 S1/S2 IgG IgG	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	3.4% (0.1-6.1%)
Solodky (Centre Leon Berard) ¹⁹¹	2020-03-01 to	Auvergne-Rhone-Alpes Lyon	Sublocal	High	244	NR	nan	Sequential	Patients seeking care for non-	5.3% (2.9-8.9%)	TODA Pharma TODA Coronadiag IgG; IgM	100.0, 100.0 (Test developer /	4.7% (1.8-7.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
	2020-04-16								COVID-19 reasons			manufacturer evaluation)	
Solodky (Centre Leon Berard) ¹⁹¹	2020-03-01 to 2020-04-16	Auvergne-Rhone-Alpes Lyon	Sublocal	High	85	NR	nan	Self-referral	Health care workers and caregivers	5.9% (1.9-13.2%)	TODA Pharma TODA Coronadiag IgG; IgM	100.0, 100.0 (Test developer / manufacturer evaluation)	4.9% (0.5-8.9%)
Germany													
Epstude (Thuringia Clinic) ¹⁹²	2020-06-15 to 2020-06-30	Thuringia	Sublocal	High	20	Mean 39.4 (SD 10.2)	70.0	Convenience	Health care workers and caregivers	5.0% (0.1-24.9%)	PerkinElmer Inc Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	42.9, 98.0 (FINDDx / MUHC independent evaluation)	20.1% (0.0-42.1%)
Epstude (Thuringia Clinic) ¹⁹²	2020-06-15 to 2020-06-30	Thuringia	Sublocal	High	45	Mean 47.8 (SD 10.4)	86.7	Convenience	Health care workers and caregivers	0.0% (0.0-7.9%)	PerkinElmer Inc Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	42.9, 98.0 (FINDDx / MUHC independent evaluation)	-
Armann (Technische Universität Dresden) ¹⁹³	2020-05-25 to 2020-06-30	Saxony	Regional	High	2045	Median 15 (students); 51 (teachers) (Range 14-16 (students); 37-57 (teachers))	56.7	Convenience	Multiple populations	0.6% (0.3-1.0%)	DiaSorin LIAISON Liaison® SARS- CoV-2 S1/S2 IgG IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	0.2% (0.0-0.4%)
Zöllkau (Universitätsklinikum Jena) ¹⁹⁴	2020-04-06 to 2020-05-13	Thuringia	Local	High	217	NR	82.9	Unclear	Pregnant or parturient women	0.6% (0.0-2.8%)	Epitope Diagnostics Not Reported IgG	80.8, 100.0 (FINDDx / MUHC independent evaluation)	0.9% (0.0-2.0%)
Schmidt (University of Hannover) ¹⁹⁵	2020-04-20 to 2020-04-30	Lower Saxony Hannover	Sublocal	High	385	18-29 (n=55); 30-49 (n=154); 50-64 (n=170); >=65 (n=6)	80.0	Convenience	Health care workers and caregivers	2.9% (1.4-5.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	1.5% (0.0-3.2%)
Korth (University Hospital Essen) ¹⁹⁶	2020-03-25 to 2020-04-21	North Rhine Essen	Sublocal	High	316	Mean 36.7 (Average age of high-risk group); 42.3	64.6	Convenience	Health care workers and caregivers	1.6% (0.5-3.7%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2-IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	1.0% (0.0-2.2%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						(Average age of low-risk group) (SD 10.7 (SD of high-risk group); 13.2 (SD of low-risk group))							
Harsch (Thuringia Clinic) ¹⁹⁷	2020-04-16 to 2020-04-21	Thuringia Saalfeld	Sublocal	High	18	Mean 44.9 (Range 21-60)	nan	Convenience	Health care workers and caregivers	0.0% (0.0-18.5%)	EUROIMMUN EUROIMMUN™ IgG	42.9, 98.0 (FINDDx / MUHC independent evaluation)	-
Behrens (Hannover Medical School) ^{198,199}	2020-03-23 to 2020-04-17	Lower Saxony	Local	High	217	Mean 36.5 (Range 18-63)	65.0	Self-referral	Health care workers and caregivers	1.4% (0.3-4.0%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	87.2, 99.3 (Test developer / manufacturer evaluation)	1.0% (0.0-2.2%)
Kern (Universitätsmedizin Marburg) ²⁰⁰	2020-04-09 to 2020-04-16		Sublocal	High	1780	10-19 (n=52, 2.9%), 20-29 (n=422, 23.7%), 30-39 (n=378, 21.2%), 40-49 (n=347, 19.5%), 50-59 (n=431, 24.2%), 60-69 (n=150, 8.4%)	79.8	Unclear	Multiple populations	1.0% (0.6-1.5%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 IgG IgA ELISA IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	0.4% (0.0-0.8%)
Kraehling (Goethe-University Frankfurt) ²⁰¹	2020-04-06 to 2020-04-14	Hesse Frankfurt	Local	Moderate	998	<30 (n=115); 30-40 (n=172); 41-50 (n=213); 51-60 (n=399); >60 (n=101)	21.5	Self-referral	Essential non-healthcare workers	0.4% (0.1-1.0%)	Author-designed N/A - Author-designed IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.2% (0.0-0.4%)
Lackermair (University Hospital Munich) ²⁰²	2020-04-02 to 2020-04-06	Bavaria	Regional	High	151	Mean 38 (Range 26-47)	83.4	Convenience	Health care workers and caregivers	2.6% (0.7-6.6%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	42.9, 98.0 (FINDDx / MUHC independent evaluation)	3.8% (0.0-8.0%)
Greece													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Psichogiou (National and Kapodistrian University of Athens) ²⁰³	2020-04-13 to 2020-05-15	Attica Athens	Local	Moderate	1495	Mean 46.4 (NR)	69.7	Convenience	Health care workers and caregivers	1.1% (0.6-1.7%)	Genebody Inc. GeneBody COVID-19 IgM/IgG detection IgG; IgM	87.0, 100.0 (Used author-adjusted estimate)	1.1% (0.7-1.6%)
Italy													
Norsa (Papa Giovanni XXII) ²⁰⁴	2020-03-04 to 2020-07-10	Lombardy	Sublocal	High	90	<28 (n=32); 38-47 (n=27); >47 (n=31)	46.7	Convenience	Patients seeking care for non-COVID-19 reasons	21.1% (13.2-31.0%)	VivaChek VivaDiag COVID-19 IgM/IgG Rapid Test IgG; IgM	65.3, 94.9 (FINDDx / MUHC independent evaluation)	25.0% (12.1-39.5%)
Cosma (University of Turin) ²⁰⁵	2020-04-16 to 2020-06-04	Piedmont Turin	Local	High	138	NR	100.0	Sequential	Pregnant or parturient women	5.8% (2.5-11.1%)	Boditech AFIAS™ COVID-19 IgG	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	4.3% (0.0-8.2%)
Lorenzo (Santagostino Medical Center) ²⁰⁶	2020-05-02 to 2020-05-31	Lombardy Milan	Local	High	119	Mean 47 (healthcare workers); 79 (family member old); 42 (family member middle age); 11 (family member youth) (SD 18 (health care workers); 6 (family member old); 12 (family member middle age); 7 (family member young);)	54.6	Convenience	Multiple populations	42.6% (33.6-52.0%)	Prima Lab IgM/IgG serological rapid tests IgM; IgG	79.1, 85.4 (FINDDx / MUHC independent evaluation)	45.7% (27.5-64.2%)
Cavaliere (Santo Stefano Hospital) ²⁰⁷	2020-04-04 to 2020-05-16	Tuscany	Local	High	134	NR	100.0	Sequential	Pregnant or parturient women	4.5% (1.7-9.5%)	Acro Biotech Inc. COVID-19 IgG/IgM Rapid Test Cassette IgG; IgM	37.0, 93.7 (FINDDx / MUHC independent evaluation)	6.9% (0.0-15.8%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Sandri (Humanitas Clinical and Research Center) ²⁰⁸	2020-04-28 to 2020-05-16	Lombardy Milan, Rozzano, Varese, Castellanza, Bergamo	Regional	Moderate	3985	Median 42 (Range 21-86)	66.8	Self-referral	Health care workers and caregivers	13.1% (12.1-14.2%)	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	9.9% (4.2-15.6%)
Denina (University of Turin) ²⁰⁹	2020-03-08 to 2020-04-30		Local	High	24	Mean 13 (Range 6-17)	66.7	Convenience	Patients seeking care for non-COVID-19 reasons	12.5% (2.7-32.4%)	DiaSorin Liaison® SARS- CoV-2 S1/S2 IgG IgG	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	13.8% (2.3-24.3%)
Vena (University of Genoa) ²¹⁰	2020-03-01 to 2020-04-30	Lombardy, Liguria	Regional	High	3609	Median 51 (IQR 41-63)	55.6	Convenience	Patients seeking care for non-COVID-19 reasons	11.0% (10.0-12.1%)	Maglumi; Realy-Tech; Biosynex MAGLUMI800TM 2019- nCoV IgG (Cat. Ref. 130219015M) and IgM (130219016M); Realy-Tech 2019 nCOV/COVID-19 IgG/IgM Rapid Test; Biosynex COVID-19 BSS test IgG; IgM	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	12.1% (10.5-13.8%)
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	6059	NR	nan	Convenience	Health care workers and caregivers	2.2% (1.8-2.6%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	1.7% (0.0-3.4%)
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	5456	NR	nan	Convenience	Health care workers and caregivers	5.2% (4.6-5.8%)	Screen Italia S.R.L Screen Test COVID-19 2019-nCoV IgG/IgM IgG; IgM	99.0, 88.0 (Author-reported independent evaluation)	-
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	652	NR	nan	Convenience	Health care workers and caregivers	2.0% (1.1-3.4%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	2.0% (0.0-4.1%)
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	1193	NR	nan	Convenience	Health care workers and caregivers	3.9% (2.9-5.2%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	4.2% (0.0-7.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	3518	NR	nan	Convenience	Health care workers and caregivers	1.6% (1.2-2.1%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	1.2% (0.0-2.5%)
Carozzi (Arezzo Hospital) ²¹¹	2020-04-01 to 2020-04-30	Tuscany	Regional	High	220	NR	nan	Convenience	Health care workers and caregivers	1.8% (0.5-4.6%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	2.3% (0.0-5.0%)
Volta (University of Brescia) ²¹²	2020-04-27 to 2020-04-27	Lombardy	Sublocal	High	76	Median 46 (IQR 23-69)	75.0	Convenience	Health care workers and caregivers	11.8% (5.5-21.2%)	DiaSorin Not Reported IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	8.8% (0.2-16.1%)
Lahner (University of Rome) ²¹³	2020-04-07 to 2020-04-27	Lazio Rome	Sublocal	High	1084	Median 46 (Range 19-69)	60.9	Convenience	Health care workers and caregivers	0.7% (0.3-1.4%)	Medical Systems 2019-nCoV IgM/IgG CLIA IgG	50.0, 99.1 (Author-reported independent evaluation)	0.5% (0.0-1.1%)
Landro (Hospital of Bergamo) ⁵⁹	Until 2020-04-24	Lombardy Bergamo	Sublocal	Unclear	3000	NR	nan	Unclear	Health care workers and caregivers	13.0% (11.8-14.3%)	Not reported Not Reported Not reported	No data	-
Paradiso (Istituto Tumori G. Paolo II) ²¹⁴	2020-03-26 to 2020-04-17	Puglia Bari	Sublocal	High	606	Median 47.5 (Range 20-73)	60.6	Convenience	Health care workers and caregivers	0.3% (0.0-1.2%)	Snibe Diagnostic MAGLUMI800TM IgG	71.0, 98.0 (FINDDx / MUHC independent evaluation)	0.3% (0.0-0.7%)
Sotgiu (Università degli Studi di Milano) ²¹⁵	2020-04-02 to 2020-04-16	Lombardy	Local	High	202	20-29 (n=27); 30-39 (n=44); 40-49 (n=57); 50-59 (n=51); 60-69 (n=23)	65.3	Convenience	Health care workers and caregivers	7.4% (4.2-11.9%)	BioMedomics BioMedomics IgM-IgG Combined Antibody Rapid Test IgG	55.5, 96.3 (FINDDx / MUHC independent evaluation)	7.0% (0.0-12.5%)
Amendola (University of Milan) ²¹⁶	2020-04-15 to 2020-04-15	Lombardy	Sublocal	High	663	Median 44 (NR)	83.7	Convenience	Health care workers and caregivers	5.1% (3.6-7.1%)	EUROIMMUN Euroimmun Anti-SARS-CoV-2 ELISA IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	2.8% (0.0-5.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Fusco (D. Cotugno' Hospital) ²¹⁷	2020-03-23 to 2020-04-02	Campania Naples	Sublocal	High	115	Median 43 (IQR 32-51.5)	48.7	Convenience	Health care workers and caregivers	1.7% (0.2-6.1%)	Snibe Diagnostic MAGLUMI 2019-nCoV IgG (CLIA) IgG	73.0, 99.0 (FINDDx / MUHC independent evaluation)	2.6% (0.0-5.4%)
Pancrazzi (Ospedale San Donato) ²¹⁸	2020-03-17 to 2020-03-21	Tuscany	Local	High	516	Mean 53.7 years (NR)	54.5	Sequential	Patients seeking care for non-COVID-19 reasons	13.0% (10.2-16.2%)	Acro Biotech Inc. Acro Biotech COVID-19 Rapid Test IgG; IgM	37.0, 93.7 (FINDDx / MUHC independent evaluation)	29.5% (7.4-50.1%)
Japan													
Chong (Kanenokuma Hospital) ²¹⁹	2020-06-12 to 2020-06-15	Kyushu	Sublocal	High	108	NR	nan	Convenience	Multiple populations	2.8% (0.6-7.9%)	Hangzhou Alltest Biotech Co. Ltd. All Test@2019-nCoV IgG/IgM RapidTest Cassette IgG	59.9, 100.0 (FINDDx / MUHC independent evaluation)	5.0% (0.1-9.3%)
Suda (Hokkaido University Graduate School of Medicine) ²²⁰	2020-05-01 to 2020-05-31	Hokkaido	Sublocal	High	300	Mean 66.5 (Range 20-84)	42.0	Unclear	Patients seeking care for non-COVID-19 reasons	0.0% (0.0-1.2%)	Roche Diagnostics Elecsys Anti-SARS-Cov2 Immunoassay IgG	83.9, 100.0 (FINDDx / MUHC independent evaluation)	0.3% (0.0-0.9%)
Nakamura (Iwate Prefectural Central Hospital) ²²¹	2020-05-18 to 2020-05-29	Honshu Iwate	Local	High	1000	Mean 40 (SD 11)	73.6	Convenience	Health care workers and caregivers	0.0% (0.0-0.4%)	Roche elecsys Roche Elecsys® Anti-SARS-CoV-2 RUO Assay IgM; IgG	83.9, 100.0 (FINDDx / MUHC independent evaluation)	0.1% (0.0-0.3%)
Jiji (SoftBank) ^{222,223}	2020-05-12 to 2020-05-18		Sublocal	Unclear	44066	NR	nan	Convenience	Multiple populations	0.4% (0.4-0.5%)	Innovita; Zhejiang Orient Gene Biotech Co., LTD Not Reported Not reported	No data	-
Fujita (National Hospital Organization Kyoto Medical Center) ²²⁴	2020-04-10 to 2020-04-20	Kansai Kyoto	Sublocal	High	92	20-29 (n=30); 30-39 (n=29); 40-49 (n=21); >=50 (n=12)	64.1	Stratified non-probability	Health care workers and caregivers	5.4% (1.8-12.2%)	DRG International COVID-19 IgG ELISA kits IgG	83.3, 100.0 (FINDDx / MUHC independent evaluation)	5.1% (0.3-9.4%)
Doi (Kobe City Medical Center General Hospital) ²²⁵	2020-03-31 to 2020-04-07	Hyogo Prefecture Kobe	Local	High	1000	0-10 (n=81); 0-19 (n=27); 20-29 (n=36); 30-39 (n=90); 40-49	51.1	Simplified probability	Patients seeking care for non-COVID-19 reasons	2.7% (1.8-3.9%)	Kurabo Industries SARS-CoV-2 Antibody Testing Kit IgG (RC - NC002) IgG	76.4, 100.0 (Test developer / manufacturer evaluation)	2.8% (0.6-4.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						(n=155); 50-59 (n=164); 60-69 (n=171); 70-79 (n=166); 80-89 (n=164); >=90 (n=19)							
Suda (Hokkaido University Graduate School of Medicine) ²²⁰	2020-03-01 to 2020-03-31	Hokkaido	Sublocal	High	300	Mean 68 (Range 20-80)	49.0	Unclear	Patients seeking care for non-COVID-19 reasons	0.3% (0.0-1.8%)	Roche Diagnostics Elecsys Anti-SARS-Cov2 Immunoassay IgG	83.9, 100.0 (FINDDx / MUHC independent evaluation)	0.3% (0.0-0.9%)
Netherlands													
Westerhuis (Erasmus Medical Centre) ²²⁶	2020-04-03 to 2020-04-07		Sublocal	High	729	6-12 months (n=17); 1-2 (n=14); 2-5 (n=24); 5-10 (n=34); 10-20 (n=139); 20-40 (n=140); 40-60 (n=140); 60-80 (n=139); 80+ (n=82)	nan	Convenience	Patients seeking care for non-COVID-19 reasons	2.3% (1.3-3.7%)	Author-designed N/A - Author-designed IgG	No data	-
Westerhuis (Erasmus Medical Centre) ²²⁶	2020-03-02 to 2020-03-06		Sublocal	High	879	6-12 months (n=41); 1-2 (n=75); 2-5 (n=42); 5-10 (n=96); 10-20 (n=131); 20-40 (n=131); 40-60 (n=134); 60-80 (n=124); 80+ (n=105)	nan	Convenience	Patients seeking care for non-COVID-19 reasons	0.1% (0.0-0.6%)	Author-designed N/A - Author-designed IgG	No data	-
Norway													
Cox (University of Bergen) ²²⁷	2020-02-28 to 2020-04-04	Western Norway Bergen	Local	High	77	NR	nan	Entire sample	Contacts of COVID patients	31.0% (20.9-42.6%)	Amant et al. N/A - Author-designed IgM; IgG; IgA	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author)	38.2% (26.5-49.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Republic of Korea													
Song (Daegu Catholic University Hospital) ²²⁸	2020-05-25 to 2020-06-05	North Gyeongsang	Local	High	198	Mean 51.7 (Range 18-82)	50.0	Convenience	Patients seeking care for non-COVID-19 reasons	7.6% (4.3-12.2%)	Shin Jin Medics Inc DIAKEY COVID-19 IgM/IgG Rapid Test Kit IgG	100.0, 92.0 (Author-reported independent evaluation)	2.7% (0.0-5.6%)
Singapore													
Kurohi (Singapore National Centre for Infectious Diseases) ⁷³	2020-02-15 to 2020-04-15	Singapore	Sublocal	Unclear	1096	NR	nan	Unclear	Health care workers and caregivers	0.0% (0.0-0.3%)	Not reported Not Reported Not reported	No data	-
Spain													
Fernández-Rivas (Institut Catala de la Salut) ²²⁹	2020-05-04 to 2020-05-22	Catalonia Barcelona	Local	Moderate	7563	Mean 43.81 (SD 12.43)	76.0	Self-referral	Health care workers and caregivers	9.4% (8.8-10.1%)	DiaSorin LIAISON Liaison® SARS- CoV-2 S1/S2 IgG IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	5.5% (1.0-9.5%)
Soriano (Universidad Autónoma de Madrid) ²³⁰	2020-04-26 to 2020-05-16	Community of Madrid Madrid	Local	High	674	Median 42 (Range 18-89)	70.2	Sequential	Multiple populations	13.8% (11.3-16.6%)	PCL Inc. PCL COVID19 IgG/IgM Rapid Gold IgG; IgM	92.9, 96.2 (FINDDx / MUHC independent evaluation)	10.1% (5.0-14.9%)
Fernandez (Hospital Universitario de Fuenlabrada) ²³¹	2020-04-14 to 2020-05-13		Sublocal	High	2439	Mean 42.1 (Range 18-65)	78.4	Convenience	Health care workers and caregivers	16.9% (15.4-18.4%)	Snibe Diagnostic MAGLUMI 2019-nCov IgG/IgM CLIA IgG	93.2, 99.2 (FINDDx / MUHC independent evaluation)	16.3% (14.1-18.9%)
Valdivia (Hospital Clínico Universitario) ²³²	2020-04-13 to 2020-04-30	Valencia	Local	High	1153	NR	nan	Unclear	Health care workers and caregivers	3.5% (2.5-4.7%)	Snibe Diagnostic MAGLUMI 2019-nCov IgG/IgM CLIA IgG; IgM	95.6, 96.0 (Test developer / manufacturer evaluation)	1.1% (0.0-2.2%)
Galan (Hospital Universitario Fundación Alcorcón) ²³³	2020-04-14 to 2020-04-27	Community of Madrid Madrid	Sublocal	High	2590	Mean 43.8 (SD 11.1)	73.9	Convenience	Health care workers and caregivers	31.6% (29.8-33.4%)	Diapro anti-SARS-CoV-2 IgG IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author)	39.8% (37.4-42.4%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Olalla (Hospital Costa del Sol) ²³⁴	2020-04-15 to 2020-04-25		Sublocal	High	498	Mean 41.5 (95% CI 40.8-42.3)	71.1	Self-referral	Health care workers and caregivers	2.2% (1.1-3.9%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG/IgM Rapid Test IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	2.1% (0.0-4.5%)
Martin (Gerencia de Atención Primaria del Área de Salud de León, Spain) ²³⁵	2020-04-01 to 2020-04-15	León León	Local	High	676	Mean 48.5 (SD 12.8)	74.1	Convenience	Health care workers and caregivers	5.9% (4.3-8.0%)	Hangzhou All Test Biotech Co Ltd All Test@2019-nCoV IgG/IgM RapidTest Cassette IgG; IgM	100.0, 100.0 (FINDDx / MUHC independent evaluation)	5.1% (2.8-7.5%)
Garcia-Basteiro (Universitat de Barcelona) ²³⁶	2020-03-28 to 2020-04-09	Catalonia Barcelona	Sublocal	Moderate	578	Mean 42.1 (SD 11.6)	72.1	Simplified probability	Health care workers and caregivers	9.3% (7.1-12.0%)	Author-designed N/A - Author-designed IgG; IgM; IgA	97.0, 98.0 (Test developer / manufacturer evaluation)	6.2% (1.8-10.3%)
Sweden													
Lidström (Uppsala University) ²³⁷	2020-05-27 to 2020-06-25	Uppsala	Regional	Moderate	8679	Mean 45 (IgG negative); 42 (IgG positive) (Range 18-85 (IgG negative); 18-78 (IgG positive))	76.7	Entire sample	Health care workers and caregivers	6.6% (6.1-7.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	15.2% (11.3-19.8%)
Rudberg (Danderyd Hospital) ²³⁸	2020-04-14 to 2020-05-08	Uppland Stockholm	Local	Moderate	2149	Mean 44 (SD 12)	84.5	Convenience	Health care workers and caregivers	19.1% (17.5-20.8%)	Author-designed Author-designed IgG	99.4, 99.1 (Test developer / manufacturer evaluation)	18.4% (16.7-20.0%)
Lindahl (Uppsala University) ²³⁹	2020-04-01 to 2020-04-20		Local	High	1005	36-50 (n=133/332); 51-65 (n=116/332)	24.3	Convenience	Health care workers and caregivers	23.3% (20.7-26.0%)	Zhejiang Orient Gene Biotech Co Ltd COVID-19 IgG / IgM Rapid Test Cassette IgG; IgM	43.4, 97.7 (FINDDx / MUHC independent evaluation)	55.0% (37.2-72.9%)
United Kingdom													

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Gulraj (Gibraltar Government) ²⁴⁰	2020-06-03 to 2020-06-17	Gibraltar	Local	Unclear	1247	NR	nan	Convenience	Health care workers and caregivers	1.4% (0.8-2.2%)	Not reported Not Reported IgG	No data	-
Pallett (Chelsea and Westminster Hospital NHS Trust) ²⁴¹	2020-04-08 to 2020-06-12	England	Local	High	504	Mean 42.4 (Range 20.3-72.1)	59.1	Convenience	Health care workers and caregivers	10.6% (8.1-13.6%)	CTK Biotech ; Zhuhai Encode Medical Engineering Onsite CTK Biotech COVID-19 split IgG/IgM Rapid Test; Encode SARS-CoV-2 split IgM/IgG One Step Rapid Test Device IgG; IgM	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.5% (7.8-15.2%)
Eyre (Oxford University Hospital) ²⁴²	2020-04-23 to 2020-06-08	England	Local	Moderate	9958	NR	nan	Convenience	Health care workers and caregivers	9.6% (9.0-10.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	22.8% (16.7-28.3%)
Bampoe (University College London) ²⁴³	2020-05-11 to 2020-06-05	England	Sublocal	High	200	Mean 37 (IQR 30-37)	83.5	Unclear	Health care workers and caregivers	14.5% (9.9-20.2%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	35.3% (21.6-48.0%)
Grant (Whittington Health NHS Trust) ²⁴⁴	2020-05-15 to 2020-06-05	England	Sublocal	High	2004	Mean 40.21 (Range 18-73)	nan	Self-referral	Health care workers and caregivers	31.6% (29.6-33.7%)	Roche Diagnostics Elecsys Anti-SARS-Cov2 Immunoassay IgG; IgM	83.9, 100.0 (FINDDx / MUHC independent evaluation)	38.3% (34.5-42.3%)
Khalil (St George's University of London) ²⁴⁵	2020-05-15 to 2020-05-28	England	Sublocal	High	190	NR	nan	Convenience	Health care workers and caregivers	22.0% (16.3-28.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	54.1% (36.5-70.8%)
Poulikakos (Salford Royal NHS Foundation Trust) ²⁴⁶	2020-05-04 to 2020-05-06	England Northwest England	Sublocal	High	281	NR	73.0	Convenience	Health care workers and caregivers	6.0% (3.5-9.5%)	Snibe Diagnostic MAGLUMI 2019-nCoV IgG (CLIA) IgG	73.0, 99.0 (FINDDx / MUHC independent evaluation)	5.9% (0.9-10.2%)
Shields (University of Birmingham) ²⁴⁷	2020-04-25 to 2020-04-26	England Birmingham	Local	High	516	Median 42 (IQR 30-51)	75.2	Convenience	Health care workers and caregivers	24.4% (20.8-28.3%)	University of Birmingham Not Reported IgA; IgG; IgM	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author)	29.9% (25.6-34.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Sikora (Rutherford Health) ²⁴⁸	2020-04-14 to 2020-04-24	England Reading, Newport, Liverpool, Bedlington	Local	High	161	Mean 43 (NR)	50.3	Convenience	Health care workers and caregivers	1.2% (0.2-4.4%)	Sugentech Sugentech SGTi-flex COVID-19 IgM/IgG IgG	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	1.1% (0.0-2.5%)
Public Health England ⁸³	2020-03-26 to 2020-04-08	England London	Sublocal	High	181	Median 34 (IQR 29-44)	67.4	Convenience	Health care workers and caregivers	45.0% (37.6-52.6%)	Not reported Not reported IgG; IgA; IgM	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	57.9% (50.1-66.6%)
Favara (The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust) ^{249 250}	2020-06-01 to 2006-07-20	England	Sublocal	High	70	NR	nan	Unclear	Health care workers and caregivers	21.4% (12.5-32.8%)	Unclear Luminex SARS-CoV-2 IgG multiplex particle-based flow cytometry assay IgG	84.0, 100.0 (Test developer / manufacturer evaluation)	24.9% (13.7-35.8%)
United States of America													
McBride (Memorial Sloan Kettering Cancer Center) ²⁵¹	2020-05-07 to 2020-06-25	New York	Sublocal	High	952	NR	nan	Convenience	Patients seeking care for non-COVID-19 reasons	5.5% (4.1-7.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	12.3% (7.7-17.4%)
Muscola (Northwell Health) ²⁵²	2020-04-20 to 2020-06-23	New York Greater New York City	Local	Moderate	40329	Median 42 (IQR 31.5-54.5)	73.7	Convenience	Health care workers and caregivers	13.7% (13.4-14.0%)	EUROIMMUN; Abbott; AnshLabs; Ortho-Clinical Diagnostics; DiaSorin; Roche Euroimmun SARS-CoV-2 ELISA (IgG); AnshLabs SARS-CoV-2 IgG ELISA; Abbott Architect SARS-CoV-2 IgG assay; Ortho-Diagnostics VITROS anti-SARS-CoV-2 IgG assay; VITROS Anti-SARS-CoV-2 Total Reagent Pack; DiaSorin Liaison; Elecsys Anti-SARS-CoV-2 kit IgG	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	12.1% (11.5-12.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Reifer (Sherman Abrams Laboratory) ²⁵³	2020-05-15 to 2020-06-15	New York New York City	Local	Unclear	28523	NR	nan	Unclear	Patients seeking care for non-COVID-19 reasons	44.0% (43.4-44.6%)	DiaSorin LIAISON Liaison® SARS- CoV-2 S1/S2 IgG IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	53.8% (43.4-63.9%)
Brant-Zawadzki (Hoag Memorial Hospital Presbyterian) ²⁵⁴	2020-05-15 to 2020-06-15	California	Local	High	2932	Mean 42.62 (SD 12.12)	72.5	Convenience	Health care workers and caregivers	1.1% (0.7-1.5%)	Ortho-Clinical Diagnostics VITROS Anti-SARS-CoV-2 IgG Reagent Pack IgG	77.4, 99.6 (FINDDx / MUHC independent evaluation)	0.8% (0.0-1.3%)
Dora (Veterans Affairs Healthcare System) ²⁵⁵	2020-06-05 to 2020-06-12	California Los Angeles	Sublocal	High	150	NR	nan	Convenience	Assisted living and long-term care facilities	17.3% (11.6-24.3%)	DiaSorin DiaSorin Liaison IgG	65.0, 100.0 (FINDDx / MUHC independent evaluation)	27.0% (15.7-37.6%)
Flannery (University of Pennsylvania) ²⁵⁶	2020-04-04 to 2020-06-03	Pennsylvania Philadelphia	Local	Moderate	1293	Median 31 (IQR 27-35)	100.0	Sequential	Pregnant or parturient women	6.2% (4.9-7.7%)	Author-designed N/A - Author-designed IgG; IgM	100.0, 98.9 (Author-reported independent evaluation)	5.4% (3.8-6.9%)
Gray (Truckee Meadows Fire Protection District) ²⁵⁷	2020-05-01 to 2020-05-31	Nevada Washoe County	Sublocal	High	132	NR	nan	Convenience	Essential non-healthcare workers	14.0% (8.6-21.1%)	Not reported Not Reported Not reported	No data	-
Stavert (Cambridge Health Alliance) ²⁵⁸	2020-04-13 to 2020-05-24	Massachusetts	Sublocal	High	24	11-64	45.8	Convenience	Patients seeking care for non-COVID-19 reasons	0.0% (0.0-14.2%)	DiaSorin DiaSorin Liaison IgG	80.8, 96.0 (FINDDx / MUHC independent evaluation)	-
Staletovich (Coral Springs City Government) ²⁵⁹	2020-05-17 to 2020-05-23	Florida Coral Springs	Local	Unclear	700	NR	nan	Self-referral	Essential non-healthcare workers	0.0% (0.0-0.5%)	Cellex Not Reported Not reported	No data	-
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-14 to 2020-05-22	Michigan Jackson	Sublocal	Unclear	867	NR	nan	Convenience	Persons who are incarcerated	12.0% (9.9-14.4%)	Not reported Not Reported Not reported	No data	-
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-14 to 2020-05-22	Michigan Detroit	Sublocal	Unclear	57	NR	nan	Convenience	Persons who are incarcerated	35.0% (22.8-48.8%)	Not reported Not Reported Not reported	No data	-

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-14 to 2020-05-22	Michigan Lenox Township	Sublocal	Unclear	1201	NR	nan	Convenience	Persons who are incarcerated	66.0% (63.2-68.7%)	Not reported Not Reported Not reported	No data	-
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-14 to 2020-05-22	Michigan Jackson	Sublocal	Unclear	1248	NR	nan	Convenience	Persons who are incarcerated	92.0% (90.4-93.4%)	Not reported Not Reported Not reported	No data	-
Leidner (Chiles Research Institute) ²⁶¹	2020-04-08 to 2020-05-22	Oregon	Regional	High	10019	Median 42 (Range 18-82)	75.7	Convenience	Multiple populations	2.5% (2.2-2.9%)	Author-designed N/A - Author-designed IgG	80.0, 100.0 (Test developer / manufacturer evaluation)	3.3% (2.6-4.0%)
Geraci (MUSC Health-Lancaster) ²⁶²	Until 2020-05-20	South Carolina Lancaster	Sublocal	High	230	NR	nan	Unclear	Health care workers and caregivers	2.2% (0.7-5.0%)	Abbott Not Reported Not reported	No data	-
Mughal (Monmouth Medical Centre) ²⁶³	2020-05-14 to 2020-05-19	New Jersey Long Branch	Sublocal	High	121	Mean 39.2 (IQR 28-48.5)	82.6	Convenience	Health care workers and caregivers	0.8% (0.0-4.5%)	SD Biosensor Standard Q COVID-19 IgM/IgG Duo rapid immunochromatography test kit IgG	96.2, 96.6 (Test developer / manufacturer evaluation)	1.2% (0.0-2.7%)
Dietrich (Tulane University) ²⁶⁴	2020-03-18 to 2020-05-15	Louisiana New Orleans	Local	High	812	Median 11.0 (IQR 4-15)	50.4	Convenience	Patients seeking care for non-COVID-19 reasons	7.6% (5.9-9.6%)	Author-designed N/A - Author-designed IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	7.0% (4.5-9.3%)
Parker-Magyar (Summit Medical Center) ²⁶⁵	2020-05-01 to 2020-05-14	New Jersey Long Hill Township	Sublocal	High	70	NR	nan	Self-referral	Essential non-healthcare workers	4.3% (0.9-12.0%)	Not reported Not Reported Not reported	No data	-
Hunter (Indiana University) ²⁶⁶	2020-04-29 to 2020-05-08	Indiana	Regional	High	734	Mean 42.8 (NR)	70.0	Convenience	Health care workers and caregivers	1.6% (0.8-2.8%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	3.0% (0.3-5.2%)
Ripperger (University of Arizona) ²⁶⁷	2020-04-30 to 2020-05-07	Arizona	Local	High	5882	Median 40 (Range 18-85)	52.4	Self-referral	Multiple populations	1.2% (1.0-1.6%)	Author-designed Author-designed IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author)	0.1% (0.0-0.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Sydney (Jacobi Medical Center) ²⁶⁸	2020-04-28 to 2020-05-04	New York New York City	Sublocal	High	1700	NR	nan	Convenience	Health care workers and caregivers	19.2% (17.4-21.2%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	47.8% (35.5-58.9%)
Reagan (Medical University South Carolina) ²⁶⁹	2020-04-27 to 2020-05-02	South Carolina Charleston	Sublocal	High	920	NR	nan	Unclear	Multiple populations	2.0% (1.2-3.1%)	Abbott Not possible to determine Not reported	No data	-
Jeremias (St Francis Hospital) ²⁷⁰	2020-03-01 to 2020-04-30	New York	Sublocal	High	1699	Mean 42.8 (SD 13.8)	74.1	Convenience	Health care workers and caregivers	9.8% (8.4-11.3%)	EUROIMMUN; Abbott Euroimmun Anti-SARS-CoV-2 ELISA IgG; SARS-CoV-2 IgG IgG	No data	-
Cohen (DaVita Clinical Research) ²⁷¹	2020-04-23 to 2020-04-30	Florida	Local	High	677	Mean 65.7 (SD +/- 14.5 years)	41.1	Convenience	Patients seeking care for non-COVID-19 reasons	5.6% (4.0-7.6%)	Diazyme Laboratories Inc DZ-Lite SARS-CoV-2 IgG IgM CLIA Kit IgG; IgM	57.1, 85.0 (Author-reported independent evaluation)	3.6% (0.0-7.8%)
Payne (US Navy) ²⁷²	2020-04-20 to 2020-04-24	Guam	Sublocal	High	382	Median 30 (IQR 24-35)	24.3	Convenience	Essential non-healthcare workers	59.7% (54.6-64.7%)	CDC CDC Pan-immunoglobulin ELISA IgG; IgM; IgA	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	78.3% (71.8-84.7%)
Kiefer (Ohio State University College of Medicine) ²⁷³	2020-04-23 to 2020-04-23	Ohio Columbus	Sublocal	High	110	Median 34 (IQR 28.8-45.0)	100.0	Convenience	Health care workers and caregivers	20.0% (13.0-28.7%)	Epitope Diagnostics Novel Coronavirus COVID-19 IgG ELISA Kit IgG; IgM	80.8, 100.0 (FINDDx / MUHC independent evaluation)	25.5% (16.2-34.9%)
Slusser (Stanford University) ^{274,275}	2020-04-08 to 2020-04-21		National	Unclear	5603	NR	nan	Convenience	Non-essential workers and unemployed persons	0.7% (0.5-1.0%)	Not reported Not Reported Not reported	No data	-
Morcuende (Columbia University Irving Medical Center)	2020-03-01 to 2020-04-21	New York New York City	Sublocal	High	91	NR	42.9	Convenience	Health care workers and caregivers	12.1% (6.2-20.6%)	Zhejiang Orient Gene Biotech Co., LTD COVID-19 IgG / IgM	93.1, 99.2 (Test developer /	12.4% (5.0-19.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
276											Rapid Test Cassette IgG; IgM	manufacturer evaluation)	
Stock (Albert Einstein College of Medicine) 277	2020-04-04 to 2020-04-20	New York	Local	High	98	Mean 37.6 (SD 10.6)	50.0	Convenience	Health care workers and caregivers	15.3% (8.8-24.0%)	Epitope Diagnostics anti-n IgG ELISA IgG	80.8, 100.0 (FINDDx / MUHC independent evaluation)	18.1% (9.8-26.4%)
Madsen (University of Utah) 278	2020-04-13 to 2020-04-19	Utah Salt Lake City	Sublocal	High	270	NR	nan	Self-referral	Health care workers and caregivers	5.9% (3.4-9.4%)	EUROIMMUN Eurommun Anti-SARS-CoV-2-IgG IgG	76.9, 97.0 (FINDDx / MUHC independent evaluation)	3.5% (0.0-6.7%)
Caban-Martinez (University of Miami) 279	2020-04-16 to 2020-04-17	Florida	Sublocal	High	203	21-30 (n=33); 31-40 (n=51); 41-50 (n=67); 51+ (n=52)	6.4	Convenience	Essential non-healthcare workers	8.9% (5.4-13.7%)	BioMedomics Rapid immunoglobulin (Ig)M-IgG combined point-of-care (POC) lateral flow immunoassay IgG; IgM	64.8, 86.9 (FINDDx / MUHC independent evaluation)	3.1% (0.0-6.8%)
Hains (Icahn School of Medicine at Mount Sinai) 280	2020-04-01 to 2020-04-15	Indiana Indianapolis	Sublocal	High	13	Median 13 (IQR 2-16)	30.8	Convenience	Patients seeking care for non-COVID-19 reasons	23.0% (5.0-53.7%)	Abnova COVID-19 Human IgM IgG Assay Kit IgM; IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	24.2% (2.2-45.2%)
Hains (Icahn School of Medicine at Mount Sinai) 280	2020-04-01 to 2020-04-15	Indiana Indianapolis	Sublocal	High	25	Median 40.5 (IQR 25-61)	88.0	Convenience	Health care workers and caregivers	44.0% (24.4-65.1%)	Abnova COVID-19 Human IgM IgG Assay Kit IgM; IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	57.2% (37.6-79.9%)
Stubblefield (Vanderbilt University Medical Center) 281	2020-04-03 to 2020-04-13	Tennessee Nashville	Sublocal	High	249	Median 33 (Range 21-70)	65.5	Convenience	Health care workers and caregivers	7.6% (4.6-11.6%)	CDC CDC Non-commercial ELISA IgM; IgG; IgA	96.0, 99.0 (Test developer / manufacturer evaluation)	6.6% (3.7-9.6%)
Goldberg (Harvard Medical School) 282	2020-04-01 to 2020-04-06	Massachusetts	Sublocal	High	140	Mean 83 (resident age); 45 (staff) (Range 54-102)	nan	Convenience	Assisted living and long-term care facilities	0.1% (0.0-2.8%)	BioMedomics COVID-19 IgM-IgG Dual Antibody Rapid Test IgG; IgM	64.8, 86.9 (FINDDx / MUHC independent evaluation)	0.8% (0.0-2.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
						(resident); NR (staff))							
Mansour (Icahn School of Medicine at Mount Sinai) ²⁸³	2020-03-24 to 2020-04-04	New York New York City	Local	High	285	Mean 38.36 (NR)	33.3	Self-referral	Health care workers and caregivers	33.0% (27.6-38.8%)	Not reported Not Reported IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	42.0% (35.1-48.1%)
Chu (US Centers for Disease Control and Prevention) ²⁸⁴	2020-01-20 to 2020-02-03	Washington	Regional	High	32	Median 45 (Range 0-78)	nan	Convenience	Contacts of COVID patients	0.0% (0.0-10.9%)	Author-designed CDC SARS-CoV-2 ELISA Not reported	96.0, 99.0 (Test developer / manufacturer evaluation)	-
North Africa and Middle East													
Egypt													
Kassem (Cairo University) ²⁸⁵	2020-06-01 to 2020-06-14		Local	High	74	Median 32 (Range 23-48)	59.5	Convenience	Health care workers and caregivers	12.2% (5.7-21.9%)	Artron Laboratories COVID-19 IgM/IgG antibody rapid diagnostic test IgG; IgM	43.2, 100.0 (FINDDx / MUHC independent evaluation)	29.7% (10.1-47.6%)
Libya													
Kammon (Al-Zintan University) ²⁸⁶	2020-04-02 to 2020-05-18	Libya Alzintan City	Local	High	77	<=40 (n = 59); >40 (n = 18)	29.9	Stratified probability	Health care workers and caregivers	0.0% (0.0-4.7%)	Guangzhou Wondfo Biotech One Step Novel COVID-19 IgM/IgG Antibody Test IgM; IgG	43.2, 100.0 (FINDDx / MUHC independent evaluation)	-
Kammon (Al-Zintan University) ²⁸⁶	2020-04-02 to 2020-05-18	Libya Alzintan City	Local	High	142	<=40 (n = 78); >40 (n = 64)	65.5	Simplified probability	Multiple populations	4.2% (1.6-9.0%)	Guangzhou Wondfo Biotech One Step Novel COVID-19 IgM/IgG Antibody Test IgM; IgG	43.2, 100.0 (FINDDx / MUHC independent evaluation)	9.0% (0.2-16.2%)
Turkey													
Alkurt (University of Health Sciences) ²⁸⁷	2020-05-30 to 2020-06-06		Local	Moderate	813	Mean 34.8 (SD 9.54)	64.0	Convenience	Health care workers and caregivers	2.7% (1.7-4.1%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	5.4% (2.1-8.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
South Asia													
India													
Ray (All India Institute of Medical Sciences) ²⁸⁸	2020-06-08 to 2020-08-08	Punjab	Local	High	212	Mean 41.2 (SD 15.4)	44.8	Convenience	Patients seeking care for non-COVID-19 reasons	19.8% (14.7-25.8%)	Translational Health Science and Technology Institute (THSTI), Faridabad THSTI ELISA IgG IgG	88.2, 99.8 (Test developer / manufacturer evaluation)	21.2% (13.5-27.3%)
Kakani (University of Chicago) ^{152,153}	2020-06-29 to 2020-07-14		Regional	Low	4202	12-24 (n=702); 25-39 (n=1480); 40-60 (n=1695); 60+ (325)	54.3	Stratified probability	Persons living in slums	54.1% (52.6-55.6%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	96.4% (91.9-100.0%)
Unclear (Ahmedabad Municipal Corporation) ²⁸⁹	2020-06-16 to 2020-07-11	Gujarat Ahmedabad	Local	Unclear	30054	NR	nan	Unclear	Multiple populations	17.6% (17.2-18.0%)	Not reported Not Reported Not reported	No data	-
Rao (Sri Jayadeva Institute of Cardiovascular Sciences and Research) ²⁹⁰	2020-05-23 to 2020-06-06	Karnataka Bengaluru	Sublocal	Unclear	1000	30-40 (n=1000)	45.0	Convenience	Health care workers and caregivers	1.0% (0.5-1.8%)	New Life Healthcare Not Reported IgG	No data	-
Pakistan													
Chughtai (Chughtai Institute of Pathology) ²⁹¹	2020-05-20 to 2020-05-30		Local	High	154	Mean 27.1 (SD 3.8)	0.0	Convenience	Essential non-healthcare workers	15.6% (10.3-22.3%)	Abbott Abbott Architect SARS-CoV-2 IgG assay IgG	41.2, 100.0 (FINDDx / MUHC independent evaluation)	39.4% (24.3-54.0%)
Southeast Asia, East Asia, and Oceania													
China													
He (Wuhan University) ²⁹²	2020-05-13 to 2020-06-10	Hubei	Sublocal	High	1059	Median 32.69 (NR)	75.3	Convenience	Health care workers and caregivers	9.3% (7.6-11.2%)	Livzon Diagnostics Diagnostic Kit for IgM/IgG Antibody to Coronavirus IgG	70.1, 100.0 (FINDDx / MUHC independent evaluation)	12.2% (9.4-15.6%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Liang (The First Affiliated Hospital of Guangzhou Medical University) ²⁹³	2020-01-19 to 2020-04-30	Hubei Wuhan	Local	High	8272	Median 55 (IQR 38-67)	50.0	Convenience	Hospital visitors	2.1% (1.8-2.5%)	Innovita 2019-nCoV Ab Test (Colloidal Gold) IgG; IgM	56.9, 96.3 (FINDDx / MUHC independent evaluation)	0.9% (0.0-1.9%)
Liang (The First Affiliated Hospital of Guangzhou Medical University) ²⁹³	2020-01-20 to 2020-04-30	Guangdong Guangzhou	Local	High	8782	Median 54 (IQR 44-62)	51.6	Convenience	Hospital visitors	0.6% (0.4-0.8%)	Shenzhen YHLO Biotech Co SARS-CoV-2 IgM/IgG CLIA kits IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	1616	Mean 53.3 (95% CI 52.4-54.2)	56.2	Sequential	Patients seeking care for non-COVID-19 reasons	1.0% (0.6-1.6%)	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	73.1, 100.0 (FINDDx / MUHC independent evaluation)	1.0% (0.0-1.7%)
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-02-29 to 2020-04-29	Hubei Wuhan	Local	Moderate	3832	Mean 37.1 (95% CI 36.7-37.4)	32.3	Convenience	Health care workers and caregivers	4.0% (3.4-4.7%)	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	73.1, 100.0 (FINDDx / MUHC independent evaluation)	4.3% (0.5-7.0%)
Liu (Sun Yat-sen University) ²⁹⁴	2020-02-07 to 2020-04-21	Hubei Wuhan	Local	High	420	Mean 35.8 (NR)	68.1	Convenience	Health care workers and caregivers	0.0% (0.0-0.9%)	YHLO SARS-CoV-2 IgM/IgG CLIA kits IgG	100.0, 99.0 (FINDDx / MUHC independent evaluation)	0.2% (0.0-0.8%)
He (Wuhan University) ²⁹²	2020-03-08 to 2020-04-19		Sublocal	High	1059	Median 32.69 (NR)	75.3	Convenience	Health care workers and caregivers	11.7% (9.8-13.8%)	Livzon Diagnostics Diagnostic Kit for IgM/IgG Antibody to Coronavirus IgG	70.1, 100.0 (FINDDx / MUHC independent evaluation)	15.7% (12.4-19.2%)
Wu (Wuhan University) ²⁹⁵	2020-04-03 to 2020-04-15	Hubei Wuhan	Sublocal	High	381	NR	nan	Unclear	Patients seeking care for non-COVID-19 reasons	10.5% (7.6-14.0%)	Innovita Biological Technology Co. Ltd 2019-nCoV Ab Test IgG; IgM	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	11.2% (6.8-15.3%)
Wu (Wuhan University) ²⁹⁵	2020-04-03 to 2020-04-15	Hubei Wuhan	Sublocal	High	1021	NR	nan	Unclear	Essential non-healthcare workers	9.6% (7.9-11.6%)	Innovita Biological Technology Co. Ltd 2019-nCoV Ab Test IgG; IgM	66.0, 96.6 (Used Bastos SR/MA data; no sens, spec, or author)	10.0% (7.6-12.7%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Xu (National Clinical Research Centre for Kidney Disease) ²⁹⁶	2020-03-09 to 2020-04-10	Hubei, Sichuan, Guangdong Wuhan, Guangzhou, Jinzhou, Honghu, Chongqing, Chengdu, Foshan	National	High	6919	Median 41 (IQR 31-56)	63.1	Self-referral	Multiple populations	2.5% (2.1-2.8%)	Bioscience Magnetic Chemiluminescence Enzyme Immunoassay Kit IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.4% (0.0-0.7%)
Xu (National Clinical Research Centre for Kidney Disease) ²⁹⁶	2020-03-09 to 2020-04-10	Hubei, Sichuan, Guangdong Wuhan, Chengdu, Guangzhou	National	High	10449	Median 50 (IQR 35-49)	52.3	Self-referral	Multiple populations	0.8% (0.6-1.0%)	Bioscience Magnetic Chemiluminescence Enzyme Immunoassay Kit IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	0.0% (0.0-0.1%)
Zhang (Huazhong University of Science and Technology) ²⁹⁷	2020-01-23 to 2020-03-27	Hubei	Sublocal	High	44	Median 6 (Range 1-15)	38.6	Sequential	Patients seeking care for non-COVID-19 reasons	0.0% (0.0-8.0%)	Not reported Not Reported IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	-
Tang (Tongji Medical College) ²⁹⁸	2020-03-08 to 2020-03-21	Hubei Wuhan	Local	Moderate	1027	Mean 60.3 (SD 13.4)	39.7	Convenience	Patients seeking care for non-COVID-19 reasons	4.6% (3.4-6.0%)	Tangshan Yingnuote Biotechnology Enterprise Co., Ltd. Tangshan Colloidal Gold Immunochromatography Assay IgG; IgM	87.3, 100.0 (FINDDx / MUHC independent evaluation)	3.9% (1.4-6.2%)
Tu (Wuhan Institute of Virology) ²⁹⁹	2020-03-19 to 2020-03-20	Hubei	Sublocal	High	325	NR	nan	Stratified probability	Health care workers and caregivers	24.3% (19.7-29.3%)	Zhu Hai Livzon Diagnostics Ins Zhu Hai Livzon ELISA IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	30.1% (24.5-35.2%)
Zhang (Shenzhen Second People's Hospital) ³⁰⁰	2020-02-29 to 2020-03-18	Guangdong	Local	High	1589	Mean 36.4 (Range 11-89)	nan	Convenience	Non-essential workers and unemployed persons	0.4% (0.1-0.8%)	Shenzhen Sciarray Biotech Ltd shenzhen ELISA IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author	0.1% (0.0-0.3%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
												adjustment available)	
Xiong (Huazhong University of Science and Technology) ³⁰¹	2020-02-12 to 2020-03-17	Hubei Wuhan	Local	Unclear	797	Median 31 (Range 23-53)	88.5	Convenience	Health care workers and caregivers	4.4% (3.1-6.1%)	Not reported Not Reported IgG	75.6, 97.6 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	2.6% (0.7-4.4%)
Zhao (Renmin Hospital of Wuhan University) ³⁰²	2020-01-14 to 2020-02-21	Hubei	Sublocal	High	1060	NR	nan	Convenience	Health care workers and caregivers	8.3% (6.7-10.1%)	Shenzhen YHLO Biotech Co Not Reported IgG; IgM	97.8, 97.8 (Used Bastos SR/MA data; no sens, spec, or author adjustment available)	6.4% (4.8-7.8%)
Chen (Nanjing University Medical School) ³⁰³	2020-02-19 to 2020-02-19	Jiangsu Nanjing	Local	High	105	Median 30 (IQR 26-62)	79.0	Convenience	Health care workers and caregivers	17.1% (10.5-25.7%)	Author-designed N/A - Author-designed IgG; IgM	93.3, 100.0 (Test developer / manufacturer evaluation)	17.6% (10.7-24.8%)
Zhang (Shengjing Hospital of China Medical University) ^{304 305}	2020-01-21 to 2020-02-16	Liaoning	Regional	High	510	Median 35 (Non-COVID-19 group); 50 years (Other disease group); 40 (Medical staff) (Range 1-86 (Non-COVID-19 group); (27 - 85) Other disease group; 25-61 (Medical staff))	62.2	Convenience	Multiple populations	0.6% (0.1-1.7%)	Shenzhen Yahuilong Biotechnology Co. Chemiluminescence Detection Kit IgG	91.7, 98.8 (FINDdx / MUHC independent evaluation)	0.4% (0.0-0.8%)
Thailand													
Nopsopon (Chulalongkorn University) ³⁰⁶	2020-04-08 to 2020-06-26		National	Moderate	857	Median 37 (IQR 27-45)	74.7	Convenience	Multiple populations	5.5% (4.1-7.2%)	Baiya Phytopharm Baiya Rapid COVID-19 IgG/IgM Test Kit IgM	94.1, 98.0 (Author-reported independent evaluation)	3.5% (0.9-5.9%)

Article Author (Study Organization)	Sampling Dates (YMD)	Location	Geographic Scope	Overall Risk of Bias	Sample Size	Age	Female (%)	Sampling method	Sample Frame	Uncorrected Seroprevalence (95% Confidence Interval)	Test Manufacturers Names Isotypes	Test Sens, Spec (Source)	Corrected Seroprevalence (90% Credible Interval)
Sub-Saharan Africa													
Malawi													
Chibwana (Malawi-Liverpool-Wellcome Trust Clinical Research Programme) ³⁰⁷	2020-05-22 to 2020-06-19	Southern Region Malawi	National	High	500	Median 31 (Range 20-64)	52.8	Convenience	Health care workers and caregivers	16.8% (13.6-20.4%)	Omega diagnostics COVID-19 IgG ELISA IgG	88.1, 93.2 (Test developer / manufacturer evaluation)	11.1% (3.6-17.5%)
Nigeria													
Asuquo (Joseph Ukpo Hospitals and Research Institutes) ³⁰⁸	2020-06-17 to 2020-06-24	Cross River State	Sublocal	High	44	NR	63.6	Unclear	Multiple populations	20.4% (9.8-35.2%)	Zhejiang Orient Gene Biotech Co., LTD Rapid test kit IgG	93.1, 99.2 (FINDDx / MUHC independent evaluation)	20.5% (9.6-31.9%)
Asuquo (Joseph Ukpo Hospitals and Research Institutes) ³⁰⁸	2020-06-17 to 2020-06-24	Cross River State	Sublocal	High	66	NR	42.4	Unclear	Multiple populations	26.0% (16.0-38.3%)	Healgen Scientific COVID-19 IgG / IgM Rapid Test Cassette IgG	96.7, 97.5 (FINDDx / MUHC independent evaluation)	25.3% (15.0-36.2%)
Togo													
Halatoko (Universite de Lome) ³⁰⁹	2020-04-23 to 2020-05-08		Local	High	955	Median 36 (IQR 32-43)	28.4	Convenience	Non-essential workers and unemployed persons	0.9% (0.4-1.7%)	Hangzhou Clongene Biotech Co, Ltd. Lungene Rapid Test IgM; IgG	65.4, 90.3 (FINDDx / MUHC independent evaluation)	0.3% (0.0-0.8%)

Supplementary Table 3. Risk of bias results

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Central Europe, Eastern Europe, and Central Asia											
Armenia											
Grigoryan (Ministry of Health of the Republic of Armenia) ¹⁷³	2020-06-29	Yes	Unclear	No	No	Unclear	Yes	Yes	No	Unclear	High
Bulgaria											
Tsaneva-Damyanova (Medical Diagnostic Laboratory "STATUS") ¹⁷⁴	2020-04-20	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Croatia											
Vilibic-Cavlek (University of Zagreb) ¹⁷⁵	2020-05-24	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Jerkovic (University of Split) ¹⁷⁶	2020-04-28	Yes	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Czechia											
Malickova (Clinical and Research Center for Inflammatory Bowel Disease) ¹⁷⁷	2020-04-15	Yes	Unclear	No	Yes	Yes	Unclear	Yes	No	Unclear	Unclear
Hungary											
Merkely (Semmelweis University) ³⁰	2020-05-16	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	No	Moderate
Romania											
MedLife (MedLife) ¹⁷⁸	2020-04-21	Yes	Unclear	No	No	Unclear	Unclear	No	No	Unclear	Unclear
Russian Federation											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Tickle (City of Moscow) ³¹	2020-06-18	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Kiselyov (Russian National Council for Combating Coronavirus) ³²	2020-06-10	Yes	Unclear	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
High-income											
Argentina											
Figar (Minister of Health, Buenos Aires City) ¹⁷⁹	2020-07-01	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Figar (Minister of Health, Buenos Aires City) ¹⁷⁹	2020-07-01	Yes	No	No	No	Unclear	No	Yes	No	Unclear	High
Australia											
Macartney (University of Sydney) ¹⁸⁰	2020-04-10	Yes	No	Yes	No	Yes	Yes	Yes	No	Unclear	Moderate
Austria											
Hackner (Karl Landsteiner University of Health Sciences) ¹⁸¹	2020-04-30	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Knabl (Medical University of Innsbruck) ³³	2020-04-27	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Reiter (Medical University of Vienna) ¹⁸²	2020-03-29	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Yes	High
Orth-Höller (Innsbruck Clinical Microbiology Laboratory) ¹⁸³	2020-03-27	Yes	No	No	Yes	No	No	Yes	No	Unclear	High
Belgium											
Herzog (University of Antwerp) ³⁴	2020-07-04	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Blairon (Iris Hospitals South) ¹⁸⁴	2020-06-19	Yes	No	Yes	Yes	Yes	Unclear	Yes	No	No	High
Herzog (University of Antwerp) ³⁴	2020-06-13	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Herzog (University of Antwerp) ³⁴	2020-05-25	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Berardis (Cliniques universitaires Saint-Luc) ¹⁸⁵	2020-05-19	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High
Martin (Université Libre de Bruxelles) ¹⁸⁶	2020-05-18	Yes	No	No	Yes	Unclear	Unclear	Yes	No	No	High
Steensels (ZiekenhuisOost- Limburg) ¹⁸⁷	2020-04-30	No	No	Yes	No	Yes	Yes	Yes	Yes	Yes	High
Herzog (University of Antwerp) ³⁴	2020-04-26	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Herzog (University of Antwerp) ³⁴	2020-04-05	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Canada											
Héma-Québec ^{35 36}	2020-07-09	No	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Public Health Ontario ^{37 38}	2020-06-30	No	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Canadian Blood Services ³⁹	2020-06-18	No	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Public Health Ontario ^{37 38}	2020-05-31	No	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Skowronski ⁴⁰	2020-05-27	No	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Public Health Ontario ^{37 38}	2020-04-30	No	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Skowronski (British Columbia Centre for Disease Control) ⁴⁰	2020-03-13	No	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Chile											
Torres (Universidade de Chile) ¹⁸⁸	2020-05-19	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	High
Torres (Universidade de Chile) ¹⁸⁸	2020-05-19	No	Yes	No	Yes	Yes	Unclear	Yes	No	Yes	High
Denmark											
Jespersen (Aarhus University Hospital) ⁴¹	2020-06-30	No	Unclear	No	No	Unclear	Yes	Yes	Unclear	Unclear	High
Jespersen (Aarhus University Hospital) ⁴¹	2020-06-30	No	Unclear	No	No	Unclear	Yes	Yes	Unclear	Unclear	High
Jespersen (Aarhus University Hospital) ⁴¹	2020-06-19	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Erikstrup (Copenhagen University Hospital) ⁴²	2020-05-03	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Petersen (University of the Faroe Islands) ⁴³	2020-05-01	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Iversen (University of Copenhagen) ⁴⁴	2020-04-22	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Iversen (University of Copenhagen) ⁴⁴	2020-04-22	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
France											
Mesnil (Rothschild Foundation Hospital) ¹⁸⁹	2020-06-22	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Yes	High
Cohen (Association Clinique et Thérapeutique Infantile du Val-de-Marne) ⁴⁵	2020-05-12	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes	High
Fumery (Picardie University) ¹⁹⁰	2020-05-11	No	No	No	Yes	Unclear	Yes	Yes	No	Yes	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Fontanet (Institut Pasteur) ⁴⁶	2020-04-30	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Solodky (Centre Leon Berard) ¹⁹¹	2020-04-16	Yes	No	No	No	No	Unclear	Yes	No	Unclear	High
Solodky (Centre Leon Berard) ¹⁹¹	2020-04-16	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Gallian (Unite des Virus Emergents) ⁴⁷	2020-04-07	No	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Germany											
Armann (Technische Universität Dresden) ¹⁹³	2020-06-30	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Epstude (Thuringia Clinic) ¹⁹²	2020-06-30	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Epstude (Thuringia Clinic) ¹⁹²	2020-06-30	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Fischer (Heart and Diabetes Center NRW) ⁴⁸	2020-06-03	No	No	Yes	No	No	Yes	Yes	No	Unclear	High
Weis (Jena University Hospital) ⁴⁹	2020-05-22	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Zöllkau (Universitätsklinikum Jena) ¹⁹⁴	2020-05-13	No	Unclear	No	Yes	Unclear	No	Yes	No	Unclear	High
Schmidt (University of Hannover) ¹⁹⁵	2020-04-30	Yes	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
Reisinger (Universitätsmedizin Rostock) ⁵⁰	2020-04-22	Yes	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Korth (University Hospital Essen) ¹⁹⁶	2020-04-21	No	No	No	No	Unclear	Unclear	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Harsch (Thuringia Clinic) ¹⁹⁷	2020-04-21	Yes	No	No	No	Unclear	Yes	Yes	No	No	High
Behrens (Hannover Medical School) ^{198,199}	2020-04-17	No	Unclear	No	No	Unclear	No	Yes	No	Unclear	High
Kern (Universitätsmedizin Marburg) ²⁰⁰	2020-04-16	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Kraehling (Goethe-University Frankfurt) ²⁰¹	2020-04-14	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Streeck (University of Bonn) ⁵¹	2020-04-06	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Low
Lackermair (University Hospital Munich) ²⁰²	2020-04-06	No	No	No	Yes	No	Unclear	Yes	No	Unclear	High
Greece											
Psichogiou (National and Kapodistrian University of Athens) ²⁰³	2020-05-15	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Moderate
Bogogiannidou (University of Thessaly) ⁵²	2020-04-30	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Ireland											
Igoe (HSE Health Protection Surveillance Centre (HPSC)) ⁵³	2020-07-16	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	No	Moderate
Israel											
Bachner (Israeli Pandemic Task Force) ^{54,55}	2020-06-02	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Unclear	High
Italy											
Norsa (Papa Giovanni XXII) ²⁰⁴	2020-07-10	No	No	No	Yes	Yes	Unclear	Yes	No	Yes	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Pagani (Università degli Studi di Milano) ⁵⁶	2020-06-07	Yes	Yes	No	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Cosma (University of Turin) ²⁰⁵	2020-06-04	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Amante (Bergamo Health Agency) ⁵⁷	2020-06-03	Yes	Unclear	Yes	No	Yes	Unclear	Unclear	No	Unclear	Moderate
Lorenzo (Santagostino Medical Center) ²⁰⁶	2020-05-31	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Fiore (University of Foggia) ⁵⁸	2020-05-31	No	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
Sandri (Humanitas Clinical and Research Center) ²⁰⁸	2020-05-16	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Cavaliere (Santo Stefano Hospital) ²⁰⁷	2020-05-16	Yes	No	No	No	Unclear	Unclear	Yes	No	Yes	High
Carozzi (Arezzo Hospital) ²¹¹	2020-04-30	Yes	No	Yes	No	Unclear	No	No	No	Unclear	High
Denina (University of Turin) ²⁰⁹	2020-04-30	Yes	No	No	Yes	Unclear	Unclear	No	No	Unclear	High
Vena (University of Genoa) ²¹⁰	2020-04-30	No	No	Yes	Yes	Yes	Yes	No	No	Unclear	High
Landro (Hospital of Bergamo) ⁵⁹	2020-04-28	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Lahner (University of Rome) ²¹³	2020-04-27	No	Yes	Yes	No	Yes	No	Yes	No	Unclear	High
Volta (University of Brescia) ²¹²	2020-04-27	No	No	No	Yes	Yes	Unclear	Yes	No	Yes	High
Landro (Hospital of Bergamo) ⁵⁹	2020-04-24	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Paradiso (Istituto Tumori G. Paolo II) ²¹⁴	2020-04-17	No	No	Yes	Yes	Unclear	Yes	Yes	No	Yes	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Sotgiu (Università degli Studi di Milano) ²¹⁵	2020-04-16	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High
Amendola (University of Milan) ²¹⁶	2020-04-15	No	No	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Valenti (Fondazione IRCCS Ca' Granda Ospedale Maggior) ⁶⁰	2020-04-08	No	Yes	Yes	Yes	Unclear	Yes	Yes	No	Yes	Moderate
Percivalle (IRCCS Policlinico San Matteo) ⁶¹	2020-04-06	No	Unclear	No	No	Yes	Yes	Yes	No	Unclear	High
Fusco (D. Cotugno' Hospital) ²¹⁷	2020-04-02	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Milani (University of Milan) ⁶²	2020-03-31	Yes	No	No	No	No	Unclear	Yes	No	Yes	High
Pancrazzi (Ospedale San Donato) ²¹⁸	2020-03-21	Yes	No	No	No	No	No	Yes	No	Unclear	High
Japan											
Nawa (Tokyo Medical and Dental University) ⁶³	2020-07-05	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Moderate
Chong (Kanenokuma Hospital) ²¹⁹	2020-06-15	Yes	No	No	No	Yes	Unclear	Yes	No	No	High
Suda (Hokkaido University Graduate School of Medicine) ²²⁰	2020-05-31	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Nakamura (Iwate Prefectural Central Hospital) ²²¹	2020-05-29	Yes	Unclear	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Takita (Navitas Clinic Tachikawa) ^{64,65}	2020-05-20	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Jiji (SoftBank) ^{222,223}	2020-05-18	Yes	No	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Fujita (National Hospital Organization Kyoto Medical Center) ²²⁴	2020-04-20	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Doi (Kobe City Medical Center General Hospital) ²²⁵	2020-04-07	No	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Suda (Hokkaido University Graduate School of Medicine) ²²⁰	2020-03-31	No	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Luxembourg											
Snoeck (Luxembourg Institute of Health) ⁶⁶	2020-05-05	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Netherlands											
Slot (Amsterdam UMC) ⁶⁷	2020-04-15	No	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Moderate
Westerhuis (Erasmus Medical Centre) ²²⁶	2020-04-07	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Westerhuis (Erasmus Medical Centre) ²²⁶	2020-03-06	No	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Norway											
Tunheim (Norwegian Institute of Public Health) ⁶⁸	2020-05-17	No	No	Yes	Yes	Yes	No	Yes	Yes	Unclear	Moderate
Cox (University of Bergen) ²²⁷	2020-04-04	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Portugal											
Rodrigues (Instituto Nacional de Saúde Doutor Ricardo Jorge) ⁶⁹	2020-07-08	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Republic of Korea											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Ji-Ho (Korea Centers for Disease Control and Prevention) ^{70,71}	2020-07-09	No	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Song (Daegu Catholic University Hospital) ²²⁸	2020-06-05	No	No	No	Yes	Unclear	No	Yes	No	Unclear	High
Noh (Korea University) ⁷²	2020-05-29	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Singapore											
Kurohi (Singapore National Centre for Infectious Diseases) ⁷³	2020-04-15	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Kurohi (Singapore National Centre for Infectious Diseases) ⁷³	2020-04-15	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Spain											
Flores (Municipality of Torrejon de Ardoz) ⁷⁴	2020-06-03	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Yes	Moderate
Fernández-Rivas (Institut Catala de la Salut) ²²⁹	2020-05-22	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Soriano (Universidad Autónoma de Madrid) ²³⁰	2020-05-16	No	Yes	Yes	Yes	No	Unclear	Yes	No	Yes	High
Fernandez (Hospital Universitario de Fuenlabrada) ²³¹	2020-05-13	No	Yes	Yes	No	Yes	Unclear	Yes	No	Yes	High
Pollán (Institute of Health Carlos III) ⁷⁵	2020-05-11	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Low
Valdivia (Hospital Clínico Universitario) ²³²	2020-04-30	No	Unclear	Yes	No	Unclear	No	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Galan (Hospital Universitario Fundación Alcorcón) ²³³	2020-04-27	No	Yes	Yes	Yes	Yes	No	Yes	No	Yes	High
Olalla (Hospital Costa del Sol) ²³⁴	2020-04-25	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Martin (Gerencia de Atención Primaria del Área de Salud de León, Spain) ²³⁵	2020-04-15	Yes	No	Yes	Yes	Unclear	No	Yes	No	Yes	High
Garcia-Basteiro (Universitat de Barcelona) ²³⁶	2020-04-09	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Moderate
Sweden											
The Local News Sweden (Werlabs) ⁷⁶	2020-07-22	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Stockholm Region Government (Sweden Public Health Authority) ⁷⁷	2020-07-15	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Lidström (Uppsala University) ²³⁷	2020-06-25	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Lundkvist (Uppsala University) ⁷⁸	2020-06-18	Yes	Yes	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Lundkvist (Uppsala University) ⁷⁸	2020-06-18	Yes	Yes	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-06-14	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-06-07	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-05-31	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-05-24	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Roxhed (KTH Royal Institute of Technology) ⁸⁰	2020-05-21	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
Sweden Public Health Authority ⁷⁹	2020-05-17	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-05-10	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Rudberg (Danderyd Hospital) ²³⁸	2020-05-08	No	Yes	Yes	Yes	No	Yes	Yes	No	No	Moderate
Sweden Public Health Authority ⁷⁹	2020-05-03	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Sweden Public Health Authority ⁷⁹	2020-04-26	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Lindhall (Uppsala University) ²³⁹	2020-04-20	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Switzerland											
Fenwick (University of Lausanne) ⁸¹	2020-06-27	Yes	Yes	No	No	Unclear	Yes	Yes	No	Unclear	High
Stringhini (Geneva University Hospitals) ⁸²	2020-05-09	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No	No	Moderate
United Kingdom											
Public Health England ⁸³	2020-08-16	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health Scotland ⁸⁴	2020-08-09	No	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Public Health England ⁸⁵	2020-08-02	Yes	Yes	Yes	No	Yes	Unclear	Yes	No	Unclear	Moderate
Public Health England ⁸⁵	2020-08-02	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Office of National Statistics ⁸⁶	2020-07-26	Yes	Yes	Yes	No	Yes	Yes	Yes	No	No	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Public Health England ⁸³	2020-07-21	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Ward (Imperial College London) ⁸⁷	2020-07-13	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Office of National Statistics ⁸⁸	2020-07-08	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	Moderate
Public Health England ⁸³	2020-07-06	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England ⁸⁹	2020-06-30	No	Yes	Yes	No	Unclear	Yes	Yes	Yes	Unclear	Moderate
Public Health Scotland ⁸⁴	2020-06-21	No	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Gulraj (Gibraltar Government) ²⁴⁰	2020-06-17	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Pallett (Chelsea and Westminster Hospital NHS Trust) ²⁴¹	2020-06-12	Yes	No	No	Yes	No	No	Yes	No	No	High
Eyre (Oxford University Hospital) ²⁴²	2020-06-08	Yes	No	Yes	Yes	Yes	Yes	No	No	Unclear	Moderate
Public Health England ⁸³	2020-06-08	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Grant (Whittington Health NHS Trust) ²⁴⁴	2020-06-05	Yes	No	Yes	No	Yes	Yes	Yes	No	No	High
Bampoe (University College London) ²⁴³	2020-06-05	Yes	Unclear	No	Yes	No	Yes	Yes	No	Unclear	High
Wells (King's College London) ⁹⁰	2020-06-02	No	Unclear	No	Yes	Unclear	Yes	Yes	No	No	High
Public Health England ⁸⁵	2020-05-31	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Unclear	Moderate
Public Health England ⁸⁵	2020-05-31	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Khalil (St George's University of London)	2020-05-28	No	No	No	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
245											
Jersey Government (Statistics Jersey) ⁹¹	2020-05-27	Yes	Yes	Yes	No	Unclear	Yes	Yes	Yes	No	Moderate
Public Health England ⁸³	2020-05-22	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Thompson (University of Oxford) ⁹²	2020-05-18	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Poulikakos (Salford Royal NHS Foundation Trust) ²⁴⁶	2020-05-06	Yes	No	No	No	No	Unclear	Yes	No	Unclear	High
Public Health England ⁸⁵	2020-04-30	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England ⁸⁵	2020-04-30	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Shields (University of Birmingham) ²⁴⁷	2020-04-26	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Public Health England ⁸³	2020-04-26	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Sikora (Rutherford Health) ²⁴⁸	2020-04-24	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Public Health England ⁸³	2020-04-24	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Thompson (University of Oxford) ⁹²	2020-04-20	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Public Health England ⁸³	2020-04-20	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England ⁸³	2020-04-16	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Public Health England ⁸³	2020-04-13	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Houlihan (University College London Hospitals) ³¹⁰	2020-04-08	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Public Health England ⁸³	2020-04-03	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Public Health England ⁸⁵	2020-03-31	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England ⁸⁵	2020-03-31	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Unclear	Moderate
Public Health England ⁸³	2020-03-27	No	Yes	Yes	No	Unclear	No	Yes	Yes	Unclear	Moderate
Favara (The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust) <small>249 250</small>	2006-07-20	Yes	Yes	No	No	Unclear	No	Yes	No	Yes	High
United States of America											
ABC7 (Riverside University Health System) ⁹³⁻⁹⁵	2020-07-20	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Zauzmer (Washington DC Public Health) ⁹⁶	2020-07-15	Yes	No	Yes	No	Unclear	Unclear	No	No	Unclear	High
Viglienzoni (University of Vermont) ⁹⁷	2020-06-30	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
McBride (Memorial Sloan Kettering Cancer Center) ²⁵¹	2020-06-25	Yes	No	Yes	Unclear	Unclear	Unclear	Yes	No	Unclear	High
Mahajan (Yale School of Medicine) ⁹⁸	2020-06-23	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Moderate
Muscola (Northwell Health) ²⁵²	2020-06-23	Yes	No	Yes	Yes	Yes	Unclear	No	No	Yes	Moderate
Spectrum News (University of Louisville) ⁹⁹	2020-06-19	Yes	No	Yes	No	Yes	Unclear	Unclear	No	No	High
Reifer (Sherman Abrams Laboratory) ²⁵³	2020-06-15	No	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
Brant-Zawadzki (Hoag Memorial Hospital Presbyterian) <small>254</small>	2020-06-15	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Sutton (Oregon Health Authority) ¹⁰⁰	2020-06-15	No	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Dora (Veterans Affairs Healthcare System) ²⁵⁵	2020-06-12	Yes	No	No	No	Unclear	Yes	Yes	No	Unclear	High
Harden (Routt County Board of Health) ¹⁰²	2020-06-10	No	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Hynes (Washoe County Health District) ¹⁰¹	2020-06-10	Yes	Yes	No	No	Unclear	Unclear	Yes	No	No	High
Rudavsky (Indiana University Fairbanks School of Public Health) ¹⁰³	2020-06-08	Yes	Yes	Yes	No	Yes	Unclear	Unclear	No	Unclear	Unclear
Flannery (University of Pennsylvania) ²⁵⁶	2020-06-03	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Gray (Truckee Meadows Fire Protection District) ²⁵⁷	2020-05-31	Yes	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Ohnesorge (Psalms/Solid Rock Medicine Group) ¹⁰⁴	2020-05-29	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Hayden (Desert Healthcare District) ¹⁰⁵	2020-05-28	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Mukherjee (Humboldt County Department of Health and Human Services) ¹⁰⁶	2020-05-26	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	High
Stavert (Cambridge Health Alliance) ²⁵⁸	2020-05-24	No	No	No	Yes	Unclear	Unclear	Yes	No	Unclear	High
Staletovich (Coral Springs City Government) ²⁵⁹	2020-05-23	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-22	Yes	Yes	No	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Jackson (Michigan Department of Corrections) ²⁶⁰	2020-05-22	Yes	Yes	Yes	No	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Leidner (Chiles Research Institute) ²⁶¹	2020-05-22	Yes	No	Yes	Yes	Yes	No	Yes	No	Unclear	High
Alfini (UW Health) ¹⁰⁷	2020-05-20	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Alfini (UW Health) ¹⁰⁷	2020-05-20	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Geraci (MUSC Health- Lancaster) ²⁶²	2020-05-20	No	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Mughal (Monmouth Medical Centre) ²⁶³	2020-05-19	No	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
McLaughlin (University of Washington) ¹⁰⁸	2020-05-19	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Boston (Boston Public Health Commission) ^{110,111}	2020-05-15	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Unclear	No	Moderate
Dietrich (Tulane University) ²⁶⁴	2020-05-15	No	No	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Feehan (Oschner Clinic Foundation) ¹⁰⁹	2020-05-15	Yes	Yes	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Sood (Stanford University School of Medicine) ¹¹²	2020-05-14	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Moderate
Parker-Magyar (Summit Medical Center) ²⁶⁵	2020-05-14	Yes	No	No	No	Unclear	Unclear	Unclear	No	Unclear	High
Angeles (University of Southern California) ¹¹⁴	2020-05-12	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-05-12	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Nesbitt (New York Blood Center) ¹¹⁵	2020-05-11	No	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	Moderate
Hunter (Indiana University) ²⁶⁶	2020-05-08	Yes	No	Yes	Yes	No	Yes	Yes	No	Unclear	High
Ripperger (University of Arizona) ²⁶⁷	2020-05-07	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Sydney (Jacobi Medical Center) ²⁶⁸	2020-05-04	Yes	No	Yes	Yes	Unclear	Unclear	Unclear	No	No	High
Shafa (Indiana University Fairbanks School of Public Health) ¹¹⁷⁻¹¹⁹	2020-05-03	Yes	No	No	Yes	Yes	Yes	Yes	No	Unclear	High
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-05-03	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-05-03	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Biggs (CDC COVID-19 Response Team) ¹¹⁶	2020-05-03	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Low
Reagan (Medical University South Carolina) ²⁶⁹	2020-05-02	No	Unclear	Yes	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Cohen (DaVita Clinical Research) ²⁷¹	2020-04-30	Yes	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Jeremias (St Francis Hospital) ²⁷⁰	2020-04-30	No	No	Yes	Yes	Yes	Unclear	No	No	No	High
Shafa (Indiana University Fairbanks School of Public Health) ¹¹⁷⁻¹¹⁹	2020-04-29	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Moderate
Rosenberg (New York State Department of Health) ¹²¹	2020-04-28	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Moderate
Chamie (University of California, San Francisco) ¹²⁰	2020-04-28	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	High
Zou (Georgia State University) ¹²²	2020-04-27	No	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-27	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Bryan (University of Washington School of Medicine) ¹²³	2020-04-26	Yes	No	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-26	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-25	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Waymer (OMNI Healthcare) ^{124,125}	2020-04-24	Yes	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Payne (US Navy) ²⁷²	2020-04-24	No	No	No	No	Unclear	Unclear	Yes	No	No	High
Dingens (Fred Hutchinson Cancer Research Center) ¹²⁶	2020-04-24	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Appa (University of California, San Francisco) ¹²⁷	2020-04-24	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	High
Kiefer (Ohio State University College of Medicine) ²⁷³	2020-04-23	No	No	No	Yes	No	Unclear	Yes	No	No	High
Paterson (Baton Rouge General Hospital) ¹²⁸	2020-04-21	No	Unclear	No	No	Unclear	Unclear	Yes	Unclear	Unclear	Unclear
Morcuende (Columbia University Irving Medical Center) ²⁷⁶	2020-04-21	No	No	No	Yes	No	Yes	Yes	No	No	High
Slusser (Stanford University) ^{274,275}	2020-04-21	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Stock (Albert Einstein College of Medicine) ²⁷⁷	2020-04-20	No	No	No	Yes	No	Unclear	Yes	No	Unclear	High
Madsen (University of Utah) ²⁷⁸	2020-04-19	No	No	No	No	Unclear	Yes	Yes	No	Yes	High
Stadlbauer (Icahn School of Medicine at Mount Sinai) ¹²⁹	2020-04-19	No	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	High
Caban-Martinez (University of Miami) ²⁷⁹	2020-04-17	No	No	No	Yes	Yes	No	Yes	No	Unclear	High
Hains (Icahn School of Medicine at Mount Sinai) ²⁸⁰	2020-04-15	No	No	No	No	No	Unclear	Yes	No	No	High
Hains (Icahn School of Medicine at Mount Sinai) ²⁸⁰	2020-04-15	No	No	No	No	No	Unclear	Yes	No	No	High
Stubblefield (Vanderbilt University Medical Center) ²⁸¹	2020-04-13	No	No	No	Yes	Yes	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-10	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-08	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Goldberg (Harvard Medical School) ²⁸²	2020-04-06	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	High
Bendavid (University of Stanford) ¹³⁰	2020-04-04	No	Yes	Yes	Yes	No	No	Yes	Yes	Unclear	High
Mansour (Icahn School of Medicine at Mount Sinai) ²⁸³	2020-04-04	Yes	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-01	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Havers (US Centers for Disease Control and Prevention) ¹¹³	2020-04-01	No	No	Yes	Yes	Unclear	Yes	Yes	Yes	Unclear	Moderate
Schuchat (University of Washington) ¹³¹	2020-03-31	No	No	No	No	Unclear	Unclear	Unclear	No	Unclear	High
Chu (US Centers for Disease Control and Prevention) ²⁸⁴	2020-02-03	Yes	No	No	No	Unclear	Yes	Yes	No	Yes	High
Latin America and Caribbean											
Brazil											
Menezes (Universidade Federal de Pelotas) ¹³²	2020-06-24	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Moderate
Pelotas (Universidade Federal de Pelotas) ¹³³	2020-06-07	Yes	Yes	Yes	No	Yes	No	Yes	No	Unclear	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Vieira (Centro de Operações de Emergências em Saúde Pública)	2020-05-31	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-24	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Hallal (Universidade Federal de Pelotas) ¹³⁵	2020-05-21	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Low
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-17	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ¹³⁶	2020-05-15	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Gomes (Secretaria de Estado da Saúde do Espírito Santo) ¹³⁶	2020-05-15	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Unclear	Moderate
Watanabe (Grupo Fleury) ¹³⁸	2020-05-12	Yes	Yes	No	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Tess (Universidade de São Paulo) ¹³⁷	2020-05-12	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Moderate
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-05-11	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-10	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-05-03	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Filho (Universidade do Estado do Rio de Janeiro) ¹⁴⁰	2020-04-27	No	No	Yes	Yes	Unclear	No	Yes	Yes	Yes	Moderate
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-04-27	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-04-26	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Adriano (Centro de Operações de Emergências em Saúde Pública) ¹³⁴	2020-04-19	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	Moderate
Silveira (Universidade Federal de Pelotas) ¹³⁹	2020-04-13	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Low
Ecuador											
Brutto (The Atahualpa Project) ¹⁴²	2020-05-31	Yes	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
Brutto (Universidad Peruana Cayetano Heredia) ¹⁴¹	2020-05-31	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	High
Peru											
Peruvian Government (National Center for Epidemiology, Prevention and Control of Diseases) ¹⁴³⁻¹⁴⁵	2020-07-09	Yes	Yes	Yes	No	Unclear	No	Yes	No	Unclear	High
North Africa and Middle East											
Egypt											
Kassem (Cairo University) ²⁸⁵	2020-06-14	No	No	No	Yes	Unclear	Yes	Yes	No	No	High
Iran											
Shakiba (Guilan University) ¹⁴⁶	2020-04-30	Yes	Yes	No	Yes	Unclear	No	Yes	Yes	No	Moderate
Jordan											
Sughayer (King Hussein Cancer Centre) ¹⁴⁷	2020-06-15	No	Yes	Yes	Yes	Unclear	Yes	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Libya											
Kammon (Al-Zintan University) ²⁸⁶	2020-05-18	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	High
Kammon (Al-Zintan University) ²⁸⁶	2020-05-18	No	Unclear	No	Yes	Yes	No	Yes	No	Yes	High
Turkey											
Alkurt (University of Health Sciences) ²⁸⁷	2020-06-06	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
South Asia											
India											
Ray (All India Institute of Medical Sciences) ²⁸⁸	2020-08-08	No	No	No	Yes	Yes	No	Yes	No	Unclear	High
Bedi (Delhi National Centre for Disease Control) ¹⁴⁸	2020-08-07	No	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Husain (King George's Medical University) ¹⁴⁹	2020-07-19	No	Yes	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Hindustan Times (Thyrocare) ^{150,151}	2020-07-19	Yes	Yes	Yes	No	No	Unclear	Unclear	No	Unclear	High
Kakani (University of Chicago) ^{152,153}	2020-07-19	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Low
Mishra (Haryana Health Department) ¹⁵⁴	2020-07-15	No	Yes	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Kakani (University of Chicago) ^{152,153}	2020-07-14	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Unclear	Low
Unclear (Ahmedabad Municipal Corporation) ²⁸⁹	2020-07-11	Yes	No	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Kumar (Thiruvananthapuram Health Department) ¹⁵⁷	2020-07-10	Yes	Unclear	Yes	No	Unclear	Unclear	Unclear	No	Unclear	Unclear
Saxena (Indian Center for Disease Control) ^{155,156}	2020-07-10	Yes	Yes	Yes	No	Unclear	Yes	Yes	No	Unclear	Moderate
Rao (Sri Jayadeva Institute of Cardiovascular Sciences and Research) ²⁹⁰	2020-06-06	Yes	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	Unclear
Koshy (Indian Council of Medical Research) ¹⁵⁸⁻¹⁶¹	2020-05-25	Yes	Yes	Yes	No	Yes	Unclear	Yes	No	Unclear	Moderate
Pakistan											
Younas (National Institute of Blood Diseases & Bone Marrow Transplantation) ¹⁶²	2020-07-15	No	No	No	Yes	No	Unclear	No	No	Unclear	High
Chughtai (Chughtai Institute of Pathology) ²⁹¹	2020-05-30	Yes	No	No	Yes	No	Yes	Yes	No	Unclear	High
Southeast Asia, East Asia, and Oceania											
China											
Chang (Beijing Hospital) ¹⁶³	2020-04-30	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Liang (The First Affiliated Hospital of Guangzhou Medical University) ²⁹³	2020-04-30	Yes	Unclear	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Liang (The First Affiliated Hospital of Guangzhou Medical University) ²⁹³	2020-04-30	Yes	Unclear	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-04-29	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-04-29	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias [†]
Liu (Zhongnan Hospital of Wuhan University) ¹⁶⁴	2020-04-29	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Moderate
Ling (Chinese Center for Disease Control and Prevention) ¹⁶⁵	2020-04-28	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Moderate
Liu (Sun Yat-sen University) ²⁹⁴	2020-04-21	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
He (Wuhan University) ²⁹²	2020-06-10	No	No	Yes	Yes	Unclear	No	Yes	No	Unclear	High
Wu (Wuhan University) ²⁹⁵	2020-04-15	Yes	Unclear	No	No	Unclear	Unclear	Yes	No	Unclear	High
Wu (Wuhan University) ²⁹⁵	2020-04-15	No	Unclear	Yes	No	Unclear	Unclear	Yes	No	Unclear	High
Xu (National Clinical Research Centre for Kidney Disease) ²⁹⁶	2020-04-10	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Xu (National Clinical Research Centre for Kidney Disease) ²⁹⁶	2020-04-10	Yes	No	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	High
Xu (Institute of Blood Transfusion) ¹⁶⁶	2020-04-02	No	Yes	Yes	Yes	No	Unclear	Yes	No	Unclear	High
Zhang (Huazhong University of Science and Technology) ²⁹⁷	2020-03-27	No	No	No	Yes	Yes	Unclear	Yes	No	Unclear	High
Tang (Tongji Medical College) ²⁹⁸	2020-03-21	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Moderate
Tu (Wuhan Institute of Virology) ²⁹⁹	2020-03-20	Yes	No	No	No	Unclear	Unclear	Yes	No	Unclear	High
Zhang (Shenzhen Second People's Hospital) ³⁰⁰	2020-03-18	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Unclear	High

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Xiong (Huazhong University of Science and Technology) ³⁰¹	2020-03-17	Unclear	Unclear	Yes	Yes	Unclear	Unclear	Yes	No	Unclear	Unclear
To (Queen Mary Hospital) ¹⁶⁷	2020-03-17	Yes	Yes	Yes	No	Yes	No	Yes	No	Unclear	Moderate
Chang (Beijing Hospital) ¹⁶³	2020-03-15	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Chang (Beijing Hospital) ¹⁶³	2020-03-15	No	Yes	Yes	Yes	Yes	Unclear	Yes	No	Unclear	High
Zhao (Renmin Hospital of Wuhan University) ³⁰²	2020-02-21	Yes	No	Yes	No	Unclear	Unclear	Yes	No	Yes	High
Chen (Nanjing University Medical School) ³⁰³	2020-02-19	No	Yes	No	Yes	Yes	Yes	Yes	No	Yes	High
Zhang (Shengjing Hospital of China Medical University) ^{304 305}	2020-02-16	No	No	No	Yes	Unclear	Yes	Yes	No	Unclear	High
To (Queen Mary Hospital) ¹⁶⁷	2020-02-13	No	No	Yes	No	No	No	Yes	No	Unclear	High
To (Queen Mary Hospital) ¹⁶⁷	2020-01-31	No	No	Yes	No	No	No	Yes	No	Unclear	High
Hallowell (US Centers for Disease Control and Prevention) ¹⁶⁸	2020-01-28	Yes	Yes	No	Yes	Yes	Unclear	Yes	No	Yes	Moderate
Malaysia											
Sam (University Malaya) ¹⁶⁹	2020-06-06	No	No	Yes	No	Unclear	Yes	Yes	No	Unclear	High
Thailand											
Nopsopon (Chulalongkorn University) ³⁰⁶	2020-06-26	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Sub-Saharan Africa											

Article Author (Study Organization)	Sampling End Date (YMD)	Item 1: Appropriate sample frame*	Item 2: Probability sampling method	Item 3: Adequate sample size	Item 4: Subjects & setting described	Item 5: Good coverage of sample	Item 6: Sens > 90% & spec > 95%	Item 7: Same tests for all subjects	Item 8: Appropriate analysis	Item 9: Adequate response rate	Overall Risk of Bias†
Ethiopia											
Kempen (Kuwait University) ¹⁷⁰	2020-05-21	No	No	No	Yes	Unclear	Yes	Yes	No	Yes	High
Kenya											
Uyoga (KEMRI-Wellcome Trust Research Programme) ¹⁷¹	2020-06-16	No	No	Yes	Yes	No	No	Yes	No	Unclear	High
Malawi											
Chibwana (Malawi- Liverpool-Wellcome Trust Clinical Research Programme) ³⁰⁷	2020-06-19	Yes	No	No	Yes	Yes	No	Yes	No	Unclear	High
Nigeria											
Majiya (Ibrahim Badamasi Babangida University) ¹⁷²	2020-06-30	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Unclear	Moderate
Asuquo (Joseph Ukpo Hospitals and Research Institutes) ³⁰⁸	2020-06-24	Unclear	Yes	No	No	No	Unclear	Yes	No	Unclear	High
Togo											
Halatoko (Universite de Lome) ³⁰⁹	2020-05-08	Yes	Yes	Yes	Yes	Unclear	No	Yes	No	Unclear	High

Supplementary Table 4. Summary of seroprevalence data for general and special population sub-groups

Population	No. of studies	Median sample size [IQR]	Median unadjusted seroprevalence [IQR]	No. of studies with adjustable estimates	Median adjusted seroprevalence [IQR]	Risk of Bias
<i>Study examining general population seroprevalence</i>	184	1200 [750-3873]	3.6% [1.5-6.3%]	155	3.2% [1.0-6.4%]	L: 5%, M: 51%, H: 36%, U: 8%
Household and community samples	107	1071 [554-4030]	4.1% [1.7-8.1%]	83	3.5% [1.2-8.5]	L: 9%, M: 50%, H: 29%, U: 12%
Residual sera	40	1200 [884-1777]	2.9% [1.0-5.0%]	39	2.7% [1.0-4.3]	L: 0%, M: 55%, H: 45%, U: 0%
Blood donors	37	2199 [904-7691]	3.2% [2.0-6.8]	33	2.8% [0.9-6.8]	L: 0%, M: 49%, H: 46%, U: 5%
<i>Study examining special population</i>	153	516 [150-1282]	5.5% [1.6-14.4%]	129	5.4% [1.5-18.4%]	L: 1%, M: 12%, H: 77%, U: 10%
Health care workers and caregivers	81	500 [181-1485]	6.0% [2.2-14.5%]	72	6.3% [2.1-18.8%]	L: 1%, M: 14%, H: 77%, U: 9%
Patients seeking care for non-COVID-19 reasons	25	381 [149-879]	5.3% [2.3-11.0%]	21	6.3% [2.8-17.8%]	L: 0%, M: 8%, H: 88%, U: 4%
Multiple populations	16	1350 [418-7694]	2.5% [0.9-7.6%]	13	3.3% [0.4-9.0%]	L: 0%, M: 6%, H: 81%, U: 12%
Essential non-healthcare workers	10	308 [166-923]	9.2% [2.0-15.2%]	7	10.0% [1.8-26.3%]	L: 0%, M: 10%, H: 80%, U: 10%
Pregnant or parturient women	4	177 [137-486]	5.1% [3.5-5.9%]	4	4.8% [3.4-5.7%]	L: 0%, M: 25%, H: 75%, U: 0%
Persons who are incarcerated	4	1034 [664-1212]	50.5% [29.2-72.5%]	0	-	L: 0%, M: 0%, H: 0%, U: 100%
Non-essential workers and unemployed persons	3	1589 [1272-3596]	0.7% [0.5-0.8%]	2	0.2% [0.2-0.3%]	L: 0%, M: 0%, H: 67%, U: 33%
Persons living in slums	3	873 [466-2537]	53.4% [44.7-53.8%]	3	58.7% [48.7-77.6%]	L: 33%, M: 33%, H: 33%, U: 0%
Contacts of COVID patients	3	77 [54-125]	2.3% [1.2-16.7%]	2	19.9% [10.7-29.0%]	L: 0%, M: 33%, H: 67%, U: 0%
Assisted living and long-term care facilities	2	145 [142-147]	8.7% [4.4-13.0%]	2	13.9% [7.4-20.5%]	L: 0%, M: 0%, H: 100%, U: 0%
Hospital visitors	2	8527 [8399-8654]	1.4% [1.0-1.8%]	2	0.5% [0.2-0.7%]	L: 0%, M: 0%, H: 100%, U: 0%
Students	1	1009 [1009-1009]	9.9% [9.9-9.9%]	1	5.1% [5.1-5.1%]	L: 0%, M: 0%, H: 100%, U: 0%

Abbreviations: No.= number; IQR= interquartile range; L = low; M = moderate; H = high; U = unclear; GBD = global burden of disease region

Supplementary Table 5. Summary of unadjusted meta-analysis results

Factor	Reference Group	Comparison Group	Number of Studies	Risk Ratio (95% CI)*	Heterogeneity (I ²)
Age	Adults (18-64)	Seniors (65+)	55	1.22 (1.04-1.42)	88.2%
	Adults (18-64)	Youth (0-18)	43	1.19 (1.03-1.38)	52.8%
	Adults 18-64	-	-	Reference	-
Sex/Gender	Male	Female	57	1.05 (0.97-1.14)	76.9%
Race	White	Black	19	1.89 (1.47-2.42)	89.1%
	White	Asian	12	1.44 (1.19-1.74)	68.5%
	White	Indigenous	5	3.13 (1.28-7.64)	69.7%
	White	-	-	Reference	-
Close contact with COVID-19 patients	Individuals with no close contact	Individuals with close contact	8	2.28 (1.55-3.34)	98.4%
	Health care workers with no close contact	Health care workers with close contact	13	1.35 (1.12-1.62)	89.0%
Health care worker status	Non-health care workers and caregivers	Health care workers and caregivers	9	1.19 (0.82-1.71)	94.1%

*Using adjusted seroprevalence estimates. Abbreviations: CI= confidence interval.

Supplementary Table 6. Summary of serological tests used

Manufacturer	Test Name	Isotype	No. of studies
EUROIMMUN AG	Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)	IgG	39
	Anti-SARS-CoV-2 ELISA (IgA) (manual, automated)	IgA	7
	Anti-SARS-CoV-2 ELISA (IgA) (manual, automated); Anti-SARS-CoV-2 ELISA (IgG) (manual, automated)	IgA; IgG	1
Abbott Laboratories	Abbott Architect SARS-CoV-2 IgG	IgG	37
	Abbott Alinity SARS-CoV-2 IgG	IgG	1
	Unspecified SARS-CoV-2 IgG	IgG	1
Zhejiang Orient Gene Biotech	COVID-19 IgG/IgM Rapid Test	IgG	8
		IgG; IgM	7
		IgM	7
Guangzhou Wondfo Biotech Co., Ltd	Wondfo SARS-CoV-2 Antibody Test (lateral flow method)	IgG; IgM	10
	Finecare SARS-CoV-2 Antibody test	Total Ig	3
Snibe Co., Ltd (Shenzhen New Industries Biomedical Engineering Co., Ltd)	MAGLUMI 2019-nCoV IgG (CLIA)	IgG	7
	MAGLUMI 2019-nCoV IgM (CLIA)	IgM	3
	MAGLUMI 2019-nCoV IgG (CLIA)	IgM	2
Zhuhai Livzon Diagnostics Inc	2019-nCoV IgG/IgM Antibody Detection Kit	IgG	4
		IgM	4
		IgG; IgM	2
	Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow)	IgG; IgM	1
Shenzhen Yhlo Biotech Co. Ltd	SARS-CoV-2 IgM and IgG chemiluminescence immunoassay	IgG	5
		IgM	4
	SARS-CoV-2 IgM/IgG CLIA kits	IgG	1
		IgM	1
DiaSorin SpA	LIAISON® SARS-CoV-2 S1/S2 IgG	IgG	9
	ISON® SARS-CoV-2 IgG kit	IgG	2
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd	Wantai SARS-CoV-2 Ab ELISA	Total Ig	8
	Wantai SARS-CoV-2 IgM ELISA	IgM	2
BioMedomics, Inc.	COVID-19 IgM-IgG Dual Antibody Rapid Test	IgG	3
		IgM	3


		IgG; IgM	2
Roche	Elecsys Anti-SARS-CoV-2	IgG; IgM	4
		Total Ig	3
Epitope Diagnostics, Inc.	EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit	IgG	5
	EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit	IgM	1
	EDI™ Novel Coronavirus COVID-19 IgM ELISA Kit; EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit	IgG; IgM	1
Innovita Biological Technology Co. Ltd	2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)	IgG; IgM	2
	2019 nCoV Ab test	IgG	1
		IgM	1
	2019-nCoV Ab Test (Colloidal Gold) (IgM/IgG Whole Blood/Serum/Plasma Combo)	IgG	1
SARS-CoV-2 IgG Ab Rapid Test	IgM	1	
Artron Laboratories Inc.	One Step Novel Coronavirus (COVID-19) IgM/IgG Antibody Test	IgG; IgM	3
		IgG	1
		IgM	1
Ortho Clinical Diagnostics Inc.	VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 IgG	IgG	3
	VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total	Total Ig	3
Healgen	COVID-19 IgG/IgM Rapid Test Cassette	IgG	1
		IgG; IgM	1
		IgM	1
Hangzhou Clongene Biotech Co., Ltd	2019-nCoV IgG/IgM Rapid Test	IgG	1
		IgG; IgM	1
		IgM	1
ACRO Biotech Inc.	Acro Biotech COVID-19 Rapid POC test	IgM	2
		IgG	1
	Not available	IgG; IgM	2
nal von minden GmbH	NADAL® COVID-19 IgG/IgM Test	IgG	1
		IgM	1
VivaChek Biotech (Hangzhou) Co., Ltd	VivaDiag COVID-19 IgM/IgG Rapid Test	IgG; IgM	2
Vircell S.L.	COVID-19 ELISA IgG	IgG	1
	COVID-19 ELISA IgM+IgA	IgA; IgM	1

Shenzhen Yahuilong Biotechnology Co Ltd	2019-nCoV IgG/IgM Antibody Detection Kit	IgG	1
		IgM	1
Premier Biotech	COVID-19 IgG/IgM Rapid Test Cassette	IgG; IgM	2
PRIMA Lab S.A.	PRIMA COVID-19 IgG/IgM Rapid Test	IgG; IgM	2
ImmunoDiagnostics limited	SARS-CoV-2 NP IgG ELISA Kit	IgG	1
	SARS-CoV-2 NP IgM ELISA Kit	IgM	1
Xiamen Wantai Kairui Biotechnology	Not available	Total Ig	1
Wadsworth Center, New York State Department of Health	New York SARS-CoV Microsphere Immunoassay for Antibody Detection	Total Ig	1
Tangshan Yingnuote Biotechnology Enterprise Co., Ltd.	Colloidal Gold Immunochromatography Assay (CGIA) kit	IgG; IgM	1
Sugentech, Inc.	SGTi-flex COVID-19 IgM/IgG (manual)	IgG; IgM	1
Phamatech	COVID19 RAPID TEST	IgG; IgM	1
PCL Inc.	PCL COVID19 IgG/IgM Rapid Gold	IgG; IgM	1
Multi-G B.V.	COVID-19 IgG/IgM Ab Test Cassette (Whole Blood/Serum/Plasma)	IgG	1
Hangzhou Biotest Biotech Co., Ltd	COVID-19 IgG/IgM Rapid Test Cassette	IgG; IgM	1
Hangzhou AllTest Biotech Co., Ltd	2019-nCoV IgG/IgM Rapid Test Cassette	IgG	1
DRG International, Inc.	Novel Coronavirus COVID-19 IgG	IgG	1
CTK Biotech, Inc.	OnSite COVID-19 IgG/IgM Rapid Test	IgG; IgM	1
No independent evaluation available	Not enough test information reported to match	-	55
	Author designed or validated test, not in Finddx database	-	48
	Commercially available but not in the Finddx database	-	38
	Multiple tests used in combination	-	8
	Multiple tests used NOT in combination	-	4
	Evaluations for separate isotypes, review authors report combined positivity rate (and/or isotype)	-	4
	Evaluation for combined isotype, study examined individual isotypes	-	4
	No match for index specimen type	-	2

Supplementary Table 7. Summary of meta-regression results


Study Characteristics	Analysis using uncorrected seroprevalence estimates			Analysis using corrected seroprevalence estimates		
	Change in Seroprevalence (coefficient β) ^{*,†} (95% CI)	Risk ratio (95% CI)	p-value	Change in Seroprevalence (coefficient β) ^{*,‡} (95% CI)	Risk ratio (95% CI)	p-value
Risk of Bias						
High	0.65 (0.12, 1.18)	1.92 (1.13, 3.25)	0.02	0.84 (0.12, 1.57)	2.32 (1.13, 4.81)	0.02
Moderate	0.86 (0.37, 1.35)	2.36 (1.45, 3.86)	<0.01	0.98 (0.32, 1.64)	2.66 (1.38, 5.16)	<0.01
Low	Reference	-	-	Reference	-	-
Unclear	0.13 (-0.49, 0.75)	1.14 (0.61, 2.12)	0.68	-0.30 (-2.25, 1.65)	0.74 (0.11, 5.21)	0.76
Population Group						
Household and community sample	Reference	-	-	Reference	-	-
Blood donors	-0.22 (-0.51, 0.07)	0.80 (0.60, 1.07)	0.14	-0.44 (-0.86, -0.02)	0.64 (0.42, 0.98)	0.04
Residual sera	-0.47 (-0.78, -0.16)	0.63 (0.46, 0.85)	<0.01	-0.47 (-0.90, -0.04)	0.63 (0.41, 0.96)	0.03
Estimate Grade						
National	Reference	-	-	Reference	-	-
Regional	0.08 (-0.20, 0.36)	1.08 (0.82, 1.43)	0.58	0.02 (-0.38, 0.41)	1.02 (0.68, 1.51)	0.94
Local	0.48 (0.18, 0.77)	1.62 (1.20, 2.16)	<0.01	0.52 (0.09, 0.96)	1.68 (1.09, 2.61)	0.02
Sublocal	0.88 (0.12, 1.63)	2.41 (1.13, 5.10)	0.02	0.80 (-0.29, 1.90)	2.23 (0.75, 6.69)	0.15
Days Since 100th Confirmed Case						
Per Day	0.007 (0.004, 0.011)	1.01 (1.00, 1.01)	<0.01	0.009 (0.005, 0.014)	1.01 (1.00, 1.01)	<0.01
WHO GBD Region						
High-Income	Reference	-	-	Reference	-	-
North Africa and Middle East	0.76 (-0.48, 2.00)	2.14 (0.62, 7.39)	0.23	-0.64 (-2.16, 0.87)	0.53 (0.12, 2.39)	0.40
Southeast Asia, East Asia, and Oceania	-1.46 (-1.97, -0.95)	0.23 (0.14, 0.39)	<0.01	-1.59 (-2.24, -0.93)	0.20 (0.11, 0.39)	<0.01
Central Europe, Eastern Europe, and Central Asia	0.23 (-0.56, 1.01)	1.26(0.57, 2.75)	0.57	-0.37 (-1.67, 0.93)	0.69 (0.19, 2.53)	0.57
Latin America and Caribbean	-0.48 (-0.84, -0.13)	0.61 (0.43, 0.88)	<0.01	-0.70 (-1.20, -0.21)	0.50 (0.30, 0.81)	<0.01
South Asia	0.73 (0.24, 1.22)	2.08 (1.27, 3.39)	<0.01	0.67 (-0.13, 1.46)	1.95 (0.88, 4.31)	0.10
Sub-Saharan Africa	0.89 (0.04, 1.72)	2.44 (1.04, 5.58)	0.04	1.07 (0.0001, 2.14)	2.92 (1.00, 8.50)	0.05
<p>*The regression coefficient β refers to the change in the log seroprevalence of antibodies to SARS-CoV-2 given changes in the covariate. †Details of uncorrected model: Intercept coefficient β -4.56 (95%CI -5.15, -3.98); Mixed-Effects Model (k = 184); tau² 0.4469 (SE = 0.2335); I²=99.51%. Test of Moderators (coefficients 2:16):QM(df = 15) = 83.9183, p-val < .0001.</p> <p>‡Details of corrected model: Intercept coefficient β -4.94 (95%CI -5.75, -4.13); Mixed-Effects Model (k = 155); tau² =0.8009 (SE =0.2651); I²=99.31%. Test of Moderators (coefficients 2:16):QM(df = 15) = 122.1417, p-val < .0001.</p> <p>Abbreviations: B=beta; CI = confidence interval; WHO = world health organization; GBD = global burden of disease</p>						

Supplementary Figure 1. Map of serosurvey distribution by global burden of disease region




The number of countries reporting any serosurvey in each GBD region were: Central Europe, Eastern Europe, and Central Asia (n=7); in High Income regions (n=25); in Latin America and Caribbean (n=3); in North Africa and Middle East (n=5); in South Asia (n=2); in Southeast Asia, East Asia, and Oceania (3); and in Sub-Saharan Africa (n=5).

Supplementary Figure 2. Seroprevalence to cumulative case incidence ratios using cumulative incidence on the same day as the serosurvey end date



The median ratio between corrected seroprevalence estimates and the corresponding cumulative incidence of SARS-CoV-2 infection was 11.9 (IQR 6.0 – 24.2).

Supplementary Figure 3. Seroprevalence to cumulative case incidence ratios using cumulative incidence 14 days prior to the serosurvey end date



The median ratio between corrected seroprevalence estimates and the corresponding cumulative incidence of SARS-CoV-2 infection was 16.9 (IQR 9.2 – 56.7)

References

1. Wolters Kluwer. COVID-19 Tools and Resources for Clinicians: Expert Searches [Internet]. 2020. Available from: https://tools.ovid.com/coronavirus/?utm_source=marketo&utm_medium=email&utm_campaign=0-v035&utm_term=all%20ovid&mkt_tok=eyJpIjoiWkRRM01qWXIPRFV5TnpKbCIsInQiOiIyVZWOUYyRFJJYlg1ZUR4T29sY0tCMGpWcHBVbnpTQWpLTGZQb0RjbnlidUQ2U3lVekxCWjNrN0U4SkZLOE9sM0IHTUlmdXEzM XJcL0pWQkhSzdGYU92cXJlRXZ4T3BMc2tmT1ZFMmh2Z09cL0d1MEh6RnowK2NjMGRUbEZSdGQ0VmpQ UmpybkIjWEpPVnFDUTdnZnlRUT09In0%3D
2. Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2. *Ann Intern Med*. 2020 Jun 4;173(6):450–60.
3. Boseley S. WHO warns that few have developed antibodies to Covid-19. *The Guardian* [Internet]. 2020 Apr 20; Available from: <https://www.theguardian.com/society/2020/apr/20/studies-suggest-very-few-have-had-covid-19-without-symptoms>
4. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc*. 2015 Sep;13(3):147–53.
5. Naing L, Winn T, Ruslil B. Practical issues in calculating the sample size for prevalence studies. *Arch Orofasc Sci*. 2006;1:9–14.
6. U.S. Food & Drug Administration. Emergency Use Authorization for SARS-CoV-2 Antibody Tests [Internet]. 2020 [cited 2020 May 5]. Available from: <https://www.fda.gov/media/137470/download>.
7. World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection [Internet]. 2020 Mar. Available from: <https://apps.who.int/iris/handle/10665/331656>
8. Institute for Health Metrics and Evaluation. Global Burden of Disease Study 2019 (GBD 2019) Data Resources [Internet]. [cited 2020 Nov 11]. Available from: <http://ghdx.healthdata.org/gbd-2019>;
9. Institute for Health Metrics and Evaluation. Institute for Health Metrics and Evaluation Frequently Asked Questions [Internet]. [cited 2020 Nov 11]. Available from: <http://www.healthdata.org/gbd/faq>
10. World Health Organization. Mortality and global health estimates [Internet]. World Health Data Platform. 2020. Available from: <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates>
11. FIND. SARS-CoV-2 diagnostics: performance data [Internet]. 2020. Available from: <https://www.finddx.org/covid-19/dx-data/>
12. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ*. 2020 Jul 1;370:m2516.
13. Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. *J Med Virol* [Internet]. 2020 Jul 24 [cited 2020 Nov 12];n/a(n/a). Available from: <https://doi.org/10.1002/jmv.26349>
14. Gelman A, Carpenter B. Bayesian analysis of tests with unknown specificity and sensitivity. *J R Stat Soc Ser C Appl Stat*. 2020 Nov 1;69(5):1269–83.
15. Betancourt M. A Conceptual Introduction to Hamiltonian Monte Carlo. *ArXiv170102434 Stat* [Internet]. 2018 Jul 15 [cited 2020 Nov 12]; Available from: <http://arxiv.org/abs/1701.02434>
16. Bolotin S, Tran V, Osman S, Brown KA, Buchan SA, Joh E, et al. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. *medRxiv*. 2020 Jan 1;2020.09.28.20200915.
17. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv*. 2020 Jan 1;2020.10.26.20219725.
18. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020 Oct 28;eabd7728.
19. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol*. 2020 Oct 8;5(52):eabe5511.
20. Wilson N, Kvalsvig A, Barnard LT, Baker M. Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality. *Emerg Infect Dis J*. 2020;26(6):1339.
21. Vanella P, Wiessner C, Holz A, Krause G, Moehl A, Wiegel S, et al. The role of age distribution, time lag between reporting and death and healthcare system capacity on case fatality estimates of COVID-19. *medRxiv*. 2020 Jan 1;2020.05.16.20104117.
22. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020 Aug 25;324(8):782–93.
23. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis*. 2020 Jul 28;71(15):778–85.
24. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. 2020 May;20(5):533–4.
25. United Nations, Department of Economics and Social Affairs, Population Division. 2019 Revision of World Population Prospects [Internet]. [cited 2020 Nov 11]. Available from: <https://population.un.org/wpp/>

26. European Centre for Disease Prevention and Control. Sources - Worldwide data on COVID-19 [Internet]. 2020 [cited 2020 Nov 11]. Available from: <https://www.ecdc.europa.eu/en/publications-data/sources-worldwide-data-covid-19>
27. European Centre for Disease Prevention and Control. Sources – EU/EEA and UK regional data on COVID-19 [Internet]. 2020 [cited 2020 Nov 11]. Available from: <https://www.ecdc.europa.eu/en/publications-data/sources-eueea-and-uk-regional-data-covid-19>
28. John Hopkins Center for Systems Science and Engineering. COVID-19 Time Series Summary [Internet]. GitHub Repository. 2020. Available from: https://github.com/CSSEGISandData/COVID-19/tree/master/csse_covid_19_data/csse_covid_19_time_series
29. Wikimedia Foundation. 2019–20 coronavirus pandemic by country and territory [Internet]. Wikipedia. 2020. Available from: https://en.wikipedia.org/wiki/2019%E2%80%9320_coronavirus_pandemic_by_country_and_territory
30. for the HUNGarian COroNaVirus-19 Epidemiological Research (H-UNCOVER) investigators, Merkely B, Szabó AJ, Kosztin A, Berényi E, Sebestyén A, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. *GeroScience*. 2020 Aug;42(4):1063–74.
31. Odinkov E. Large-scale antibody testing reveals that over 2 million Muscovites may already have contracted Covid-19 [Internet]. RT. 2020. Available from: <https://www.rt.com/russia/493055-moscow-mass-antibody-testing/>
32. Kiselyov S. 1 in 7 Russians Have ‘Coronavirus Immunity’ – Official [Internet]. The Moscow Times. 2020. Available from: <https://www.themoscowtimes.com/2020/06/10/1-in-7-russians-have-coronavirus-immunity-official-a70540>
33. Knabl L, Mitra T, Kimpel J, Roessler A, Volland A, Walser A, et al. High SARS-CoV-2 Seroprevalence in Children and Adults in the Austrian Ski Resort Ischgl. *medRxiv*. 2020 Aug 22;2020.08.20.20178533.
34. Herzog S, Bie JD, Abrams S, Wouters I, Ekinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a serial prospective cross-sectional nationwide study of residual samples. *medRxiv*. 2020 Oct 1;2020.06.08.20125179.
35. Héma-Québec. BLOOD DONOR SEROPREVALENCE STUDY: 2.23% OF QUEBEC ADULTS CONTRACTED COVID-19 [Internet]. Héma-Québec. 2020. Available from: <https://www.hema-quebec.qc.ca/publications/communiqués/archives/2020/communiqués-2020/etude-seroprevalence-resultats.en.html>
36. COVID-19 Immunity Task Force. The COVID-19 Immunity Task Force welcomes the results of the blood donor seroprevalence study led by Hema-Quebec [Internet]. 2020 Aug. Available from: <https://www.covid19immunitytaskforce.ca/the-covid-19-immunity-task-force-welcomes-the-results-of-the-blood-donor-seroprevalence-study-led-by-hema-quebec/>
37. Public Health Ontario. COVID-19 Seroprevalence in Ontario: March 27, 2020 to June 30, 2020 [Internet]. Public Health Ontario; 2020 Jul p. 10. (COVID-19 Serosurveillance Summary). Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/epi/2020/07/covid-19-epi-seroprevalence-in-ontario.pdf?la=en>
38. COVID-19 Immunity Task Force. COVID-19 Immunity Task Force welcomes first results from public health Ontario’s serosurveillance program [Internet]. COVID-19 Immunity Task Force; 2020 Jul. Available from: <https://www.covid19immunitytaskforce.ca/covid-19-immunity-task-force-welcomes-first-results-from-public-health-ontarios-serosurveillance-program/>
39. Canadian Blood Services. COVID-19 Seroprevalence Report – August 19, 2020 [Internet]. 2020 Aug. Available from: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/09/COVID-19-Public-Report_2.pdf
40. Skowronski DM, Sekirov I, Sabaiduc S, Zou M, Morshed M, Lawrence D, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. *medRxiv*. 2020 Jul 15;2020.07.13.20153148.
41. Jespersen S, Mikkelsen S, Greve T, Kaspersen KA, Tolstrup M, Boldsen JK, et al. SARS-CoV-2 seroprevalence survey among 18,000 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region. *medRxiv* [Internet]. 2020 Aug 12 [cited 2020 Oct 27]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.08.10.20171850>
42. Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *medRxiv*. 2020 Apr 28;2020.04.24.20075291.
43. Petersen MS, Strøm M, Christiansen DH, Fjallsbak JP, Eliassen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands. *Emerg Infect Dis*. 2020 Nov;26(11):2760–2.
44. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. *Lancet Infect Dis*. 2020 Aug 3;
45. Cohen R, Jung C, Ouldali N, Sellam A, Batard C, Cahn-Sellem F, et al. Assessment of spread of SARS-CoV-2 by RT-PCR and concomitant serology in children in a region heavily affected by COVID-19 pandemic. *medRxiv* [Internet]. 2020 Jun 14; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.12.20129221v1>
46. Fontanet A, Grant R, Tondeur L, Madec Y, Grzelak L, Cailleau I, et al. SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission. *medRxiv*. 2020 Jun 29;2020.06.25.20140178.

47. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. *Antiviral Res.* 2020 Sep;181:104880.
48. Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Eurosurveillance* [Internet]. 2020 Jul 16 [cited 2020 Nov 12];25(28). Available from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.28.2001285>
49. Weis S, Scherag A, Baier M, Kiehntopf M, Kamradt T, Kolanos S, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR- sampled and quarantined community after a COVID-19 outbreak - the CoNAN study [Internet]. p. 21. Available from: <https://doi.org/10.1101/2020.07.15.20154112>
50. Reisinger EC, von Possel R, Warnke P, Geerdes-Fenge HF, Hemmer CJ, Pfefferle S, et al. [Screening of Mothers in a COVID-19 Low-Prevalence Region: Determination of SARS-CoV-2 Antibodies in 401 Mothers from Rostock by ELISA and Confirmation by Immunofluorescence]. *Dtsch Med Wochenschr* 1946. 2020 Jun 22;
51. Streeck H, Schulte B, Kuemmerer B, Richter E, Hoeller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. *medRxiv.* 2020 May 8;2020.05.04.20090076.
52. Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Eurosurveillance.* 2020 Aug 6;25(31):2001369.
53. Derval Igoe, Janice Bailie, Fiona O’Callaghan, Aoife Colgan, Jeff Connell, Paul Crowley, et al. Preliminary report of the results of the Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A national seroprevalence study, June-July 2020 [Internet]. Health Protection Surveillance Centre; 2020 Aug p. 9. Available from: <https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf>
54. Ido Efrati. Up to 270,000 Israelis Had Coronavirus, New Study Concludes [Internet]. *Haaretz.* 2020. Available from: <https://www.haaretz.com/israel-news/.premium-up-to-270-000-israelis-had-coronavirus-new-study-concludes-1.8888435>
55. Michael Bachner. Initial antibody tests indicate 200,000 Israelis have had COVID-19 – report [Internet]. *The Times of Israel.* 2020. Available from: <https://www.timesofisrael.com/initial-antibody-tests-indicate-200000-israelis-have-had-covid-19-report/>
56. Gabriele Pagani, Federico Conti, Andrea Giacomelli, Dario Bernacchia, Rossana Rondanin, Andrea Prina, et al. Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass 7 population screening (SARS-2-SCREEN-CdA) [Internet]. 2020 Jun. Available from: <https://www.medrxiv.org/content/10.1101/2020.06.24.20138875v1.full.pdf>
57. Angelo Amante. Over half of people tested in Italy’s Bergamo have COVID-19 antibodies [Internet]. *The Jakarta Post.* 2020. Available from: <https://www.thejakartapost.com/news/2020/06/09/over-half-of-people-tested-in-italys-bergamo-have-covid-19-antibodies.html>
58. Fiore JR, Centra M, De Carlo A, Granato T, Rosa A, Sarno M, et al. Results from a survey in healthy blood donors in South Eastern Italy indicate that we are far away from herd immunity to SARS-CoV-2. *J Med Virol.* 2020 Aug 26;jmv.26425.
59. Armando Di Landro. Test sierologici Bergamo, arrivano i risultati di Nembro e Alzano: 61% di positivi [Internet]. *Corriere della Sera.* 2020. Available from: https://bergamo.corriere.it/notizie/cronaca/20_aprile_30/coronavirus-bergamo-primi-risultati-test-61percento-positivi-85e8e36c-8a6b-11ea-94d3-9879860c12b6.shtml
60. Valenti L. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. Pre-Print.
61. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Eurosurveillance* [Internet]. 2020 Jun 18 [cited 2020 Nov 12];25(24). Available from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.24.2001031>
62. Milani GP, Montomoli E, Bollati V, Albetti B, Bandi C, Bellini T, et al. SARS-CoV-2 infection among asymptomatic homebound subjects in Milan, Italy. *Eur J Intern Med.* 2020 Aug;78:161–3.
63. Nawa N, Kuramochi J, Sonoda S, Yamaoka Y, Nukui Y, Miyazaki Y, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study. *medRxiv.* 2020 Jul 26;2020.07.20.20155945.
64. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Regional Difference in Seroprevalence of SARS-CoV-2 in Tokyo: Results from the community point-of-care antibody testing [Internet]. *Infectious Diseases (except HIV/AIDS);* 2020 Jun [cited 2020 Nov 12]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.06.03.20121020>
65. Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic–Based Point-of-Care Antibody Testing. *J Prim Care Community Health.* 2020 Jan;11:215013272094269.
66. Snoeck C. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. Pre-Print.

67. Slot E, Hogema BM, Reusken CBEM, Reimerink JH, Molier M, Karregat JHM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak [Internet]. In Review; 2020 Apr [cited 2020 Nov 12]. Available from: <https://www.researchsquare.com/article/rs-25862/v1>
68. Gro Tunheim, Anne-Marte Bakken Kran, Gunnar Rø, Anneke Steens, Olav Hungnes, Fridtjof Lund-Johansen, et al. Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019 [Internet]. Norwegian Institute of Public Health; 2020 Jun p. 13. Available from: https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/covid-19/seroprevalence-of-sars-cov-2-in-the-norwegian-population_report-26-06-2020.pdf
69. Ana Paula Rodrigues. Resultados preliminares do primeiro Inquérito Serológico Nacional COVID-19 – Relatório [Internet]. Serviço Nacional de Saúde; 2020 Jul. Available from: <http://www.insa.min-saude.pt/resultados-preliminares-do-primeiro-inquerito-serologico-nacional-covid-19-relatorio/>
70. Yang Ji-ho. Few Koreans Test Positive for Coronavirus Antibodies [Internet]. Chosunlibo. 2020. Available from: http://english.chosun.com/site/data/html_dir/2020/07/10/2020071001864.html
71. Ock Hyun-ju. 0.03% of Koreans developed coronavirus antibodies: KCDC [Internet]. The Korea Herald. 2020. Available from: <http://www.koreaherald.com/view.php?ud=20200709000787>
72. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea. *J Korean Med Sci* [Internet]. 2020 Jul 27 [cited 2020 Oct 4];35(33). Available from: <https://doi.org/10.3346/jkms.2020.35.e311>
73. Kurohi R, Lai L. Coronavirus: Community transmission in S'pore very low, but so is herd immunity, NCID says. *The Straits Times* [Internet]. 2020 Apr 29; Available from: <https://www.straitstimes.com/singapore/health/coronavirus-community-transmission-in-spore-very-low-but-so-is-herd-immunity-says>
74. FLORES D. Coronavirus | Los test serológicos de Torrejón de Ardoz arrojan un 20,18 % de personas con anticuerpos de coronavirus [Internet]. RTVE.es. 2020 [cited 2020 Oct 7]. Available from: <https://www.rtve.es/noticias/20200617/test-serologicos-torrejón-ardož-arrojan-2018-habitantes-tiene-anticuerpos-coronavirus/2018787.shtml>
75. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet*. 2020 Jul;S0140673620314835.
76. The Local SE. 14% of coronavirus antibody tests positive in Sweden in July [Internet]. The Local SE. 2020. Available from: <https://www.thelocal.se/20200723/14-of-antibody-tests-positive-in-sweden>
77. Stockholm Region. 16 juli: Lägesrapport om arbetet med det nya coronaviruset [Internet]. Stockholm Region. 2020. Available from: <https://www.sll.se/verksamhet/halsa-och-varld/nyheter-halsa-och-varld/2020/07/16-juli-lagesrapport-om-arbetet-med-det-nya-coronaviruset/>
78. Lundkvist Å, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden. *Infect Ecol Epidemiol*. 2020 Jan 1;10(1):1806505.
79. Swedish Public Health Agency. Påvisning av antikroppar efter genomgången covid-19 hos blodgivare (Delrapport 2) [Internet]. Swedish Public Health Agency; 2020 Jun. Available from: <https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf>
80. Niclas Roxhed, Hong M-G, Bendes A, Matilda Dale, Mattsson C, Dodig-Crnkovic T, et al. A translational multiplex serology approach to profile the prevalence of anti-SARS-CoV-2 antibodies in home-sampled blood | medRxiv [Internet]. July 2 [cited 2020 Jul 6]. Available from: <https://www.medrxiv.org/content/10.1101/2020.07.01.20143966v1>
81. Fenwick C, Croxatto A, Coste AT, Pojer F, Andre C, Pellaton C, et al. Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 Jul [cited 2020 Nov 12]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.07.14.20153536>
82. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. *The Lancet* [Internet]. 2020 Jun 11 [cited 2020 Jun 12];0(0). Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31304-0/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/abstract)
83. Public Health England. National COVID-19 surveillance report: 28 August 2020 (week 35) [Internet]. Public Health England; p. 33–5. (Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report Summary of COVID-19 surveillance systems). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/912973/Weekly_COVID19_Surveillance_Report_week_35_FINAL.PDF
84. Andrew McAuley, Elizabeth Dickson, Norah Palmateer, Josie Murray, Craig Waugh, Lesley Wallace, et al. Enhanced Surveillance of COVID-19 in Scotland Population-based seroprevalence surveillance [Internet]. Public Health

- Scotland; September 30. Available from: <https://beta.isdscotland.org/find-publications-and-data/population-health/covid-19/enhanced-surveillance-of-covid-19-in-scotland/>
85. Public Health England. National COVID-19 surveillance report: 21 August 2020 (week 34) [Internet]. Public Health England; 2020 Aug p. 31–4. (Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report Summary of COVID-19 surveillance systems). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/911002/Weekly_COVID19_Surveillance_Report_week_34_FINAL.pdf
 86. Emily Connors, Eleanor Fordham. Coronavirus (COVID-19) Infection Survey pilot: England and Wales, 14 August 2020 [Internet]. Office for National Statistics; 2020 Aug. (Coronavirus (COVID-19) Infection Survey pilot). Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/englandandwales14august2020>
 87. Ward H, Atchison C, Whitaker M, Ainslie KE, Elliott J, Okell L. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults [Internet]. p. 21. Available from: <https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2.full.pdf>
 88. Emily Connors, Philippa Haughton. Coronavirus (COVID-19) Infection Survey pilot: England, 17 July 2020 [Internet]. Office for National Statistics; 2020 Jul p. 21. (Coronavirus (COVID-19) Infection Survey pilot). Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/england17july2020>
 89. Public Health England. National COVID-19 surveillance report: 7 August 2020 (week 32) [Internet]. Public Health England; 2020 Aug. (Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report Summary of COVID-19 surveillance systems). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/907954/Weekly_COVID19_Surveillance_Report_week_32_2.pdf
 90. Wells PM, Doores KM, Couvreur S, Martin Martinez R, Seow J, Graham C, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. medRxiv. 2020 Jan 1;2020.07.29.20162701.
 91. Statistics Jersey. SARS-CoV-2: Prevalence of antibodies in Jersey Community survey – round 2 [Internet]. Statistics Jersey; 2020 Jun. Available from: <https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf>
 92. Thompson CP, Grayson N, Paton R, Bolton JS, Lourenço J, Penman B, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020 [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Apr [cited 2020 Aug 10]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.04.13.20060467>
 93. ABC7.com staff. Riverside County may have more than 100,000 COVID-19 cases, antibody study suggests [Internet]. ABC News. 2020. Available from: <https://abc7.com/health/riverside-county-may-have-100000-covid-19-cases-study-says/6337677/>
 94. Nicole Hayden, Amaray D. Alvarez. Antibody tests suggest Riverside County’s COVID case tally may be 431% higher than counted [Internet]. Desert Sun. July 27. Available from: <https://www.desertsun.com/story/news/health/2020/07/27/riverside-county-estimates-175-000-residents-could-have-been-infected/5522612002/>
 95. Rob McMillan. 6 percent of Riverside County residents had COVID-19, according to antibody study [Internet]. ABC News. 2020. Available from: <https://abc7.com/riverside-county-covid-update-coronavirus-ie-covid-19/6340600/>
 96. Julie Zauzmer. D.C. has tested 13,706 blood samples. Only 809 carried coronavirus antibodies. [Internet]. The Washington Post. 2020. Available from: <https://www.washingtonpost.com/dc-md-va/2020/07/15/dc-health-lab-has-tested-13706-blood-samples-only-809-people-carried-coronavirus-antibodies/>
 97. Cat Viglienzoni. Early results of UVM research tracking COVID’s spread in Vermont [Internet]. WCAX3. 2020. Available from: <https://www.wcax.com/2020/07/17/early-results-of-uvm-research-tracking-covids-spread-in-vermont/>
 98. Mahajan S, Srinivasan R, Redlich CA, Huston SK, Anastasio KM, Cashman L, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study. medRxiv. 2020 Aug 6;2020.08.04.20168203.
 99. Spectrum News Staff. Study Finds Rate of Exposure to COVID-19 in Louisville Higher Than Expected [Internet]. Spectrum News 1. 2020. Available from: <https://spectrumnews1.com/ky/louisville/news/2020/07/23/uofl-coimmunity-project-phase-2-results>

100. Sutton M, Cieslak P, Linder M. Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample — Oregon, May 11–June 15, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Aug 14;69(32):1100–1.
101. Mary Hynes. Nevada COVID-19 infection rate 5 times higher, antibody tests show [Internet]. *Las Vegas Review Journal.* 2020. Available from: <https://www.reviewjournal.com/local/local-nevada/nevada-covid-19-infection-rate-5-times-higher-antibody-tests-show-2070094/>
102. Kari Harden. One new positive COVID-19 case in Routt County, antibody testing ramping up [Internet]. *Steamboat Pilot & Today.* 2020. Available from: <https://www.steamboatpilot.com/news/one-new-positive-covid-19-case-in-routt-county-antibody-testing-ramping-up/>
103. Shari Rudavsky. Fairbanks study indicates that ‘virus has slowed its spread’ in Indiana [Internet]. *Indy Star.* June 17. Available from: <https://www.indystar.com/story/news/health/2020/06/17/indiana-coronavirus-fairbanks-study-indicates-spread-has-slowed/3208509001/>
104. Steve Ohnesorge. Antibody testing continues in Burke County [Internet]. *WBTV.* 2020. Available from: <https://www.wbtv.com/2020/05/29/antibody-testing-continues-burke-county/>
105. Nicole Hayden. Coachella Valley far from COVID-19 herd immunity, preliminary antibody test results show [Internet]. *Desert Sun.* 2020. Available from: https://www.google.com/url?rct=j&sa=t&url=https://www.desertsun.com/story/news/health/2020/05/29/coachella-valley-far-covid-19-herd-immunity-preliminary-antibody-tests-show/5280021002/&ct=ga&cd=CAAYKzIaOTBkZWE5ODk5NGU5MTg1OTpjb206ZW46VVM&usg=AFQjCNFQxOqwjTX2Kz2_mnj1RV7Upa8rEg
106. Shomik Mukherjee. 1% of early Humboldt County coronavirus tests show antibodies [Internet]. *Times Standard.* 2020. Available from: <https://www.times-standard.com/2020/06/02/1-of-early-humboldt-county-coronavirus-tests-show-antibodies/>
107. Michelle Alfini. Antibody tests for coronavirus so far trend overwhelmingly negative [Internet]. *WKOW.* 2020. Available from: <https://wkow.com/2020/05/20/antibody-tests-for-coronavirus-so-far-trend-overwhelmingly-negative/>
108. McLaughlin C, Doll MK, Morrison KT, McLaughlin WL, OConnor T, Sholukh AM, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *medRxiv* [Internet]. 2020 Jul 21 [cited 2020 Nov 12]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.07.19.20157198>
109. Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood EG, Velasco C, Sapp E, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerg Infect Dis.* 2020 Nov;26(11):2765–8.
110. City of Boston. RESULTS RELEASED FOR ANTIBODY AND COVID-19 TESTING OF BOSTON RESIDENTS [Internet]. City of Boston. 2020. Available from: <https://www.boston.gov/news/results-released-antibody-and-covid-19-testing-boston-residents>
111. Adam Gaffin. One out of ten Bostonians has been exposed to coronavirus, according to initial testing of people in four Zip codes [Internet]. *Universal Hub.* 2020. Available from: <https://www.universalhub.com/2020/initial-antibody-testing-four-zip-codes-shows-one>
112. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10–11, 2020. *J Am Med Assoc* [Internet]. 2020 May 18 [cited 2020 May 18]; Published Online. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2766367>
113. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23–May 12, 2020. *JAMA Intern Med* [Internet]. 2020 Jul 21 [cited 2020 Jul 29]; Available from: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768834>
114. CBS Los Angeles. LA County ‘Still Far Away From Herd Immunity,’ New Antibody Numbers Show [Internet]. *CBS Los Angeles.* 2020. Available from: <https://losangeles.cbslocal.com/2020/05/20/la-county-still-far-away-from-herd-immunity-new-antibody-numbers-show/>
115. Nesbitt DJ, Jin D, Hogan JW, Chan PA, Simon MJ, Vargas M, et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats. *medRxiv.* 2020 Jan 1;2020.07.20.20157743.
116. Biggs HM, Harris JB, Breakwell L, Dahlgren FS, Abedi GR, Szablewski CM, et al. Estimated Community Seroprevalence of SARS-CoV-2 Antibodies — Two Georgia Counties, April 28–May 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jul 24;69(29):965–70.
117. Menachemi N, Yiannoutsos CT, Dixon BE, Duszynski TJ, Fadel WF, Wools-Kaloustian KK, et al. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–29, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jul 24;69(29):960–4.
118. Aaron E. Carroll. Too Many States Are Flying Blind Into Reopening. Not Indiana. [Internet]. *The New York Times.* 2020. Available from: <https://www.nytimes.com/2020/05/13/opinion/indiana-reopening-coronavirus-testing.html>

119. Dariush Shafa. Study projects only 9% of COVID-19 cases detected [Internet]. Perry County News. 2020. Available from: <https://www.perrycountynews.com/content/study-projects-only-9-covid-19-cases-detected>
120. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. *Clin Infect Dis* [Internet]. [cited 2020 Oct 27]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1234/5895337>
121. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. *Ann Epidemiol*. 2020 Aug;48:23-29.e4.
122. Zou J, Bretin A, Gewirtz A. Antibodies to SARS/CoV-2 in arbitrarily-selected Atlanta residents. *medRxiv*. 2020 May 6;2020.05.01.20087478.
123. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in Idaho. *medRxiv*. 2020 May 2;2020.04.27.20082362.
124. Alessandro Sassoon. OMNI Healthcare's COVID-19 antibody testing data for Brevard shows low rates of immunity [Internet]. Florida Today. 2020. Available from: <https://www.floridatoday.com/story/news/2020/04/24/omni-covid-19-immunity-testing-data-brevard-county-florida-antibody/3022571001/>
125. Jim Waymer. Fresh from controversy, OMNI announces COVID-19 immunity testing [Internet]. Florida Today. 2020. Available from: <https://www.floridatoday.com/story/news/2020/04/17/omni-healthcare-announces-coronavirus-immunity-testing/5147092002/>
126. Dingens AS, Crawford KH, Adler A, Steele SL, Lacombe K, Eguia R, et al. Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. *medRxiv*. 2020 Jun 30;2020.05.26.20114124.
127. Appa A, Takahashi S, Rodriguez-Barraquer I, Chamie G, Sawyer A, Consortium C, et al. Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community. *medRxiv*. 2020 Aug 17;2020.08.15.20175786.
128. Blake Paterson. Takeaways from coronavirus antibody tests: Infections might be more widespread than cases suggest [Internet]. The Advocate. 2020. Available from: https://www.theadvocate.com/baton_rouge/news/coronavirus/article_b499efa0-8983-11ea-a3f1-af936ecb1d2c.html
129. Stadlbauer D, Tan J, Jiang K, Hernandez M, Fabre S, Amanat F, et al. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. *medRxiv* [Internet]. 2020 Jun 29 [cited 2020 Nov 12]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.06.28.20142190>
130. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv* [Internet]. 2020 Apr 17 [cited 2020 Apr 22]; Available from: <https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1>
131. Anne Schuchat. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24–April 21, 2020 [Internet]. US Department of Health and Human Services/Centers for Disease Control and Prevention; 2020 May. (Morbidity and Mortality Weekly Report). Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6918e2-H.pdf>
132. Menezes AMB, Victora CG, Hartwig FP, Silveira MF, Horta BL, Barros AJD, et al. High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey. *medRxiv*. 2020 Aug 12;2020.08.10.20171942.
133. Universidade Federal de Pelotas. EPICOVID19-BR divulga novos resultados sobre o coronavírus no Brasil [Internet]. Universidade Federal de Pelotas; 2020 Jul. Available from: <https://bit.ly/Epicovid19BRfases1-3>
134. Vieira MA da C e S, Vieira CP de B, Borba A de S, Melo MC de C, Oliveira M de S, Melo RM, et al. Sequential serological surveys in the early stages of the coronavirus disease epidemic: limitations and perspectives. *Rev Soc Bras Med Trop*. 2020;53:e20200351.
135. Hallal P, Hartwig F, Horta B, Victora GD, Silveira M, Struchiner C, et al. Remarkable variability in SARS-CoV-2 antibodies across Brazilian regions: nationwide serological household survey in 27 states. *medRxiv* [Internet]. 2020 May 30 [cited 2020 Jun 1]; Available from: <https://www.medrxiv.org/content/10.1101/2020.05.30.20117531v1>
136. Costa Gomes C, Cerutti Jr. C, Zandonade E, Noia Maciel EL, Carvalho de Alencar FE, Almada GL, et al. A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage. *medRxiv* [Internet]. 2020 Jun 16 [cited 2020 Jun 16]; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.13.20130559v1>
137. Tess BH, Granato CFH, Alves MCGP, Pintao MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of Sao Paulo, Brazil, ten weeks after the first reported case. *medRxiv* [Internet]. 2020 Jun 29 [cited 2020 Nov 12]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.06.29.20142331>
138. Phillippe Watanabe. Nos bairros de SP mais afetados pela Covid-19, só 5% tiveram contato com o vírus [Internet]. Folha De S. Paulo. 2020. Available from: <https://www1.folha.uol.com.br/eqilibrioesaude/2020/05/nos-bairros-de-sp-mais-afetados-pela-covid-19-so-5-tiveram-contato-com-o-virus.shtml>

139. Silveira M, Barros A, Horta B, Pellanda L, Victora G, Dellagostin O, et al. Repeated population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. medRxiv. 2020 May 10;2020.05.01.20087205.
140. Filho LA, Szwarcwald CL. Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil. :10.
141. Del Brutto OH, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. SARS-CoV-2 in Rural Latin America. A Population-based Study in Coastal Ecuador. Clin Infect Dis [Internet]. [cited 2020 Oct 15]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1055/5876901>
142. Del Brutto OH, Mera RM, Recalde BY, Costa AF. Social Determinants of Health and Risk of SARS-CoV-2 Infection in Community-Dwelling Older Adults Living in a Rural Latin American Setting. J Community Health [Internet]. 2020 Jul 15 [cited 2020 Nov 12]; Available from: <http://link.springer.com/10.1007/s10900-020-00887-9>
143. Ministerio de Salud. Estudio de prevalencia determina que el 25,3% de la población de Lima y Callao estaría infectada de Covid-19 [Internet]. Ministerio de Salud. 2020. Available from: <https://www.gob.pe/institucion/minsa/noticias/216013-estudio-de-prevalencia-determina-que-el-25-3-de-la-poblacion-de-lima-y-callao-estaria-infectada-de-covid-19>
144. Peruvian Government. Estudio de prevalencia determina que el 25.3% de la población de lima y Callao adquirió la infección por SARS-COV2 [Internet]. Peruvian Government; 2020 Jul. Available from: https://twitter.com/DGE_MINSA/status/1287768430960168961
145. Peruvian Government. Minsa divulga ficha técnica del estudio que revela que el 25.3% de Lima y Callao adquirió el COVID-19 [Internet]. Gestion. 2020. Available from: <https://gestion.pe/peru/coronavirus-peru-minsa-divulga-ficha-tecnica-del-estudio-que-revela-que-el-253-de-lima-y-callao-adquirio-el-covid-19-cuarentena-estado-de-emergencia-nndc-noticia/>
146. Shakiba M, Nazari SSH, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. medRxiv. 2020 May 1;2020.04.26.20079244.
147. Sughayer MA, Mansour A, Al Nuirat A, Souan L, Ghanem M, Siag M. Covid-19 Seroprevalence rate in healthy blood donors from a community under strict lockdown measures. medRxiv [Internet]. 2020 Jun 7 [cited 2020 Jun 7]; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.06.20123919v1.full.pdf+html>
148. Aneesha Bedi. 28.3% of Delhi's population now exposed to Covid, shows second sero survey, up from 23.4% [Internet]. The Print. 2020. Available from: <https://theprint.in/health/28-3-of-delhis-population-now-exposed-to-covid-shows-second-sero-survey-up-from-23-4/484455/>
149. Yusra Husain. 4% 'healthy' blood donors in Lucknow found with Covid antibodies [Internet]. The Times of India. 2020. Available from: <https://timesofindia.indiatimes.com/city/lucknow/4-healthy-blood-donors-in-city-found-with-covid-antibodies/articleshow/77044828.cms>
150. India.com News Desk. COVID-19: People From Bhiwandi, Anand Vihar Have Antibodies Against Corona? Check Report [Internet]. India.com. 2020. Available from: <https://www.india.com/news/india/covid-19-people-from-bhiwandi-anand-vihar-have-antibodies-against-corona-check-report-4092355/>
151. HT Correspondent. 15 per cent population may have virus antibodies, says private lab data [Internet]. Hindustan Times. 2020. Available from: <https://www.hindustantimes.com/india-news/15-per-cent-population-may-have-virus-antibodies-says-private-lab-data/story-mUddlj9kxI4vRzYu4KMUil.html>
152. Suresh Kakani. SARS-Cov2 Sero-prevalence study in Mumbai: NITI-Aayong-BMC-TIFR study [Internet]. IDFC Institute; 2020 Jul. Available from: https://www.idfcinstitute.org/site/assets/files/15834/sero_press__28_07_2020.pdf
153. Malani A, Shah D, Kang G, Lobo GN, Shastri J, Mohanan M, et al. Seroprevalence of SARS-CoV-2 in slums and non-slums of Mumbai, India, during June 29-July 19, 2020. medRxiv [Internet]. 2020 Sep 1 [cited 2020 Nov 12]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.08.27.20182741>
154. Archana Mishra. Sero survey: 1,544 tested, 180 found with Covid-19 antibodies in Haryana [Internet]. Hindustan Times. 2020. Available from: <https://www.hindustantimes.com/gurugram/sero-survey-1-544-tested-180-found-with-covid-19-antibodies-in-haryana/story-k7DUZ8WH4jYqAzCsUmXkEJ.html>
155. Astha Saxena. New plan to check Covid spread in Delhi: Sero survey every month [Internet]. The Indian Express. 2020. Available from: <https://indianexpress.com/article/cities/delhi/delhi-coronavirus-latest-updates-sero-surveys-6518032/>
156. PIB Delhi. Sero-prevalence study conducted by National Center for Disease Control NCDC, MoHFW, in Delhi, June 2020 [Internet]. Indian Ministry of Health and Family Welfare; 2020 Jul. Available from: <https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1640137>
157. Aswin Kumar. Initial trend: Positivity rate low in antibody testing [Internet]. The Times of India. 2020. Available from: <https://timesofindia.indiatimes.com/city/thiruvananthapuram/initial-trend-positivity-rate-low-in-antibody-testing/articleshow/76363847.cms>
158. Sumi Dutta. 15-30% people in containment areas exposed to COVID-19: ICMR's serosurvey [Internet]. The New Indian Express. 2020. Available from: <https://www.newindianexpress.com/nation/2020/jun/08/15-30-people-in-containment-areas-exposed-to-covid-19-icmrs-serosurvey-2153893.html>
159. Jacob Koshy. News Analysis | India may have undercounted cases [Internet]. The Hindu. 2020. Available from: <https://www.thehindu.com/news/national/news-analysis-india-may-have-undercounted-cases/article31822079.ece>

160. Rhythma Kaul. Over 24k samples collected for random antibody tests [Internet]. Hindustan Times. 2020. Available from: <https://www.hindustantimes.com/india-news/over-24k-samples-collected-for-random-antibody-tests/story-Pec8jZE03DMQ0zOQwr4KEN.html>
161. Swatee Kher. Six Maharashtra districts have higher Covid-19 prevalence than nation's finding [Internet]. The Times of India. 2020. Available from: <https://timesofindia.indiatimes.com/city/pune/6-maha-districts-have-higher-ncov-prevalence-than-nations-finding/articleshow/76500273.cms>
162. Younas A, Waheed S, Khawaja S, Imam M, Borhany M, Shamsi T. Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan. *Transfus Apher Sci*. 2020 Aug;102923.
163. Le Chang, Wangheng Hou, Lei Zhao, Yali Zhang, Yanbin Wang, Linfeng Wu, et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. *medRxiv*. 2020 Jul 14;32.
164. Liu T, Wu S, Tao H, Zeng G, Fuling Zhou, Guo F, et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan – implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. *medRxiv* [Internet]. 2020 Jun 16; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.13.20130252v1>
165. Ling R, Yu Y, He J, Zhang J, Xu S, Sun R, et al. Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China. *medRxiv*. 2020 Aug 25;28.
166. Xu R, Huang J, Duan C, Liao Q, Shan Z, Wang M, et al. Low prevalence of antibodies against SARS-CoV-2 among voluntary blood donors in Guangzhou, China. *J Med Virol* [Internet]. [cited 2020 Oct 27];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26445>
167. To KK-W, Cheng VC-C, Cai J-P, Chan K-H, Chen L-L, Wong L-H, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. *Lancet Microbe*. 2020 Jul;1(3):e111–8.
168. Hallowell BD, Carlson CM, Jacobs JR, Pomeroy M, Steinberg J, Tenforde MW, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020. *Emerg Infect Dis*. 2020 Sep;26(9):1998–2004.
169. Sam I-C, Chong YM, Tan C'W, Chan YF. Low postpandemic wave SARS-CoV-2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. *J Med Virol* [Internet]. [cited 2020 Oct 2];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.26426>
170. Kempen JH, Abashawl A, Kinfemichael H, Nigussie Difabachew M, Menkir AA, Assefa MT, et al. SARS CoV-2 Serosurvey in Addis Ababa, Ethiopia. *medRxiv* [Internet]. 2020 Jun 23 [cited 2020 Jun 24]; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.23.20137521v1>
171. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. *medRxiv* [Internet]. 2020 Jul 29 [cited 2020 Aug 7]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.07.27.20162693>
172. Majiya H, Aliyu-Paiko M, Balogu VT, Musa DA, Salihu IM, Kawu AA, et al. Seroprevalence of COVID-19 in Niger State. *medRxiv* [Internet]. 2020 Aug 5 [cited 2020 Nov 12]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.08.04.20168112>
173. Anna Grigoryan. Antibodies found in Armenia's 61 medical workers from 380 examinations: testing continues [Internet]. Armen Press. 2020. Available from: <https://armenpress.am/eng/news/1020040/>
174. Tsaneva-Damyanova D. SARS-CoV-2: seroepidemiological pattern in northeastern Bulgaria. *Biotechnol Biotechnol Equip*. 2020 Jan 1;34(1):441–6.
175. Vilibic-Cavlek T, Stevanovic V, Tabain I, Betica-Radic L, Sabadi D, Peric L, et al. Severe acute respiratory syndrome coronavirus 2 seroprevalence among personnel in the healthcare facilities of Croatia, 2020. *Rev Soc Bras Med Trop* [Internet]. 2020 [cited 2020 Oct 17];53. Available from: http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0037-86822020000100914&lng=en&nrm=iso&tlng=en
176. Jerkovic I, Ljubic T, Basic Z, Kruzic I, Kunac N, Bezic J, et al. SARS-CoV-2 antibody seroprevalence in industry workers in Split-Dalmatia and Sibenik-Knin County, Croatia. *medRxiv*. 2020 May 15;2020.05.11.20095158.
177. Malickova K, Kratka Z, Luxova S, Bortlik M, Lukas M. Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics? *Scand J Gastroenterol*. 2020 Jul 14;1–3.
178. MedLife. Concluzii preliminare, studiu MedLife: "Cel mai probabil populatia nu are imunitate dobandita natural pentru COVID 19. Respectarea masurilor de protectie si extinderea testarii reprezinta sansa noastra de a functiona in siguranta si de a reporni economia" [Internet]. MedLife. 2020. Available from: <https://www.medlife.ro/comunicat-de-presa/concluzii-preliminare-studiu-medlife-cel-mai-probabil-populatia-nu-are-imunitate-dobandita-natural-pentru-covid-19-respectarea-masurilor-de-protectie-si-extinderea-testarii-reprezinta-sansa-noastra-de-a-functiona-in-siguranta-si-de-a>
179. Figar S, Pagotto V, Luna L, Salto J, Wagner Manslau M, Mistchenko A, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. *medRxiv* [Internet]. 2020 Jul 16 [cited 2020 Nov 13]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.07.14.20153858>

180. Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. *Lancet Child Adolesc Health*. 2020 Nov;4(11):807–16.
181. Hackner K, Errhalt P, Willheim M, Grasl M-A, Lagumdžija J, Riegler W, et al. Diagnostic accuracy of two commercially available rapid assays for detection of IgG and IgM antibodies to SARS-CoV-2 compared to ELISA in a low-prevalence population. *Res Sq [Internet]*. 2020 Aug 19 [cited 2020 Nov 13]; Available from: <https://www.researchsquare.com/article/rs-50887/v1>
182. Reiter T, Pajenda S, Wagner L, Gaggl M, Atamaniuk J, Holzer B, et al. Covid-19 serology in nephrology health care workers. *medRxiv*. 2020 Jan 1;2020.07.21.20136218.
183. Orth-Höller D, Eigentler A, Weseslindtner L, Möst J. Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection. *Emerg Microbes Infect*. 2020 Jan 1;9(1):1692–4.
184. Blairon L, Mokrane S, Wilmet A, Dessilly G, Kabamba-Mukadi B, Beukinga I, et al. Large-scale, molecular and serological SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium after COVID-19 outbreak. *J Infect*. 2020 Jul;S0163445320305144.
185. Berardis S, Verroken A, Vetillart A, Struyf C, Gilbert M, Gruson D, et al. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis. *J Cyst Fibros*. 2020 Aug;S1569199320308213.
186. Martin C, Montesinos I, Dauby N, Gilles C, Dahma H, Van Den Wijngaert S, et al. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. *J Hosp Infect*. 2020 Sep;106(1):102–6.
187. Steensels D, Oris E, Coninx L, Nuyens D, Delforge M-L, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. *JAMA*. 2020;(7501160).
188. Torres JP, Piñera C, De La Maza V, Lagomarcino AJ, Simian D, Torres B, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Prevalence in Blood in a Large School Community Subject to a Coronavirus Disease 2019 Outbreak: A Cross-sectional Study. *Clin Infect Dis*. 2020 Jul 10;ciaa955.
189. Mesnil M, Joubel K, Yavchitz A, Miklaszewski N, Devys J-M. Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study). *Anaesth Crit Care Pain Med*. 2020 Oct;39(5):595–6.
190. Fumery M, Matias C, Brochot E. Seroconversion of Immunoglobulins to SARS-CoV2 in Patients With Inflammatory Bowel Disease Patients Treated by Biologics. *J Crohns Colitis*. 2020 Jul 22;jjaa154.
191. Solodky ML, Galvez C, Russias B, Detourbet P, N'Guyen-Bonin V, Herr A-L, et al. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. *Ann Oncol*. 2020 Aug;31(8):1087–8.
192. Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and oncological staff of a municipal clinic. *GMS Hyg Infect Control* 15Doc18 [Internet]. 2020 Jul 23 [cited 2020 Oct 15]; Available from: <https://www.egms.de/en/journals/dgkh/2020-15/dgkh000353.shtml>
193. Armann JP, Unrath M, Kirsten C, Lueck C, Dalpke A, Berner R. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seroprevalence and transmission rates. *medRxiv*. 2020 Jan 1;2020.07.16.20155143.
194. Zöllkau J, Baier M, Scherag A, Schleußner E, Groten T. Periodenprävalenz von SARS-CoV-2 in einer unselektierten Stichprobe schwangerer Frauen in Jena, Thüringen. *Z Für Geburtshilfe Neonatol*. 2020 Aug;224(04):194–8.
195. Schmidt SB, Grüter L, Boltzmann M, Rollnik JD. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. Adrish M, editor. *PLOS ONE*. 2020 Jun 25;15(6):e0235417.
196. Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. *J Clin Virol*. 2020 Jul;128:104437.
197. Harsch IA, Skiba M, Konturek PC, Epstude J. Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward. *GMS Hyg Infect Control [Internet]*. 2020 May 14 [cited 2020 Jun 18];15. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273321/>
198. Behrens GM, Cossmann A, Stankov MV, Schulte B, Streeck H, Foerster R, et al. Strategic anti-SARS-CoV-2 serology testing in a low prevalence pandemic: The COVID-19 Contact (CoCo) Study in health care professionals. *medRxiv*. 2020 Aug 7;2020.08.06.20169250.
199. Behrens GMN, Cossmann A, Stankov MV, Schulte B, Streeck H, Förster R, et al. Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. *Infect Dis Ther [Internet]*. 2020 Sep 4 [cited 2020 Nov 13]; Available from: <http://link.springer.com/10.1007/s40121-020-00334-1>
200. Kern PM, Müller H-H, Menzel T, Weisser H. Studie zur Immunität gegen SARS-CoV-2: Keine signifikante humorale Immunität gegen SARS-CoV-2 im medizinischen Personal eines Klinikums der Maximalversorgung und in der Stadtregion Fulda. *Klin*. 2020 Jun;49(06):268–73.
201. Kraehling V, Kern M, Halwe S, Mueller H, Rohde C, Savini M, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. *medRxiv*. 2020 May 25;2020.05.20.20107730.

202. Lackermeier K, Williams F, Grzanna N, Lehmann E, Fichtner S, Kucher HB, et al. Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing. *Fam Pract*. 2020 Aug 7;:cmaa078.
203. Psychogiou M, Karabinis A, Pavlopoulou I, Basoulis D, Konstantinos L, Rapti V, et al. Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. *medRxiv [Internet]*. 2020 Jun 23; Available from: <https://www.medrxiv.org/content/10.1101/2020.06.23.20137620v1>
204. Norsa L, Cosimo P, Indriolo A, Sansotta N, D'Antiga L, Callegaro A. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment. *Gastroenterology*. 2020 Aug;:S0016508520351179.
205. Cosma S, Borella F, Carosso A, Sciarrone A, Cusato J, Corcione S, et al. The “scar” of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy. *J Med Virol*. 2020 Aug 13;:jmv.26267.
206. Lorenzo D, Carrisi C. COVID-19 exposure risk for family members of healthcare workers: An observational study. *Int J Infect Dis*. 2020 Sep;:98:287–9.
207. Cavaliere AF, Carabaneanu AI, Perelli F, Matarrese D, Brunelli T, Casprini P, et al. Universal screening for SARS-CoV-2 in pregnant women admitted for delivery: how to manage antibody testing? *J Matern Fetal Neonatal Med*. 2020 Jul 28;:1–2.
208. Maria Teresa Sandri, Elena Azzolini, Valter Torri, Sara Carloni, Michele Tedeschi, Massimo Castoldi, et al. IgG serology in health care and administrative staff populations from 7 hospitals representative of different exposures to SARS-CoV-2 in Lombardy, Italy. *medRxiv [Internet]*. 2020 May 26; Available from: <https://www.medrxiv.org/content/10.1101/2020.05.24.20111245v1.full.pdf>
209. Denina M, Pellegrino F, Morotti F, Coppo P, Bonsignori IM, Garazzino S, et al. All that glitters is not COVID: low prevalence of seroconversion against SARS-CoV-2 in a pediatric cohort of patients with Chilblain-like lesions. *J Am Acad Dermatol [Internet]*. 2020 Aug 8 [cited 2020 Sep 25]; Available from: <http://www.sciencedirect.com/science/article/pii/S0190962220324099>
210. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. *J Clin Med*. 2020 Sep;:9(9):2780.
211. Carozzi FM, Cusi MG, Pistello M, Galli L, Bartoloni A, Anichini G, et al. Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: results from a large-scale screening program based on rapid serological testing. *medRxiv [Internet]*. 2020 Aug 4 [cited 2020 Nov 13]; Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.07.30.20149567>
212. Dalla Volta A, Valcamonico F, Pedersini R, Fornaro C, Tovazzi V, Monteverdi S, et al. The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures. *Front Oncol*. 2020 Aug 18;:10:1574.
213. Lahner E, Dilaghi E, Prestigiacomo C, Alessio G, Marcellini L, Simmaco M, et al. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy. *Int J Environ Res Public Health [Internet]*. 2020 Jun [cited 2020 Jul 21];:17(12). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345358/>
214. Paradiso AV, Summa simona D, Silvestris N, Tommasi S, Tufaro A, Palma GD, et al. COVID-19 SCREENING AND MONITORING OF ASYMPTOMATIC HEALTH WORKERS WITH A RAPID SEROLOGICAL TEST. *medRxiv*. 2020 May 8;:2020.05.05.20086017.
215. Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital. *BMC Pulm Med*. 2020 Dec;:20(1):203.
216. Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, et al. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. *Infect Control Hosp Epidemiol*. 2020 Aug 6;:1–2.
217. Fusco FM, Pisaturo M, Iodice V, Bellopede R, Tambaro O, Parrella G, et al. COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study. *J Hosp Infect*. 2020 Aug;:105(4):596–600.
218. Pancrazzi A, Magliocca P, Lorubbio M, Vaggelli G, Galano A, Mafucci M, et al. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. *Clin Biochem*. 2020 Oct;:84:87–92.
219. Yong Chong, Naoki Tani, Hideyuki Ikematsu, Nobuto Terazawa, Hitoshi Nakashima, Nobuyuki Shimono, et al. Genetic testing and serological screening for SARS-CoV-2 infection in a COVID-19 outbreak in a nursing facility in Japan. *Res Sq [Internet]*. 2020 Nov 14; Available from: <https://doi.org/10.21203/rs.3.rs-64266/v1>
220. Suda G, Ogawa K, Kimura M, Maehara O, Kitagataya T, Ohara M, et al. Time-dependent changes in the seroprevalence of COVID-19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID-19. *Hepatal Res*. 2020 Oct 1;:50(10):1196–200.
221. Nakamura A, Sato R, Ando S, Oana N, Nozaki E, Endo H, et al. Seroprevalence of Antibodies to SARS-CoV-2 in Healthcare Workers in Non-epidemic Region: A Hospital Report in Iwate Prefecture, Japan. *medRxiv*. 2020 Jan 1;:2020.06.15.20132316.

222. Denyer S. Japanese firm's blanket testing of employees could serve as model [Internet]. 2020. Available from: <https://www.lmtonline.com/news/article/Japanese-firm-s-blanket-testing-of-employees-15355433.php>
223. Jiji K. 0.43% found positive in SoftBank-led coronavirus antibody tests. The Japan Times [Internet]. 2020 Jun 10; Available from: <https://www.japantimes.co.jp/news/2020/06/10/national/softbank-coronavirus-antibody-tests/>
224. Fujita K, Shinpei Kada, Osamu Kanai, Hiroaki Hata, Takao Odagaki, Noriko Satoh-Asahara, et al. Quantitative SARS-CoV-2 antibody screening of healthcare workers in the southern part of Kyoto city during the COVID-19 peri-pandemic period. medRxiv [Internet]. 2020 May 20; Available from: <https://doi.org/10.1101/2020.05.12.20098962>
225. Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. medRxiv. 2020 May 1;2020.04.26.20079822.
226. Westerhuis BM, de Bruin E, Chandler FD, Ramakers CRB, Okba NMA, Li W, et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. medRxiv. 2020 Aug 24;2020.08.21.20177857.
227. Cox RJ, Brokstad KA, Krammer F, Langeland N, Bergen COVID-19 Research Group. Seroconversion in household members of COVID-19 outpatients. Blomberg B KK Lartey S, Linchausen DW, Mohn KG, Real FG, Bansal A, Bredholt G, Madsen A, Onanygo TB, Trieu MC, Vahokoski J, Zhou F, editor. Lancet Infect Dis. 2020;(101130150).
228. Song S-K, Lee D-H, Nam J-H, Kim K-T, Do J-S, Kang D-W, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea. J KOREAN Med Sci. 2020 Jul 27;35(29).
229. Fernández-Rivas G, Quirant-Sánchez B, González V, Doladé M, Martínez-Caceres E, Piña M, et al. Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. medRxiv. 2020 Jun 26;2020.06.24.20135673.
230. Soriano V, Meiriño R, Corral O, Guallar MP. Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. Clin Infect Dis [Internet]. 2020 Jun 16 [cited 2020 Nov 14];(ciaa769). Available from: <https://doi.org/10.1093/cid/ciaa769>
231. Garralda Fernandez J, Molero Vilches I, Bermejo Rodriguez A, Cano de Torres I, Colino Romay EI, Garcia-Arata I, et al. Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain. medRxiv. 2020 Jan 1;2020.07.26.20162529.
232. Valdivia A, Torres I, Huntley D, Alcaraz MJ, Albert E, Solano de la Asunción C, et al. Caveats in interpreting SARS-CoV-2 IgM+/IgG- antibody profile in asymptomatic health care workers. J Med Virol [Internet]. 2020 Aug 6 [cited 2020 Nov 14];n/a(n/a). Available from: <https://doi.org/10.1002/jmv.26400>
233. Galan I, Velasco M, Casas ML, Goyanes MJ, Rodriguez-Caravaca G, Losa JE, et al. SARS-CoV-2 Seroprevalence Among All Workers in a Teaching Hospital in Spain: Unmasking the risk. medRxiv. 2020 Jan 1;2020.05.29.20116731.
234. Olalla J, Correa AM, Martín-Escalante MD, Hortas ML, Martín-Sendarrubias MJ, Fuentes V, et al. Search for asymptomatic carriers of SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience. QJM Int J Med [Internet]. 2020 Aug 10 [cited 2020 Nov 14];(hcaa238). Available from: <https://doi.org/10.1093/qjmed/hcaa238>
235. Martín V, Fernández-Villa T, Lamuedra Gil de Gomez M, Mencía-Ares O, Rivero Rodríguez A, Reguero Celada S, et al. Prevalence of SARS-CoV-2 infection in general practitioners and nurses in primary care and nursing homes in the Healthcare Area of León and associated factors. COVID19 En Aten Primaria. 2020 Aug 1;46:35–9.
236. Garcia-Basteiro A.L., Moncunill G., Tortajada M., Vidal M., Guinovart C., Jimenez A., et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11(1):3500.
237. Lidstrom A.-K., Sund F., Albinsson B., Lindback J., Westman G. Work at inpatient care units is associated with an increased risk of SARS-CoV-2 infection; a cross-sectional study of 8679 healthcare workers in Sweden. Ups J Med Sci. 2020;(Lidstrom, Sund, Westman) Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, Uppsala, Sweden):1–6.
238. Rudberg A-S, Havervall S, Manberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in health care workers. medRxiv. 2020 Jan 1;2020.06.22.20137646.
239. Lindahl JF, Hoffman T, Esmailzadeh M, Olsen B, Winter R, Amer S, et al. High seroprevalence of SARS-CoV-2 in elderly care employees in Sweden. Infect Ecol Epidemiol. 2020 Jan 1;10(1):1789036.
240. Gulraj P. After in-house GHA screening programme, Govt rethinks its plans for anti-body tests. Gibraltar Chronicle [Internet]. 2020 Jun 17; Available from: <https://www.chronicle.gi/after-in-house-gha-screening-programme-govt-rethinks-its-plans-for-anti-body-tests/>
241. Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al. Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. Lancet Respir Med. 2020 Sep;8(9):885–94.

242. Eyre DW, Lumley SF, O'Donnell D, Campbell M, Sims E, Lawson E, et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. *eLife*. 2020 Aug 21;9.
243. Bampoe S, Lucas DN, Neall G, Sceales P, Aggarwal R, Caulfield K, et al. A cross-sectional study of immune seroconversion to SARS-CoV-2 in frontline maternity health professionals. *Anaesthesia*. 2020 Dec 1;75(12):1614–9.
244. Grant JJ, Wilmore SMS, McCann NS, Donnelly O, Lai RWL, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. *Infect Control Hosp Epidemiol*. 2020 Aug 4;1–3.
245. Khalil A, Hill R, Wright A, Ladhani S, O'Brien P. SARS-CoV-2-Specific Antibody Detection in Healthcare Workers in a UK Maternity Hospital: Correlation With SARS-CoV-2 RT-PCR Results. *Clin Infect Dis*. 2020 Aug 8;ciaa893.
246. Poulidakos D., Sinha S., Kalra P.A. SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England. *J Clin Virol*. 2020;129((Poulidakos) Clinical Director of Renal Services, Salford Royal NHS Foundation Trust, United Kingdom):104545.
247. Shields AM, Faustini SE, Perez-Toledo M, Jossi S, Aldera EL, Allen JD, et al. SARS-CoV-2 seroconversion in health care workers. *medRxiv*. 2020 May 19;2020.05.18.20105197.
248. Sikora K, Barwick I, Hamilton C. Serological prevalence of antibodies to SARS CoV-2 amongst cancer centre staff. *medRxiv*. 2020 May 1;2020.05.16.20099408.
249. Favara DM, Cooke A, Doffinger R, Houghton S, Budriunaite I, Bossingham S, et al. First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS). *medRxiv*. 2020 Jun 23;2020.06.22.20136838.
250. Favara DM, Cooke A, Doffinger R, McAdam K, Corrie P, Ainsworth NL. COVID-19 Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology Workforce. *Clin Oncol R Coll Radiol G B*. 2020;(ayi, 9002902).
251. McBride SM, Bundick K, Hubbeling H, Freret M, Modlin L, Kamboj M, et al. Results and Impact of Intensive SARS-CoV-2 Testing in a High Volume, Outpatient Radiation Oncology Clinic in a Pandemic Hotspot. *medRxiv*. 2020 Aug 14;2020.08.11.20172551.
252. Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. *JAMA-J Am Med Assoc*. 2020 Sep 1;324(9):893–5.
253. Reifer J, Hayum N, Heszel B, Klagsbald I, Strevva VA. SARS-CoV-2 IgG antibody responses in New York City. *Diagn Microbiol Infect Dis*. 2020 Nov 1;98(3):115128.
254. Brant-Zawadzki M, Fridman D, Robinson P, Zahn M, German R, Breit M, et al. SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study. *medRxiv*. 2020 Jul 25;2020.07.20.20158329.
255. Dora AV, Winnett A, Fulcher JA, Sohn L, Calub F, Lee-Chang I, et al. Using Serologic Testing to Assess the Effectiveness of Outbreak Control Efforts, Serial Polymerase Chain Reaction Testing, and Cohorting of Positive Severe Acute Respiratory Syndrome Coronavirus 2 Patients in a Skilled Nursing Facility. *Clin Infect Dis [Internet]*. 2020 Aug 28 [cited 2020 Nov 15];(ciaa1286). Available from: <https://doi.org/10.1093/cid/ciaa1286>
256. Flannery DD, Gouma S, Dhudasia MB, Mukhopadhyay S, Pfeifer MR, Woodford EC, et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci Immunol*. 2020;5(49).
257. Gray A. Prevalence Of COVID-19 Antibodies In Washoe Co. Expected To Be Low. 2020 Jun 22; Available from: <https://www.kunr.org/post/prevalence-covid-19-antibodies-washoe-co-expected-be-low#stream/0>
258. Stavert R, Meydani-Korb A, de Leon D, Osgood R, Blau J, Luu T. Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic. *J Am Acad Dermatol*. 2020 Dec 1;83(6):1753–5.
259. Staletovich J. South Florida Cities Test Employees For Antibodies. *WLRN [Internet]*. 2020 May 22; Available from: <https://www.wlrn.org/health-care/2020-05-22/south-florida-cities-begin-testing-employees-for-covid-19-antibodies>
260. Jackson A. Almost everyone at one Michigan prison tests positive for COVID-19 antibodies. *Detroit Free Press [Internet]*. 2020 May 28; Available from: https://www.petoskeynews.com/news/state-region/almost-everyone-at-one-michigan-prison-tests-positive-for-covid-19-antibodies/article_423c1ef0-a018-5b50-b746-c93fcb82f71f.html
261. Leidner R, Frary A, Cramer J, Ball D, Weerasinghe R, Schmidt M, et al. Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort. *medRxiv*. 2020 Aug 18;2020.08.16.20176107.
262. Geraci L. Antibody tests show just 2% exposure rate to COVID-19. *The Lancaster News [Internet]*. 2020 May 23; Available from: <https://www.thelancasternews.com/content/antibody-tests-show-just-2-exposure-rate-covid-19>
263. Mughal MS, Kaur IP, Patton CD, Mikhail NH, Vareechon C, Granet KM. The prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in intensive care unit (ICU) healthcare personnel (HCP) and its implications—a single-center, prospective, pilot study. *Infect Control Hosp Epidemiol*. 2020/06/12 ed. 2020;1–2.
264. Dietrich ML, Norton EB, Elliott D, Smira AR, Rouelle JA, Bond NG, et al. SARS-CoV-2 Seroprevalence Rates of Children in Louisiana During the State Stay at Home Order. *medRxiv*. 2020 Jul 8;2020.07.07.20147884.
265. Parker-Magyar A. Few among Long Hill first responders test positive for COVID-19 antibodies. *Echoes Sentinel News [Internet]*. 2020 Jun 1; Available from: https://www.google.com/url?rct=j&sa=t&url=https://www.newjerseyhills.com/echoes-sentinel/news/few-among-long-hill-first-responders-test-positive-for-covid-19-antibodies/article_007ac367-b3b2-5375-b471-

- f0a817998f62.html&ct=ga&cd=CAAYFDIaOTBkZWE5ODk5NGU5MTg1OTpj206ZW46VVM&usg=AFQjCNH Wg839bXiyzOxO1Y7-QOECGMRCMw
266. Hunter BR, Dbeibo L, Weaver CS, Beeler C, Saysana M, Zimmerman MK, et al. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure. *Infect Control Hosp Epidemiol.* undefined/ed;1–2.
 267. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. *medRxiv.* 2020 Aug 16;2020.08.14.20174490.
 268. Sydney ER, Kishore P, Laniado I, Rucker LM, Bajaj K, Zinaman MJ. Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx. *Infect Control Hosp Epidemiol.* 2020/08/26 ed. 2020;41(11):1348–9.
 269. Reagan N. Results show 2% of tested MUSC staff have COVID-19 antibodies. *Live 5 News* [Internet]. 2020 May 4; Available from: <https://www.live5news.com/2020/05/04/results-show-tested-musc-staff-have-covid-antibodies/>
 270. Jeremias A, Nguyen J, Levine J, Pollack S, Engellenner W, Thakore A, et al. Prevalence of SARS-CoV-2 Infection Among Health Care Workers in a Tertiary Community Hospital. *JAMA Intern Med* [Internet]. 2020 Aug 11 [cited 2020 Nov 15]; Available from: <https://doi.org/10.1001/jamainternmed.2020.4214>
 271. Cohen DE, Marlowe G, Contreras G, Sosa MA, Mendoza JM, Lenz O, et al. Assessment of a Laboratory-Based SARS-CoV-2 Antibody Test Among Hemodialysis Patients: A Quality Improvement Initiative. *medRxiv.* 2020 Aug 4;2020.08.03.20163642.
 272. Payne DC, Smith-Jeffcoat SE, Nowak G, Chukwuma U, Geibe JR, Hawkins RJ, et al. SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore Roosevelt, April 2020. Tiller R GR Rogers S, Whitaker B, Kondas A, Smith P, Lee C, Graziano J, editor. *MMWR Morb Mortal Wkly Rep.* 2020;69(23):714–21.
 273. Kiefer MK, McKiever ME, Russo JR, Ma'ayeh M, Gee SE, Smith DD, et al. Exposure and seroconversion to severe acute respiratory syndrome coronavirus 2 among obstetrical healthcare providers following a contained outbreak. *Am J Obstet Gynecol.* 2020 Oct 1;223(4):601-603.e2.
 274. Slusser S. MLB antibody study: 0.7% of those tested had been exposed to coronavirus. *San Francisco Chronicle* [Internet]. 2020 May 10; Available from: <https://www.sfchronicle.com/athletics/article/MLB-antibody-study-7-percent-exposed-to-15260314.php>
 275. McCormack J. What the Coronavirus-Antibody Study of Major League Baseball Tells Us. *National Review* [Internet]. 2020 May 11; Available from: <https://www.nationalreview.com/2020/05/coronavirus-antibody-study-major-league-baseball-herd-immunity/>
 276. Morcuende M, Guglielminotti J, Landau R. Anesthesiologists' and Intensive Care Providers' Exposure to COVID-19 Infection in a New York City Academic Center: A Prospective Cohort Study Assessing Symptoms and COVID-19 Antibody Testing. *Anesth Analg.* 2020 Sep;131(3):669–76.
 277. Stock AD, Bader ER, Cezayirli P, Inocencio J, Chalmers SA, Yassari R, et al. COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing. *Front Med.* 2020;7:471.
 278. Madsen T, Levin N, Niehus K, Law K, Mayer J, Chapman M, et al. Prevalence of IgG antibodies to SARS-CoV-2 among emergency department employees. *Am J Emerg Med.* 2020 May 3;
 279. Caban-Martinez AJ, Schaefer-Solle N, Santiago K, Louzado-Feliciano P, Brotons A, Gonzalez M, et al. Epidemiology of SARS-CoV-2 antibodies among firefighters/paramedics of a US fire department: a cross-sectional study. *Occup Environ Med.* 2020 Dec 1;77(12):857.
 280. Hains D.S., Schwaderer A.L., Carroll A.E., Starr M.C., Wilson A.C., Amanat F., et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. *JAMA - J Am Med Assoc.* 2020;(Hains, Schwaderer, Carroll, Starr, Wilson) Department of Pediatrics, Indiana University, 699 Riley Hospital Dr, RR230, Indianapolis, IN 46202, United States):8438.
 281. Stubblefield WB, Talbot HK, Feldstein LR, Tenforde MW, Rasheed MAU, Mills L, et al. Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19—Nashville, Tennessee. *Clin Infect Dis* [Internet]. 2020 Jun 6 [cited 2020 Nov 15];(c1aa936). Available from: <https://doi.org/10.1093/cid/c1aa936>
 282. Goldberg SA, Lennerz J, Klompas M, Mark E, Pierce VM, Thompson RW, et al. Presymptomatic Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Among Residents and Staff at a Skilled Nursing Facility: Results of Real-time Polymerase Chain Reaction and Serologic Testing. *Clin Infect Dis* [Internet]. 2020 Jul 15 [cited 2020 Nov 15];(c1aa991). Available from: <https://doi.org/10.1093/cid/c1aa991>
 283. Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A. Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. *J Gen Intern Med.* 2020 Aug 1;35(8):2485–6.
 284. Chu VT, Freeman-Ponder B, Lindquist S, Spitters C, Kawakami V, Dyal JW, et al. Investigation and Serologic Follow-Up of Contacts of Early Confirmed Case-Patient with COVID-19, Washington, USA. *Emerg Infect Dis.* 2020 Aug;26(8):1671–8.

285. Kassem AM, Talaat H, Shawky S, Fouad R, Amer K, Elnagdy T, et al. SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility. *Arab J Gastroenterol.* 2020 Sep 1;21(3):151–5.
286. Kammon A, El-Arabi AA, Erhouma EA, Mehemed TM, Mohamed OA. Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya. *medRxiv.* 2020 May 26;2020.05.25.20109470.
287. Alkurt G, Murt A, Aydin Z, Tatli O, Agaoglu NB, Irvem A, et al. Seroprevalence of Coronavirus Disease 2019 (COVID-19) Among Health Care Workers from Three Pandemic Hospitals of Turkey. *medRxiv.* 2020 Aug 22;2020.08.19.20178095.
288. Ray A, Singh K, Chattopadhyay S, Mehdi F, Batra G, Gupta A, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in hospitalized patients at a tertiary referral center in North India. *medRxiv.* 2020 Aug 26;2020.08.22.20179937.
289. Unclear. Ahmedabad has no herd immunity, only 17.6% have antibodies. *The Times of India* [Internet]. Available from: <https://timesofindia.indiatimes.com/city/ahmedabad/ahmedabad-has-no-herd-immunity-only-17-6-have-antibodies/articleshow/77137851.cms>
290. Rao S. Covid-19: Jayadeva says its survey hints at herd immunity. *Times of India* [Internet]. 2020 Jun 6; Available from: <https://timesofindia.indiatimes.com/city/bengaluru/covid-19-jayadeva-says-its-survey-hints-at-herd-immunity/articleshow/76228490.cms>
291. Chughtai O, Batool H, Khan M, Chughtai A. Frequency of COVID-19 IgG Antibodies among Special Police Squad Lahore, Pakistan. *J Coll Physicians Surg Pak.* 2020 Jul 1;30(7):735–9.
292. He L, Zeng Y, Zeng C, Zhou Y, Li Y, Xie X, et al. Positive Rate of Serology and RT-PCR for COVID-19 among healthcare workers during different periods in Wuhan, China. *J Infect* [Internet]. [cited 2020 Nov 15]; Available from: <https://doi.org/10.1016/j.jinf.2020.08.027>
293. Liang W, Lin Y, Bi J, Li J, Liang Y, Wong S-S, et al. Serosurvey of SARS-CoV-2 among hospital visitors in China. *Cell Res.* 2020 Sep 1;30(9):817–8.
294. Liu M, Cheng S-Z, Xu K-W, Yang Y, Zhu Q-T, Zhang H, et al. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study. *BMJ* [Internet]. 2020;369. Available from: <https://www.bmj.com/content/369/bmj.m2195>
295. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. *J Med Virol.* 2020 Oct 1;92(10):1795–6.
296. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. *Nat Med.* 2020 Aug 1;26(8):1193–5.
297. Zhang A, Hu Q, Liu A, Wang S, Jin S, Wang Y, et al. Prevention of COVID-19 infection in a pediatric oncology ward in Wuhan. *Pediatr Blood Cancer.* 2020 Oct 1;67(10):e28424.
298. Tang H, Tian J-B, Dong J-W, Tang X-T, Yan Z-Y, Zhao Y-Y, et al. Serologic Detection of SARS-CoV-2 Infections in Hemodialysis Centers: A Multicenter Retrospective Study in Wuhan, China. *Am J Kidney Dis.* 2020 Oct 1;76(4):490-499.e1.
299. Tu D, Shu J, Wu X, Li H, Xia Z, Zhang Y, et al. Immunological detection of serum antibodies in pediatric medical workers exposed to varying levels of SARS-CoV-2. *J Infect* [Internet]. [cited 2020 Nov 15]; Available from: <https://doi.org/10.1016/j.jinf.2020.07.023>
300. Zhang C, Lin L, Tang D, Liu F, Li M, Li Q, et al. Antibody responses to SARS-CoV-2 in healthy individuals returning to Shenzhen. *J Med Virol* [Internet]. 2020 Jul 25 [cited 2020 Nov 15];n/a(n/a). Available from: <https://doi.org/10.1002/jmv.26355>
301. Xiong S, Guo C, Dittmer U, Zheng X, Wang B. The prevalence of antibodies to SARS-CoV-2 in asymptomatic healthcare workers with intensive exposure to COVID-19. *medRxiv.* 2020 Jun 2;2020.05.28.20110767.
302. Zhao D, Wang M, Wang M, Zhao Y, Zheng Z, Li X, et al. Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China. *Int J Infect Dis.* 2020 Oct 1;99:219–25.
303. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. *J Infect.* 2020/06/04 ed. 2020 Sep;81(3):420–6.
304. Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. *medRxiv.* 2020 Mar 10;2020.03.04.20030916.
305. Zhang J, Zhang X, Liu J, Ban Y, Li N, Wu Y, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. *Int Immunopharmacol.* 2020 Nov 1;88:106861.
306. Nopsopon T, Pongpirul K, Chotirosniramit K, Hiransuthikul N. COVID-19 Antibody in Thai Community Hospitals. *medRxiv.* 2020 Jul 4;2020.06.24.20139188.
307. Chibwana MG, Jere KC, kamng'ona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in Health Care Workers but relatively low numbers of deaths in urban Malawi. *medRxiv.* 2020 Aug 5;2020.07.30.20164970.
308. Asuquo MI, Effa E, Otu A, Ita O, Udoh U, Umoh V, et al. Prevalence of IgG and IgM antibodies to SARS-CoV-2 among clinic staff and patients. *medRxiv.* 2020 Jul1;2020.07.02.20145441.

309. Halatoko WA, KONU YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. medRxiv. 2020 Aug 7;2020.08.07.20163840.
310. Houlihan C.F., Vora N., Byrne T., Lewer D., Kelly G., Heaney J., et al. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers. *Lancet Lond Engl.* 2020;((Houlihan) Department of Clinical Virology, University College London Hospitals, London W1T 4EU, UK; Department of Infection and Immunity, University College London, London, UK; Department of Clinical Research, London School of Hygiene&Tropical Medicine, London, UK).